

© Copyright 2018

Jason Thomas Stevens

**Controlling Enzyme Expression Dynamics to Improve Production  
from Engineered Biosynthetic Pathways**

Jason Thomas Stevens

A dissertation  
submitted in partial fulfillment  
of the requirements for the degree of

Doctor of Philosophy

University of Washington

2018

Reading Committee:

James Carothers, Chair

Wendy Thomas

Paul Wiggins

Program Authorized to Offer Degree:

Bioengineering

University of Washington

**Abstract**

Controlling Enzyme Expression Dynamics to Improve Production  
from Engineered Biosynthetic Pathways

Jason Thomas Stevens

Chair of the Supervisory Committee:

Assistant Professor James Carothers

Chemical Engineering

Metabolic engineering promises to reduce our reliance on non-renewable chemical synthesis methods by harnessing microbial metabolisms to convert simple renewable resources, such as sugars, into useful chemicals, such as biofuels. Most metabolic engineering efforts require expressing heterologous enzymes in a microbial host, such as *E. coli*. Both the process of producing enzymes and the chemical metabolites that are produced can have deleterious impacts on host

fitness, however. Here we detail efforts to use experimental and computational methods to better understand how to mitigate the deleterious impact of a metabolic pathway on its host. Firstly, we sought to computationally predict how metabolic pathway titers could be improved, and product toxicity reduced, by implementing genetic feedback networks that can sense pathway metabolite concentrations in a cell and respond by up- or down-regulating enzyme levels. To this end, we developed a computational methodology for modeling and simulating large sets of genetic feedback networks acting on a metabolic pathway that produces 4-aminocinnamic acid, or 4-ACA. Our analysis revealed genetic feedback network architectures and implementations that promise to improve pathway titers. Secondly, we experimentally analyzed the burden imposed by expressing a Phenylalanine Ammonia Lyase enzyme, PAL2 from *Arabidopsis thaliana*, which converts 4-aminophenylalanine (4-AF) to 4-ACA in *Escherichia coli* cells. We uncovered how the timing and level of induction of a PAL2-superfolder GFP fusion (PAL2-sfGFP) influences cell growth, expression of PAL2-sfGFP, and *in vivo* cellular catalysis of 4-AF to 4-ACA conversion. We then identified stationary phase promoters that can be used to autonomously express high levels of PAL2-sfGFP, increase conversion, and reduce deleterious impacts. Lastly, we produced 4-AF from glucose in *E. coli* using a three-enzyme operon, PapABC, from *Pseudomonas fluorescens*, achieving titers of around 100 mg/L, forming the basis for a pathway to produce 4-ACA. Together, this work serves to improve our understanding of how to mitigate the deleterious impacts of a metabolic pathway on its host by using

computational model analysis and by controlling *in vivo* enzyme expression dynamics.

# Table of Contents

<b>Table of Contents</b>	<b>1</b>
<b>List of Figures</b>	<b>3</b>
<b>List of Tables</b>	<b>4</b>
<b>Chapter 1   Introduction</b>	<b>7</b>
Abstract	7
1.1   Selected Topics in Metabolic Engineering	7
1.1.1   Introduction	7
1.1.2   Producing Aromatic Compounds with <i>E. coli</i>	8
1.1.3   Toxicity and Burden in Metabolic Engineering	11
1.1.4   Programming Gene Expression of Metabolic Pathway Enzymes in <i>E. coli</i>	14
1.1.4.1   Promoters	14
1.1.4.2   Ribosome Binding Sites	16
1.1.4.3   mRNA Transcript Stability	17
1.1.4.4   Dynamic Control of Gene Expression	18
1.1.5   Kinetic Models of Metabolic Pathway Gene Expression	21
1.2   Dissertation Organization	24
<b>Chapter 2   Computational Analysis of Genetic Control Systems for Metabolic Pathway Engineering</b>	<b>26</b>
Abstract	26
2.1   Introduction	27
2.2   Methods	33
2.3   Results and Discussion	36
2.4   Supplementary Information	49
2.5   Modular Modeling with PyMDC	54
2.6   Conclusions and Future Work	56
<b>Chapter 3   Programming Enzyme Expression Dynamics to Reduce Cellular Burden and Improve Expression and <i>In Vivo</i> Catalysis</b>	<b>60</b>
Abstract	60
3.1   Introduction	61
3.2   Materials and Methods	66
3.3   Results	70

3.5   Discussion	80
3.6   Supplementary Information	85
<b>Chapter 4   Production of 4-aminocinnamic Acid from Glucose with E. coli</b>	<b>98</b>
Abstract	98
4.1   Introduction	98
4.2   Materials and Methods	102
4.3   Shikimate Production	106
4.4   HPLC Detection of 4-AF	107
4.5   4-AF Production Using <i>S. venezuelae</i> Operon	108
4.6   4-AF Production Using <i>P. fluorescens</i> Operon	110
4.7   4-AF-responsive Dynamic Control of Gene Expression	113
4.8   Detecting 4-AF Using RNA Aptamer Ribosensors In Vitro	116
4.9   Conclusions and Future Directions	117
<b>Chapter 5   Conclusions</b>	<b>120</b>
<b>References</b>	<b>122</b>
<b>Appendix A   Genetic Sequences</b>	<b>136</b>
pPAL2.1	136
pSFGFP.1	139
pJTS123	141
pJTS111	144
pDSY2F	146
pJTS16	148
pJTS76D	152
pJTS76W	155

## List of Figures

2.1   Engineered <i>p</i> -aminostyrene (p-AS) pathway and control system design space	32
2.2   Mechanistic model and genetic control mechanisms	38
2.3   Relative production yields across the entire design space	41
2.4   Performance of core topologies	43
2.5   Relative production yields for Core Topology 12 (CT 12)	46
2.6   Dependence of relationship between sensor input and node output on aptazyme ligand-activation ratio	48
2.7   Base module hierarchy of PyMDC	57
3.1   Construct and experimental designs	71
3.2   Measurements of burden and expression of PAL2-sfGFP and sfGFP	72
3.3   Flow cytometry measurements of population distributions	74
3.4   Induction times relative to uninduced culture growth rate	77
3.5   <i>In vivo</i> conversion of 4-AF to 4-ACA at 24 hours post-inoculation	78
3.6   Comparison of tet and $\sigma^{38}$ promoters	79
4.1   Biosynthesis pathway for chorismate from D-erythrose-4-phosphate (E4P)	100
4.2   Biosynthesis of 4-ACA from chorismate	102
4.3   4-AF-HCl effect on expression from 5' UTR aRED constructs	114
4.4   HCl effect on expression from 5' UTR aRED constructs	115



## List of Tables

4.1   Shikimate production data	107
4.2   Highest observed 4-AF titers for the constructs shown	111
4.3   Impact of growth temperature on 4-AF titer	112
4.4   Impact of induction time on pathway titer	113

## **Acknowledgments**

This work is the synthesis of innumerable insights and ideas, most of which were not my own. It would not have been possible without the care, resources, and time of many others, some of whom I would like to acknowledge here. I would first like to thank James Carothers, my adviser, for providing me with an amply supplied and sunny lab in which to do my work and the freedom to pursue the questions that interested me in a manner that allowed me to maintain a healthy lab-life balance. I would like to thank my labmates for creating a positive and helpful environment and for assisting me with navigating the challenges of doing rigorous lab work. I would especially like to thank Willy Voje, for our many conversations on lab and life that continually bolstered and strengthened me over these five and a half years and for encouraging my adventures in music that made these years so much more rich and exciting. I would also like to thank my fellow BioEs Andrew Wang, Blake Bluestein, Bob Lamm, David Younger, and Jon Tsui for being the most tremendous set of friends. Grad school was infinitely more fun and manageable with you all. I would also like to thank the many other people I've had the immense good fortune to call friends: Anna, Arjun, Caitlin, Claire, Eric, Jessica, Jasmin, Joe, Leandra, Leli, Stephanie, Sunny, Surya, and others. I would like to thank my family for their constant and unwavering support. Lastly, I would like to thank Christine Texeira for being the most thoughtful and supportive and funny person/girlfriend. The time we've spent together was the greatest reward to come out of grad school.

**Dedicated to my parents**

# Chapter 1 | Introduction

Part of this work (located in Section 1.1.4) was published as and reprinted with permission from:

Programming Gene Expression by Engineering Transcript Stability Control and Processing in Bacteria. Stevens JT, Carothers JM. Synthetic Biology: Parts, Devices, Applications. 2018 May. Copyright Wiley-VCH Verlag GmbH & Co. KGaA.

## Abstract

What follows is a brief overview of several topics of relevance to the work presented in this dissertation. Topics include: the production of aromatic compounds, which is the class of compounds discussed in this work; toxicity and burden to cellular hosts that arises during metabolic engineering efforts; programming gene expression in microbes; and a discussion of kinetic modeling of genetic and metabolic networks. This is followed by an overview of how this dissertation is organized.

## 1.1 | Selected Topics in Metabolic Engineering

### 1.1.1 | Introduction

Metabolic engineering seeks to harness the capacity for living systems – often microbes – to convert renewable materials, such as sugars, into valuable compounds, such as drugs or biofuels, via metabolic processes [1]. This conversion is done by a series of enzymes expressed by microbes that act like an assembly line,

converting one compound into the next until the final product is made. Microbes natively produce hundreds of enzymes and compounds, and the repertoire of possible metabolic products can be expanded by introducing new enzymes from other microbes, plants, or mammalian systems [2]. Many thousands of potential metabolic pathways have now been identified as feasible means of production in microbes. The challenge lies in improving the titer, yield, and rate of production until a bio-based manufacturing process is economically competitive with traditional, often petroleum-based, synthesis.

The last fifteen years have seen an explosion of interest and research in metabolic engineering and related areas. The time it takes to optimize a metabolic pathway has been greatly reduced due to advances in gene assembly, automation, gene expression engineering, high-throughput analysis platforms, predictive modeling, and fundamental advances in understanding the biology underpinning metabolic pathways. Yet, it can still require many person-years and millions of dollars to fully develop a novel metabolic pathway. There is still much to understand about microbial behavior, how it foils engineering efforts, and how it can be exploited or overcome.

### **1.1.2 | Producing Aromatic Compounds with *E. coli***

Aromatic monomers are attractive targets for microbial synthesis, as many aromatic polymers possess desirable properties such as high thermal resistance and mechanical strength, making them potentially useful in a wide variety of

advanced applications [3]. *E. coli* natively produces three aromatic amino acids: phenylalanine, tyrosine, and tryptophan, making it a good host for microbial production of aromatics. The metabolic pathway is largely the same for all three compounds, with a branch point at chorismate, a precursor for numerous other metabolic products in *E. coli*. This pathway is well studied and often the starting point for biosynthesis of novel aromatic compounds in *E. coli*.

Native regulation exists that needs to be overcome in order to produce high levels of aromatics, however. Expression of several enzymes in the pathway is subject to transcriptional negative feedback, whereby a transcriptional regulator binds to a product then downregulates enzyme expression. Three enzymes, which catalyze the same reaction, are also subject to feedback inhibition, whereby a downstream product inhibits the enzyme from creating more product. Both transcriptional negative feedback and feedback inhibition are used to control levels of compounds in a cell, which is helpful in natural environments but can thwart attempts to produce high levels of a compound in an engineering context. In the case of aromatic biosynthesis, the regulators TyrR and TrpR bind aromatic amino acids and tryptophan, respectively, then downregulate two different points in chorismate biosynthesis, *aroG* and *aroL*. *aroG*, *aroF*, and *aroH* (all DAHP synthases) are feedback inhibited by phenylalanine, making the reaction they catalyze a key regulatory point for the pathway. Thus, attempts to overproduce aromatics often include expressing a feedback-resistant *aroG* mutant [4], defunctionalizing or knocking out *tyrR* and *trpR*, and/or overexpressing the enzymes that are

downregulated, *aroG* and *aroL* [5]. These measures eliminate most of the negative feedback and thereby greatly increase the limit of aromatic production.

The intermediate in the *E. coli* aromatic pathway that has attracted perhaps the most attention is shikimate, a precursor to many important compounds, including Tamiflu. Using, amongst other means, the aforementioned strategies to undo native pathway regulation, yields on glucose of around 30% have been reported [6]. This work is the foundation for producing most aromatics in *E. coli*.

Of interest to our lab is a pathway for microbial production of 4-aminostyrene (4-AS), which has yet to be produced in microbes, for two principal reasons. The first is that a precursor to 4-AS, 4-aminocinnamic acid (4-ACA), is highly toxic to *E. coli*, making this pathway a potential testbed for studying the mitigation of product toxicity to host cells. The second is that an RNA aptamer exists for another precursor in the pathway, 4-aminophenylalanine (4-AF), which could be used to develop both *in vitro* RNA ribosensors and *in vivo* RNA-based genetic controllers [7], which could be used to develop genetic control systems to mitigate product toxicity. Similar pathways to the 4-AS pathway, namely, the 4-hydroxystyrene [8] and styrene [9] pathways, also note product toxicity as a hinderance to achieving higher titers.

In 2003 [10] and 2004 [11], two pathways were used to produce 4-aminophenylalanine (4-AF) in *E. coli*, albeit without the goal of optimal production. This work was later built on to develop a 4-AF pathway with a 17% yield on glucose [12]. PAL4, a phenylalanine ammonia lyase from *A. thaliana*, has been

used to convert 4-AF to 4-ACA using resting cells [13,14], and produced in growing cells to a level of 3 mg/L [15]. Thus, there is still much work to be done to create high levels of 4-ACA and 4-AS in cells.

### **1.1.3 | Toxicity and Burden in Metabolic Engineering**

While toxicity and burden can result in similar, unwanted phenotypes in engineered cells, such as poor growth and low productivity [16–18], they stem from different sources. Toxicity arises from deleterious interactions of a substance, such as a compound or protein, with microbial physiology, as an antibiotic would. Many molecules under study for metabolic pathway engineering exhibit toxicity, often at concentrations much lower than desired titers [19]. Burden arises from the load that is placed on a cell by extraneous processes, such as producing heterologous enzymes or genetic controller proteins. Both toxicity and burden can prevent cells from achieving their optimal potential as cellular factories; thus, these phenomena, and how to mitigate their effects, are active areas of study [19–21].

Much of toxicity mitigation research relates to methods for extracting the offending substance from microbes themselves or from the culture. Efflux pumps are used by microbes to expel unwanted molecules, such as antibiotics. Studies to find [22] or engineer [18,23] efflux pumps to expel toxic metabolic products-of-interest have shown promise. To remove toxic metabolites from culture, several means have been developed for chemical extraction and recovery, such as solvent layers that sequester metabolites [24,25].



Much of the focus of burden research is on the zero-sum game of resource allocation within cells. When cells are tasked with performing new functions, such as producing large quantities of enzymes, the materials and energy to perform this function necessarily come from the cellular pool reserved for robust growth and homeostasis. It is thought that ribosomes are the limiting quantity in a cell, and a simple model of ribosome allocation can predict reductions in growth rate due to overexpression of protein [16]. Including an additional simple model of nutrient/energy allocation can allow for predictions of the interplay between nutrient quality, heterologous protein expression level, and growth rate [26]. But cells do not always exist in steady-state, as these models assume, especially in a batch reactor, common in metabolic engineering. The pool of available ribosomes per cell expands as cells adjust to new media [27]; for instance, when starting a culture for an experiment or production reaction. As the ribosome concentration per cell increases, eventually plateauing as cells reach maximum growth rate, the expected cost per protein decreases. This suggests a benefit to waiting to induce cells until protein cost is lowest, and indeed delayed induction has been seen to result in more protein than earlier induction, up to a point where cells have exhausted the resources to create more protein [28–31].

Burden can be measured several ways, as burden can manifest several ways. The most common indicator of burden is a reduction in growth (e.g. growth rate or final OD600) [17,27,32,33], mostly stemming from the sequestration of growth-related resources mentioned above. Resource sequestration can be seen

more directly, however, by looking for evidence of retroactivity [34,35]. Retroactivity is the indirect effect of one process on another by using a shared resource; for example, two mRNA transcripts using the shared resource of ribosomes. A “capacity monitor,” such as the production rate of a constitutively expressed fluorescent protein, can be used to measure the burden of heterologous expression [17]. What’s more, changes in capacity correlate with changes in growth rate. By comparing how much heterologous protein is produced to how much capacity is reduced, inefficiencies can be found.

A more indirect and less well-studied means of measuring burden is to look at the cell’s stress response. It has been repeatedly observed that protein overexpression can lead to a heat-shock response [36–39], likely due to nascent polypeptide chains of heterologous protein sequestering chaperones, such as DnaK, GroEL, and GroES, which then frees the normally chaperone-complexed heat-shock sigma factor  $\sigma 32$  to mount a heat-shock response [39–42]. This heat-shock response results in, amongst other things, protease expression, which can reduce protein levels [43,44]. It is therefore possible to measure burden indirectly by monitoring heat-shock activity.

Lastly, burden can be observed indirectly by the occurrence of deleterious changes to heterologous DNA, e.g., plasmids. Because burden slows growth, cells with less burden have a fitness advantage. This allows cells with broken burden-imposing components to overtake the culture. Plasmid loss [45,46], recombination [47,48], and mutations [17,48] have all been observed in cells

expressing heterologous proteins, and are thus plausible and measurable proxies for burden.

### **1.1.4 | Programming Gene Expression of Metabolic Pathway Enzymes in *E. coli***

When engineering a metabolic pathway, the most critical choices are often those of how to express the heterologous enzymes necessary for the pathway to function. The choice, conscious or not, of promoter system, ribosome binding site, mRNA stability, copy number (and plasmid- versus chromosome-based), codon choice, time of induction, etc., all have a large effect on how many enzymes are present in cells, the stoichiometry of those enzymes, how quickly cells make the enzymes, and when cells make them. These outcomes largely determine the performance of the pathway, and so much attention must be paid to these choices. A few will be discussed here.

#### **1.1.4.1 | Promoters**

Promoters can be split into two classes: inducible and uninducible. The inducibility of a promoter is typically dependent on the presence of a transcription factor that targets that promoter. Inducer molecules bind the transcription factor and then prevent it from occluding RNA polymerase binding, allowing transcription to occur. Uninducible promoters are often constitutive, that is, always active and transcribing. But some promoters, such as those that require a non-standard sigma factor, are not always active. Sigma factors are the proteins that bind DNA and

recruit RNA polymerase. In growing cells, the most abundant sigma factor is  $\sigma 70$ , encoded by the *rpoD* gene. In cases of stress, such as heat-shock or starvation, alternative sigma factors, such as  $\sigma 32$  (*rpoH*) or  $\sigma 38$  (*rpoS*) become more abundant so as to express a suite of genes to respond to the stress. As the abundance of these sigma factors is very low during normal exponential growth, their affiliated promoters are effectively silenced until a stress condition arises.

An important aspect of the inducibility of a promoter is how it affects the timing of expression. As mentioned in Section 1.1.4, induction timing is an important consideration when optimizing a metabolic pathway, and can dramatically impact titers [49]. Inducible promoters have the advantage of offering complete control over induction timing; inducer can be added manually at any concentration at any point during culture growth. Inducer efflux may preclude precise control over induction duration [50–52], however, or necessitate additional measures to remove efflux apparatus. Though some promoters suffer from low levels of “leaky,” i.e., constitutive, expression, many are tightly controlled. The primary drawback of inducible promoters is the cost of inducer molecules on an industrial scale, which has led to research into alternative, autonomous, induction systems.

Stress-responsive promoters and quorum-sensing (QS)-based promoters (which effectively generate their own inducer, HSL) have garnered a great deal of interest. They have both been used to autonomously express pathway enzymes, and QS-based systems have been used to autonomously and simultaneously express pathway enzymes and downregulate or degrade enzyme from competing

pathways. While autonomous promoters offer the benefit of not requiring expensive inducers, they have their own drawbacks. QS-based promoters are tunable but require significant screening of variants to change the rate of HSL production and sensitivity to HSL [53]. Stress-responsive promoters are not tunable and thus require specific conditions before expression occurs. Being tuned to cellular needs, many stress promoters are weak [54] or many turn on when cells are unable to produce high levels of protein [55,56]. The more-or-less fixed induction timing of some stress promoters may be fortuitous, however. Many  $\sigma^{38}$ -based promoters turn on in late exponential phase [57], which may coincide with the optimal time to induce expression [30], and can reach high levels of expression.

#### **1.1.4.2 | Ribosome Binding Sites**

Promoters generate the mRNA transcripts, but ribosomes still need to translate the mRNA into the actual enzymes of the metabolic pathway. The primary means of controlling translation is the sequence of the ribosome binding site (RBS), where the 16S rRNA of the ribosome binds the mRNA. The RBS sequence determines the strength of this interaction, which governs the translation initiation rate and thus the overall translation rate. While there are well-used RBSs with characterized relative strengths, sequence context can change the strength of an RBS, and fine-grained adjustments may be required. The RBS Calculator [58], first introduced in 2009, generates bespoke RBS sequences to achieve desired translation rates in a

given context. The predictions it makes of RBS strength can differ significantly from expectations, however, requiring at least a small library of generated sequences to find one that matches requirements. For pathways with multiple genes, finding the “right” RBS for each gene requires full combinatorial [59], or design-of-experiment-based [60], sampling of “expression space,” i.e., the possible RBS strengths of all of the genes, to find the set of RBSs that leads to the highest titers.

#### **1.1.4.3 | mRNA Transcript Stability**

Ribosomes can only translate an mRNA for as long as its lifetime, often only a few minutes [61]. RNA is degraded through multi-step pathways that can begin as soon as a transcript has been synthesized by an RNA polymerase. Degradation of mRNA typically begins with a rate-limiting, RNase E-mediated phosphodiester bond cleavage of the mRNA. This cleavage is followed by subsequent rounds of 3' → 5' degradation [62], carried out in concert by the degradosome [63–66]. RNase E [67], an endoribonuclease, is thought to bind and process transcripts primarily via 5' entry at a monophosphorylated (5'-P) end. As transcripts are synthesized natively with 5'-PPP, it was hypothesized and then shown that 5'-P RNAs are created in cells through the removal of the gamma- and beta-phosphate from 5'-PPP RNAs [68] by RppH, an RNA pyrophosphohydrolase [69].

mRNA transcript stability is determined through the collective impact of a multitude of sequence and structural features. 5' terminus identity (i.e., 5'-PPP

versus 5'-P versus 5'-OH) and the presence of stable secondary structures within the 5' untranslated region (UTR) affect 5' end accessibility by RppH and RNase E. Active translation creates steric hindrance and ribosome occlusion that reduces internal accessibility by RNase E. 3' end accessibility by PNPase varies according to 3' UTR secondary structure, polyadenylation state, and the presence or absence of sRNAs that mediate degradation. Because RNAs can be transcribed and degraded within the space of only a few minutes, variations in transcript stability can have dramatic effects on RNA levels. This implies that gene expression can be controlled quickly by modulating the sequence and structural features that directly affect transcript stability. Several mechanisms to control transcript stability have been studied, for instance, 5' and 3' UTR hairpins [70–74], 5' UTR cleavage [7], and antisense RNA/small RNA binding [75–79].

#### **1.1.4.4 | Dynamic Control of Gene Expression**

Generally, choices of promoters, RBS, transcript stability, and other factors, result in an open-loop system. Open-loop systems do not contain explicit feedback loops. The system components must be tuned just-so in order to achieve the desired result. In contrast to this are closed-loop systems, which do contain feedback loops, and, therefore, sensors and actuators to implement the feedback. Closed-loop systems in a metabolic engineering context are typically referred to as dynamic control systems. The goal of most published dynamic control systems is to balance pathway enzyme levels and/or to control levels of a toxic metabolite to

minimize its product toxicity. This is implemented with a sensor to detect a relevant metabolite and an actuator to downregulate a relevant enzyme. Commonly, the sensor and actuator are the same thing, namely, a transcription factor that can bind a metabolite and downregulate a promoter controlling enzyme expression.

Most examples of dynamic control systems have been deployed in fatty acid biosynthesis [32,80,81], as two transcription factors, FadR and FapR, have been found to respond to the fatty acid precursors fatty acyl-CoAs and malonyl-CoA, respectively. These control systems operate by putting pathway enzymes under control of these metabolite-regulated promoters. When the metabolite-of-interest is produced at a sufficient quantity, the promoters are expected to be up- or down-regulated in order to either balance enzyme levels or reduce product toxicity. While all of these papers report increases in titer with the introduction of control systems, levels of the regulated enzymes are not reported, making it impossible to know if the dynamic control systems operate as intended. All increases in titer could potentially be attributed to changing promoter strengths of these regulated promoters; that is, all strain comparisons have different promoters, and it is unclear if the strengths of these promoters are the cause of the titer improvement. Another dynamic control system, where a pinene-sensitive transcription factor controls expression of an efflux pump to expel pinene and increase tolerance, does not contain direct evidence that the efflux pump expression is being dynamically changed due to feedback regulation. Like the



aforementioned papers, it relies on promoter engineering and its results can potentially be explained by promoter strengths alone. Thus, more rigorous quantification of the relationship between the levels of negative regulator, its target, and the molecule being sensed is needed to better understand how these systems function. Indeed, the field is in need of a demonstration that dynamic control can function on the time-scale of a typical batch culture, and moreover that it can outperform static control by some metric. Furthermore, it is not clear that tuning the expression of dynamic control components is inherently any easier than tuning the expression of the regulated enzyme. In fact, it may be better to engineer static expression to reach a set-point than to overshoot and require dynamic control to reach a set-point.

The label of “dynamic control” can also apply to work that utilizes stress-responsive promoters to regulate pathway enzyme levels [82–91]. In these cases, there is typically no feedback, and hence they are not closed-loop systems. They therefore are implemented with different goals in mind. Typically, the benefit arises from the system creating a two-stage fermentation, meaning that induction is delayed until late exponential phase, allowing cells to grow without the burden of expressing pathway enzymes. The dynamic control often stems from the use of stress-responsive promoters: these promoter systems wait until some stressor is present, such as starvation or heat-shock, to produce enzymes. As with the aforementioned closed-loop systems, it is often unclear in these studies how much promoter strength contributes to the improvement seen. The comparisons are

insufficient to rule out the possibility that the autonomous promoter is better because it makes more protein than the manual induction control, and thus the dynamics are unimportant. In one study that did track protein levels, this seems to be the case [83].

Similarly, “dynamic control” often contains work that uses quorum-sensing (QS) components to autonomously turn on pathway enzyme expression. The goal is the same as with stress-responsive promoters, but the mechanism is slightly different. In this case, cells express an enzyme to make a small molecule, e.g., HSL, that can diffuse to other cells in the culture. An HSL-responsive transcription factor, e.g., LuxR, responds to HSL by not binding its associated promoter, allowing for pathway enzyme expression. Thus, as cells accumulate HSL, by both producing it and importing HSL from other cells, pathway expression increases. By controlling levels of the HSL-producing enzyme and the HSL-responsive transcription factor, the system can be tuned to turn on at different points during culture growth. Several groups have used QS components to autonomously express enzymes [91–96]. Other groups have gone a step further to not only express enzymes, but to also downregulate competing pathways in order to redirect flux to their pathway [53,87,97].

### **1.1.5 | Kinetic Models of Metabolic Pathway Gene Expression**

Models are used in synthetic biology and metabolic engineering for many reasons. They can suggest hypotheses and predict experimental outcomes to guide

experimental efforts. This can reduce labor costs by reducing the number of experiments that need to be performed and eliminating dead-end lines of inquiry. They can also be used to evaluate current understanding of a system, by integrating current knowledge into a model and assess its predictive capacity.

In metabolic engineering, models are often used to evaluate flux using flux-balance analysis (FBA). FBA models are linear systems of reaction stoichiometries, the fluxes of which are optimized for growth. This enables predictions of how adding or removing reactions affects flux in a metabolic pathway. However, these models are steady-state and time-invariant and thus cannot capture dynamic processes, such as genetic feedback networks.

In synthetic biology, models are often used to study dynamic processes in genetic networks. The models tend to be comprised of systems of deterministic ordinary differential equations that describe how species such as proteins and mRNAs change over time. By solving these systems, the behavior of a complex genetic network over time can be evaluated by studying the behavior of its constituent species.

A crucial choice in modeling a system is determining the complexity of the model, i.e., how realistic versus how abstract. While realistic, or mechanistic, models can potentially better capture the real-world behavior of a system, they involve large numbers of species and reaction rates, and it may be impossible to find reliable reaction rates in many cases. Abstract models can provide a parsimonious reflection of system behavior, but it can be impossible to relate

model parameters to real-world biological processes. Thus abstract models and mechanistic models can serve different purposes. Abstract models can be used to understand system dynamics, while mechanistic models can be used for more fine-grained analysis of parameters that have a real-world counterpart. Mechanistic models that accurately reflect system behavior can thus be useful for informing engineering decisions. For instance, if simulations show that a behavior only occurs with transcription factors with a certain range of binding energies, this would lead researchers to using transcription factors with that characteristic in their system. It should be noted that many aspects of genetic systems are not easily tunable, so it may be difficult or impossible to do what a model suggests would improve a system.

For systems of differential equations that cannot be solved, parameter sampling can provide an accurate picture of the system's behavior. The parameter space can be constrained to physiologically relevant ranges, such as the span of reported measurements from the literature. This allows attention and computational resources to be focused only on the subset of model input-output space that is relevant for engineering.

## 1.2 | Dissertation Organization

This document is organized into five chapters. The first chapter (this chapter) is an overview of topics relevant to the subsequent chapters, intended to establish a foundation of literature and ideas that supports the work that was done.

The second chapter, “Computational Analysis of Genetic Control Systems for Metabolic Pathway Engineering,” is primarily a published research article on the subject of analyzing kinetic models of genetic feedback control systems acting on a metabolic pathway. The goal of this work was to evaluate the potential for RNA-based feedback control systems to regulate metabolic pathway enzyme levels to mitigate product toxicity and thereby improve titers.

The third chapter, “Programming Enzyme Expression Dynamics to Reduce Cellular Burden and Improve Expression and In Vivo Catalysis,” is a research article that examines the burden imposed by a particular enzyme, the origins of that burden, and how burden can be mitigated by using autonomous promoters and by programming expression dynamics. There is a novel focus on expression dynamics with respect to burden, which is enabled by using a fluorescent protein fusion of the enzyme under study. The paper suggests strategies for improving production from metabolic pathways.

The fourth chapter, “Production of 4-aminocinnamic Acid from Glucose in *E. coli*,” is work toward building a pathway for producing 4-aminocinnamic acid (4-ACA) in *E. coli*, which could serve in the future as a testbed pathway for studying both product toxicity and enzyme expression burden.

The fifth and last chapter consists of overall conclusions and a discussion.

# Chapter 2 | Computational Analysis of Genetic Control Systems for Metabolic Pathway Engineering

Part of the work in this chapter (Sections 2.1-2.4) is adapted and reprinted with permission from:

Designing RNA-based genetic control systems for efficient production from engineered metabolic pathways. Stevens JT, Carothers JM. ACS Synth Biol. 2015 Feb 20;4(2):107-15. Copyright 2015 American Chemical Society.

## Abstract

Engineered metabolic pathways can be augmented with dynamic regulatory controllers to increase production titers by minimizing toxicity and helping cells maintain homeostasis. We investigated the potential for dynamic RNA-based genetic control systems to increase production through simulation analysis of an engineered *p*-aminostyrene (*p*-AS) pathway in *E. coli*. To map the entire design space, we formulated 729 unique mechanistic models corresponding to all of the possible control topologies and mechanistic implementations in the system under study. 2,000 sampled simulations were performed for each of the 729 system designs to relate the potential effects of dynamic control to increases in *p*-AS production (total of  $3 \times 10^6$  simulations). Our analysis indicates that dynamic control strategies employing aptazyme-regulated expression devices (aREDs) can yield >10-fold improvements over static control. We uncovered generalizable trends in successful control architectures and found that highly performing RNA-based

control systems are experimentally tractable. Analyzing the metabolic control state space to predict optimal genetic control strategies promises to enhance the design of metabolic pathways.

## **2.1 | Introduction**

Metabolic pathways found in natural systems have evolved complex control circuitry that responds dynamically to chemical and physical inputs to actuate genetic regulatory functions, minimize the buildup of toxic intermediates, and maintain homeostasis [98]. Many pathways that are targets for metabolic engineering contain: cytotoxic intermediates; metabolites that are inadvertently lost from the cell; or enzymes or proteins whose overexpression depletes metabolic resources, generates toxic compounds, or otherwise have deleterious effects on cellular physiology [99]. Constructing chemically-responsive genetic systems to solve control problems in engineered metabolic pathways could therefore lead to optimized production titers [25] of industrially- and medically-relevant compounds in microbial hosts.

In principle, there are a number of regulatory mechanisms that could be applied to solve pathway control problems and enable high levels of production. In seminal work, Farmer and Liao engineered a dynamic controller comprised of a promoter and its associated transcriptional activator, which induces transcription in conditions of excess flux, reducing toxic metabolic intermediate (acetate) accumulation and improving final titers of lycopene [82]. More recently, a fatty



acid/acyl-CoA-inducible transcriptional repressor (TR), FadR, was used to program enzyme expression levels in response to high levels of fatty acyl-CoA, minimizing the buildup of toxic intermediates and increasing Fatty Acid Ethyl Ester (FAEE) biodiesel production [80]. In the latter case, simulation analysis identified a broad range of genetic control parameter values under which the dynamically-regulated system was expected to generate higher levels of FAEE than a comparable system of static controllers. Elsewhere, modeling has shown that dynamic control of efflux pump expression [22] can expand the functional design space by removing toxic intermediates or products from cells more effectively than pump expression under static control [100].

An RNA-based approach for constructing sensors (e.g., ligand-responsive aptamers) and actuators (e.g., catalytic ribozymes) to control mRNA transcript stability may obviate the need to rely on pre existing genetic components and increase the speed and efficacy with which dynamic control systems can be constructed [Stevens and Carothers 2018]. *In vitro* selection [101] can be used to select aptamers that bind in physiological conditions to a variety of target ligands. Using these aptamers, catalytic ribozymes with activities that are responsive to desired metabolites (aptazymes) can be generated and further assembled into dynamic regulators (sensor-actuators) of gene expression in bacteria, yeast, and mammalian cells [7,102,103]. Aptazymes and other aptamer-based RNA components have been used as pathway biosensors to implement higher-order functions [104], for *in vivo* enzyme evolution [103], and for screening metabolite-producing strains

[105]. Building on this work, model-driven processes were developed for engineering aptazyme-regulated expression devices (aREDs) [7], to produce quantitatively-predictable genetic outputs in *E. coli*. In these devices, *cis*-aptazyme cleavage within the 5' UTR results in a programmable increase in mRNA half-life in response to a target ligand (Fig. SI.2.1). Because aREDs can be readily built from component parts separately generated and characterized, it may be possible to engineer and then combine multiple genetic devices to give predictable systems-level functions. If so, fundamental questions about the space of genetic control system architecture designs and the corresponding functions may then become accessible to experiment, including: 1) the effect of increasing the complexity of control systems, 2) the degree to which the desired architectures can actually be implemented using RNA-based genetic controls, and 3) whether formal processes can be developed for identifying design specifications.


To begin to address these long-term questions, and better understand the space of potential designs for RNA-based genetic control systems, we are engineering an RNA-regulated *p*-aminostyrene (*p*-AS) production pathway in *E. coli* (Fig. 2.2.1a). *p*-AS is an industrially-relevant vinyl aromatic monomer with properties amenable to advanced applications in photonics, photolithography, and biomedicine [106]. Cytotoxicity of intermediates in production pathways have made substituted styrenes, like *p*-AS, challenging to produce in microbes[8]. Production of *p*-AS in *E. coli* therefore offers an excellent test case for demonstrating the utility of genetic control systems. The pathway enzymes and metabolic products are

well-defined, and it provides control problems to address to optimize titers (Fig. 2.2.1, in blue). These problems include an intermediate, *p*-AF, leaking from cells [7]; another intermediate, *p*-ACA, exhibiting cytotoxicity (Fig. SI.2.2a); L-amino acid oxidases (LAAOs) potentially depleting the aromatic amino acid pool and creating hydrogen peroxide as a byproduct; and efflux pump overexpression (for *p*-ACA removal) also generating toxicity (Fig. SI.2.2b).

Although flux balance analysis [107] and metabolic control analysis [108] can be used to study metabolic pathways and control systems, results obtained with those methods can be difficult to formulate in terms of kinetic parameters for the genetic components needed to build the system. Elsewhere, the importance of developing new formalisms to relate network topology and kinetic parameters in engineered circuits has been noted [109]. To maximize engineering tractability, the challenge is to create approaches for mapping potential design space inputs to production outputs in terms of measurable and tunable kinetic parameters. These parameters can then be associated with specific genetic components required for building metabolic control systems.

Our approach is to overlay a dynamic control layer onto an engineered metabolic pathway and sample kinetic parameters to identify functional control architectures that improve production. Specifically, we automated the generation of coarse-grained mechanistic models for 728 unique control architectures. To sample the underlying design space and account for parameter uncertainty within each of the 728 control architectures, we computed the *p*-AS production yields

expected with dynamic control for 2,000 unique parameter instances, for a total of  $1.5 \times 10^6$  solutions. The impact of dynamic control on *p*-AS production was evaluated by comparison to parameter-matched systems comprised only of static control functions (i.e., those that could be obtained with promoter [110], RBS [111], or ribozyme-regulated expression device [7] (rRED) tuning). We discovered control architectures that dramatically increase the likelihood of generating high *p*-AS production and show that the choice of mechanistic implementation may be important for effectively coordinating the stoichiometries of intermediates, enzymes, and efflux pumps. Moreover, we find that large improvements in *p*-AS yield are within reach of currently-achievable controller component specifications and expect that the approach described here will be useful for driving the design of functional metabolic production systems.



**Figure 2.1.** Engineered *p*-aminostyrene (*p*-AS) pathway and control system design space. A) The proposed pathway includes optimized modules for converting glucose to chorismate (steps 1-9) [112], along with the PapABC operon from *Streptomyces venezuelae* and an *E. coli* deaminase to convert chorismate to *p*-aminophenylalanine (*p*-AF, steps 10-13) [10]. *p*-AF is converted to *p*-aminocinnamic acid (*p*-ACA) via an L-amino acid oxidase (LAAO, step 14) and *p*-ACA export occurs via an efflux pump (step 15), after which it can be converted to *p*-AS (step 16). Blue and green dashed lines indicate sensing functions, responsive to metabolites, and orange dashed lines indicate actuation functions using aptazyme-regulated expression devices [7] (aREDs) as genetic controllers to integrate the sensing information. B) There are a total of 729 ways to control the system with four actuators and two sensing molecules (*p*-AF and *p*-ACA), which comprises the control system design space. To map the effect of control on *p*-AS production, unique models were created for all 728 dynamic architectures (the 729<sup>th</sup>

is all static control) and the outputs from each were simulated 2,000 times with Latin Hypercube-sampled parameter instances, along with 2,000 parameter-matched static control reference instances.

## 2.2 | Methods

### Modeling

p-AS production systems were modeled as sets of deterministic ordinary differential equations (ODEs). All 728 architectures were automatically generated as PySCeS [113] v. 0.9.0 model files using custom Python scripts to write models in the PySCeS modeling language. Models were comprised of mechanistic differential equations described in Fig. 2.2 and S. I. Table 1. Incorporating the control problems into the model was achieved by adding a first-order loss reaction for p-AF and introducing a toxicity term into the model that placed a general fitness disadvantage on cells by slowing all non-degradation and dilution reaction rates [80]. The value of this toxicity term (see S. I. Table 1) was dynamically dependent on the concentration of p-ACA, LAAO, and efflux pump. Toxicity coefficient ranges were modeled so that p-ACA slows growth by half at ~10 mM (Fig. SI.2.2), and so that the efflux pump and LAAO slow growth when present in the thousands of molecules range.

Two full sets (one static and one dynamic) of model reactions for the best Core Topology 12 architecture are in the S. I. materials, along with four parameter sets for instances with relative yield performance ranked 1<sup>st</sup>, 50<sup>th</sup>, 1000<sup>th</sup>, and 1950<sup>th</sup>.

A data chart with final relative yield values and statistics is also provided.

For time-course simulations (Fig. 2.6 and Fig. SI.2.7), data were collected from simulations of the architecture (270) of Core Topology 12 with the highest median  $Y_{rel}$ , using the parameter set from the best instance (highest  $Y_{rel}$ ) of that architecture (see Fig. 2.5). All parameters except the three aRED LARs were kept constant, and the aptazyme ligand-activation ratios (LARs) were all set to 1, 5, and 100 and the models re-evaluated.

### Simulation

Models were simulated on the University of Washington Hyak Computing Cluster using custom software for set-up and analysis. Models were simulated to 48 h, the length of a typical batch reactor run, using the LSODA ODE [114] solver packaged with PySCeS v. 0.9.0.

### Yield Calculations

Yield ( $Y$ ) on glucose for an architecture instance was calculated by summing internal (int) and external (ext) p-ACA molecule counts ( $N_{p-ACA,int}$  and  $N_{p-ACA,ext}$ ) and dividing that by the total number of chorismate molecules ( $N_{chor}$ ) produced:  $Y = (N_{p-ACA,int} + N_{p-ACA,ext}) / N_{chor}$ . Relative yield ( $Y_{rel}$ ), for static or dynamic cases, is  $Y$  divided by the median relative yield value of all static controllers:  $Y_{rel} = Y / \text{Median}(Y_{static})$ . Note that, for the purposes of this study, p-AS is used

interchangeably with p-ACA, as the conversion is extracellular.

### Parameter Sampling

Parameters were sampled using the Latin Hypercube Sampling [115] method from uniform distributions centered around nominal values gathered from the literature. Latin Hypercube Sampling aims to approximate an output distribution with fewer inputs by dividing up input space and sampling within the divided regions. This makes it less likely that large regions of input space will go unsampled. Ranges for the sampling, and sources for nominal values, are given in S. I. Table 1. The sampled parameter sets were generated using the lhs method in the lhs package for R.

### Statistical Analysis

Mann-Whitney testing was performed in R using the wilcox.test method. The Mann-Whitney test is a non-parametric statistical test with the null hypothesis that the two populations being tested are from the same distribution. All tests had a one-sided alternative hypothesis of one population being greater than the other. Two-sided Spearman Rank Correlations were performed in R using the cor.test method. Spearman Rank Correlation is a non-parametric statistical test that assesses the monotonicity of the relationship between two variables. One-way ANOVA was performed in R using the lm and anova methods. ANOVA is a statistical test that compares the differences between group means to determine the likelihood of data originating from the same distribution. The null hypothesis is that



the data are from the same distribution.

### Experimental Measurements of Toxicity




An overnight culture of *E. coli* MG1655 was inoculated 1:100 into fresh MOPS EZ (Teknova) media and allowed to reach an OD600 of 0.1. 200  $\mu$ l of culture was then placed into wells of a black 96-well plate with a clear bottom (Corning) and amounts of inducer or *p*-ACA (in DMSO) were added to cultures. Final DMSO concentration in media (vol/vol) was kept at or below 2% to avoid DMSO toxicity. The plate was then placed into a Tecan M1000 plate reader with orbital shaking at 37 C for 12 hours. OD600 measurements were taken every 10 minutes.

## **2.3 | Results and Discussion**

We first formulated a genetic control framework for the *p*-AS pathway (Fig. 2.2.1) consisting of three control nodes, where a node is defined as a possible target of positive or negative dynamic regulation. These three control nodes were chosen to be genetic expression of 1) the Pap operon enzymes (PapA, PapB, and PapC) that convert chorismate to *p*-AF, controlling pathway flux; 2) the LAAO that converts *p*-AF to *p*-ACA, producing a toxic intermediate; and 3) the efflux pump that exports *p*-ACA from the cell. The total number of potential ways of regulating these three nodes, that is, positive, negative, or no dynamic regulation, comprise the control state space. (Note that there are 27 combinations, or core topologies, with the 27<sup>th</sup> being no dynamic regulation at any node.) Two different ligands were examined as

sensing metabolites, and four different genetic regulatory mechanisms were examined as potential means of implementing actuation, at each node (see Fig. 2.2 for mechanistic details). Altogether, the combinations of sensors and actuators lead to 729 distinct architectures for creating a control system (Fig. 2.2.1b).

While aREDs can be fashioned into positive or negative actuators, we reasoned that coupling dynamic aREDs with transcriptional repressors (TRs) or translation-repressing sRNAs could result in composite devices with enhanced functions compared to aREDs alone. Composite devices have not been built experimentally; however, the individual components have been used with success [7,78,116], and it is expected that composite devices are experimentally tractable. We thus investigated one positive actuator and three negative actuators, two of which are composite devices. As positive actuators, aREDs were employed where ligand-binding increases genetic output by extending mRNA half-life, increasing target mRNA levels relative to the basal level (aRED<sup>ACT</sup>, controller C1; Fig. SI.2.1). Controller C2 generates negative actuation because ligand-binding represses aptazyme cleavage activity that would otherwise increase mRNA half-life (aRED<sup>REP</sup>; Fig. 2.2, in red; Fig. SI.2.1). Controller C3 is a composite device for negative actuation where ligand-binding activates aptazyme cleavage which programs an increase in the half-life of an sRNA engineered to inhibit translation from a target mRNA (aRED<sup>ACT</sup>-sRNA; Fig. 2.2, in blue). Controller C4 is a composite device for negative actuation where ligand-binding activates aptazyme cleavage, increasing the mRNA half-life of a transcriptional repressor (aRED<sup>ACT</sup>-TR; Fig. 2.2, in orange).




**Figure 2.2.** Mechanistic model and genetic control mechanisms. Reactions in the red module correspond to aptazyme-regulated expression device (aRED) function. aREDs program genetic expression through ligand-responsive aptazyme cleavage in the 5' UTR that increases RNA half-life by selectively removing the binding target of RppH-mediated degradation [68] (Fig. SI.2.1). Reactions in the orange module correspond to transcriptional repressors (TR) where binding operator regions in target promoter sequences downregulates transcription initiation [117]. Reactions in the blue module describe a small RNA (sRNA) mechanism that represses translation by binding a complementary sequence of a target mRNA near the ribosome binding site or start codon and inhibiting ribosomal interactions [118]. The blue or orange modules can be combined with a red module (controller C1: aRED<sup>ACT</sup> or C2: aRED<sup>REP</sup>) to create an aRED<sup>ACT</sup>-sRNA controller (C3) or an aRED<sup>ACT</sup>-TR controller (C4). Small orange circles represent ligand; A and B represent chemicals. Rate constants are drawn beside arrows. S.I. Table 1 gives full descriptions, mathematical expressions, and ranges for the sampled rate constants.

We determined architecture performance by creating 728 unique coarse-grained biochemical models (Fig. 2.2), corresponding to each possible dynamic control architecture (see Methods). Each of these 728 models was evaluated 2,000 times with Latin-hypercube-sampled [115] parameter values constrained to biochemically plausible ranges (S. I. Table 1). Each of these 2,000 parameter sets is referred to as an instance of that architecture. Models were formulated to emphasize measurable and tunable kinetic design parameters. Sampling parameter values thus allows exploration of the design space, in the case of tunable parameters, and additionally accounts for parameter uncertainty within the cell in the case of non-tunable parameters. For each architecture instance, i.e., parameter set, the yield on glucose was computed (see Methods). Yields were then normalized to the median yield for static controllers to arrive at relative yield ( $Y_{rel}$ ).

Yield comparisons are thus relative to static control, which contains no dynamic regulation, though parameters still vary by sampling.

To broadly ascertain how dynamic control can influence production, distributions of relative yields for all of the parameter sets were analyzed. The distribution of  $Y_{rel}$  for the full set of dynamic control architecture instances shows a wide range of production levels relative to static control levels, a large portion of which is worse than static control (Fig. 2.3). However, 137 out of the 728 (~19%) architectures have median  $Y_{rel}$  greater than one, and expected  $p$ -AS production from the top 5% of architectures is almost three times higher than that of comparable systems with only static control. While a subset of the static control parameter sets can produce results comparable to the best dynamic controllers, as evidenced by comparing the largest  $Y_{rel}$  values for dynamic and static control (Fig. SI.2.3), the distributions of highly-performing controllers are shifted toward higher  $Y_{rel}$ . Taken together, these results show that dynamic control can greatly increase the likelihood of obtaining high  $p$ -AS production yields across the space of system architectures that we studied.




**Figure 2.3.** Relative production yields across the entire design space.  $\log_{10}$  relative yields ( $Y_{rel}$ ) are plotted for all static control parameter instances (top), all dynamic control parameter instances (middle), and all instances for architectures with median  $Y_{rel}$  in the top 5% (i.e.,  $Y_{rel} > 2.11$ ). The vertical red line denotes median  $Y_{rel}$  within a set. Black shading indicates the  $Y_{rel}$  95% confidence interval. As depicted at right, static control systems have no sensing and no actuation, while there are 728 possible combinations of sensing and actuation functions defining the set of dynamic control system architectures under study.

We then investigated whether dynamic control system performance can be understood at the level of core topology, or the set of actuator functions combined across the three nodes. All 728 dynamic control architectures were grouped according to the 26 distinct core topologies (Fig. SI.2.4) and we then evaluated the performance of the control architectures as a set. For example, Core Topology 1 (CT 1) consists of the 12 architectures corresponding to all the possible combinations of sensor targets and controllers that can lead to positive actuation at Node 1, negative actuation at Node 2, and no actuation at Node 3. Predicted  $p$ -AS

production varies dramatically between core topologies, as indicated by median  $Y_{rel}$  values that span more than two orders of magnitude (Fig. 2.4). Notably, several of the core topologies have both high  $Y_{rel}$  and only small variations in the midrange, or 1<sup>st</sup> to 3<sup>rd</sup> quartile, of the  $Y_{rel}$  values, indicating that most of the architectures in those core topologies enable high levels of production (Fig. 2.4, blue points at bottom right). Combined, these results are consistent with the idea that there are regions of the dynamic control design space defined by the core topologies that reliably outperform systems with only static controllers.

Variation in performance among the architectures within a core topology can be almost as large as the variation between core topologies, where nearly 100-fold differences in  $Y_{rel}$  at the midrange are observed in some cases (Fig. 2.4, upper points). For example, Architecture 270 (Arch 270) within CT 12 (Fig. 2.4, labeled) has the second-highest median  $Y_{rel}$  (3.6) out of 728 architectures examined, even though the median relative yield for CT 12 itself is only 0.7. Thus, although classifying control system architectures according to core topology can help identify high- and low- performing system designs, core topology alone does not fully-determine production yields.



**Figure 2.4.** Performance of core topologies. Each circle corresponds to all of the architectures within a given core topology. Placement on the horizontal axis indicates the median relative yield ( $Y_{rel}$ ) of all instances of the core topology. Placement on the vertical axis indicates the  $\log_{10}$ -difference of the 25<sup>th</sup> to 75<sup>th</sup> percentile range of architecture  $Y_{rel}$  (i.e., the inter-quartile range). Color denotes the 95<sup>th</sup> percentile  $Y_{rel}$  for architectures within the core topology. Core Topology 12 is identified by call-out (see text).


We can begin to understand how variation in expected yields within a core topology arises by examining architecture-level details. For instance, there are 24 different architectures in CT 12, all with aRED-mediated positive actuation at Nodes 1 and 3, and negative actuation at Node 2. However,  $Y_{rel}$  for the best CT 12 architecture (270) is 20-fold higher than for the worst architecture (266) (Fig. 2.5). Arch 270 and Arch 266 employ different Node 2 actuation mechanisms and have very different sets of sensing metabolite-actuator linkages. As a result, significant differences in *p*-AS production across the sampled parameter spaces are observed



(Mann-Whitney  $W = 3.7 \times 10^5$ ,  $P < 2.2 \times 10^{-16}$ ). One-way ANOVA shows that the type of controller employed for negative actuation at Node 2 has a significant impact on  $p$ -AS production within CT 12 ( $F = 435.4$ ,  $P < 2.2 \times 10^{-16}$ ). For CT 12 architectures with C2 controllers (aRED<sup>REP</sup>), more than 22% (3,611 out of 16,000) of the simulated parameter instances gave high-performing production yields better than 95% of the static control system instances. In contrast, for CT 12 architectures with controllers C3 (aRED<sup>ACT</sup>-sRNA) and C4 (aRED<sup>ACT</sup>-TR) at Node 2, only 4.1% and 0.42% of the parameter instances, respectively, resulted in predicted  $p$ -AS levels at the 95<sup>th</sup> percentile of static control system production.

Interestingly, within the CT 12 architectures, Node 2 controllers with high levels of repression appear to have deleterious effects on production (Fig. SI.2.5). For C3 controllers, there is a negative correlation (Spearman rank correlation coefficient,  $R_s = -0.38$ ,  $P < 2.2 \times 10^{-16}$ ) between  $p$ -AS production and the sRNA-target mRNA association rate, the latter being a design variable directly increasing translation repression in the model. Similarly, for C4 controllers, tighter TR-DNA binding results in less  $p$ -AS production ( $R_s = -0.71$ ,  $P < 2.2 \times 10^{-16}$ ) across a range of TR  $k_d$ s similar to those reported for the well-known Lac repressor (LacI-DNA  $k_d \sim 10^{-7}$  to  $10^{-9}$  M [119]). Counter-intuitively, these data show that actuators with strong repression characteristics are not always well-suited to the problem of implementing negative feedback in this system. Instead, the choice of controller may be important for creating fine-grained modulation that can mitigate regulatory problems while maintaining high levels of flux through the pathway.

To confirm that the observed differences in predicted *p*-AS production are caused by the dynamic control layer, we simulated production for the 24 CT 12 architectures with deactivated aREDs. The design variable for aptazyme folding, needed for ligand-responsive cleavage, was set to zero and  $Y_{rel}$  was re-computed for all the CT 12 architectures with the same 2,000 parameter instances as before (Fig. SI.2.6). Over the entire design space,  $Y_{rel}$  values obtained with deactivated aptazymes are lower than for actuators with functional controllers, indicating that dynamic, ligand-responsive control is needed for highest performance (One-Way ANOVA  $F = 1914$ ,  $P < 2.2 \times 10^{-16}$ ). Similarly, for the best-performing CT 12 architecture (Arch 270), predicted *p*-AS production with functional aptazymes is significantly better than when the controllers are disabled (Mann-Whitney  $W = 2.9 \times 10^6$ ,  $P < 2.2 \times 10^{-16}$ ). These results suggest that aRED-mediated dynamic control is responsible for the improvements in production obtained relative to systems comprised only of static controllers.




**Figure 2.5.** Relative production yields for Core Topology 12 (CT 12). CT 12 comprises the entire set of architectures that effect positive actuation on Nodes 1 (PapABC operon) and 3 (Efflux Pump), and negative actuation on Node 2 (LAAO). Shown are  $\log_{10}$  relative yields ( $Y_{rel}$ ) alongside a schematic for all CT 12 instances (top), all instances for the CT 12 architecture (266) with the lowest median  $Y_{rel}$  (middle), and all instances for the CT 12 architecture (270) with the highest median  $Y_{rel}$  (bottom). The vertical red line denotes median  $Y_{rel}$  within a set. Black shading indicates the  $Y_{rel}$  95% confidence interval.

Because aRED function is central to the connection between dynamic sensing and actuation, we examined the feasibility of engineering aptazymes that can meet component specifications needed for high-performing systems. As previously described [7], aptazyme ligand-activation ratio (LAR), or cleavage rate in the presence versus absence of ligand (i.e.,  $k_{obs+}/k_{obs-}$ ), has a significant impact on aRED genetic output. In fact, differences in LAR and transcript half-life have been shown to account for as much as 85% of the variation in relative ligand-responsive


expression [7]. *p*-AF-responsive aptazymes with LARs of ~5-6 have been successfully engineered [7], and aptazymes responsive to other molecules with LARs >100 have been characterized [120]. New methods that combine kinetic RNA folding design, *in vitro* selection [121,122] and *in vivo* screening [123] should enable the rapid generation of *p*-ACA aptazymes with similar LARs.

Notably, for aRED controllers with aptazyme LAR = 5 (see Methods), predicted *p*-AS production from the best-performing CT 12 architecture (270) is almost 6 times higher than for static controllers and 3 times higher than for controllers without ligand-responsive actuation (i.e., LAR = 1). When LAR = 100, predicted *p*-AS yields are 16 times greater than for systems with static control (Fig. 2.6; Fig. SI.2.7). As expected [124], positive feedback results in faster rise times to steady-state for genes expressed from Nodes 1 (*pap* operon) and 3 (efflux pump operon), with the slopes of the rise increasing 4-8 times as the LAR increases from 1 to 5 to 100. Negative actuation at Node 2 results in the downregulation of LAAO expression as a function of time, with the degree of repression increasing along with aptazyme LAR. Overall, we can see that the aRED-mediated controllers program outputs from each node in response to changing sensor inputs (*p*-ACA concentrations), with the net effect of lowering steady-state chorismate concentrations and increasing *p*-AS production. The fact that even aptazymes with modest LARs can enable substantial increases in *p*-AS production highlights the potential for engineering aRED-based systems to dramatically-improve metabolic pathway function.

a)




b)



**Figure 2.6.** Dependence of relationship between sensor input and node output on aptazyme ligand-activation ratio. A) The predicted level of sensor input ( $p$ -ACA) and outputs (i.e., folded proteins) for each of the three nodes in the CT 12 Arch 270 system are plotted, as a function of time, relative to parameter-matched systems of static controllers. B) The relative levels of initial input (chorismate) and final output ( $p$ -AS) are plotted as a function of time. Colors indicate the modeled aptazyme ligand-activation ratio or the cleavage rate in the presence versus the absence of ligand ( $k_{obs+}/k_{obs-}$ ) specified for the aRED controllers in the system.


## 2.4 | Supplementary Information

Note: some supplementary information is omitted here (Fig. SI.2.4, Table SI.1, Chart SI.1, Equation CSVs, and Parameter CSVs) due to size and format constraints. Please see the published work for these materials.




**Figure SI.2.1.** Pictorial representation of aRED function. Non-cleaved, that is, most, mRNA is terminated with a 5'-PPP, and is subject to RppH-dependent dephosphorylation to a 5'-P, which enables RNase E-mediated degradation. Aptazyme cleavage leads to a 5'-OH, which is not recognized by RppH. Degradation therefore occurs via a slower RppH-independent mechanism and half-life of the mRNA increases, leading to increased expression<sup>1,2</sup>. This is similar in function to the *glmS* ribozyme<sup>3</sup>, though with the opposite outcome. Aptazymes can be designed so that ligand binding leads to either higher or lower levels of cleavage than the basal rate. If ligand binding leads to higher levels of cleavage, then  $k_{obs+}/k_{obs-} > 1$  and this is

an aRED<sup>ACT</sup> device. If ligand binding leads to lower levels of cleavage, then  $k_{obs+}/k_{obs-} < 1$  and this is an aRED<sup>REP</sup> device.




**Figure SI.2.2.** Toxicity data for p-ACA and AcrAB efflux pump. A) p-ACA inhibits *E. coli* MG1655 growth when added to the extracellular media at increasing concentrations. Ribbon bands around the lines indicate standard error from six experimental replicates. B) AcrAB efflux pump expression inhibits *E. coli* MG1655 growth when expressed highly. AcrA and AcrB genes were under control of a lacUV5 promoter and expression induced with IPTG.

A)




B)




**Figure SI.2.3.** Dynamic controller performance at the highest end of the relative yield distribution. A) Relative yield values for all architecture instances for dynamic control and static control were sorted and the top 1000 values were plotted against each other (note: these are not parameter matched). This illustrates that nearly all of the space of top relative yield values reachable by dynamic control are also reachable by static control. B) The highest ten relative yield values for an architecture instance are shown, with the relative yield value on the vertical axis and the relative yield ratio with respect to parameter-matched static control on the horizontal axis. Color denotes the architecture of the instance.




A)




B)



**Figure SI.2.5.** The relationship between binding parameters and negative actuator performance. Scatterplots are shown of A) relative yield values versus sRNA duplex formation rates for a single Core Topology 12 architecture, B) relative yield values versus TR-DNA kd for a single Core Topology 12 architecture. Trend lines were generated using the default generalized additive model method implemented using the `stat_smooth` function from `ggplot2`. The trend lines indicate that weaker binding characteristics of the negative regulators are consistent with higher performance of the control system.



**Figure SI.2.6.** Production yield distributions for models with non-folding, de-activated aptazymes. Shown are histogram plots of log<sub>10</sub>-scaled relative yields for all Core Topology 12 parameter sets, all parameter sets of Arch 266 of Core Topology 12, and all parameter sets of Arch 270 of Core Topology 12 (chosen for comparison to Fig. 2.5). A vertical red line denotes the median value for the set. Black coloring indicates the 95% confidence interval.




**Figure SI.2.7.** Relationships between sensor inputs and node outputs. A) Time-course data of species levels relative to the static control case for different performance levels. These data use parameter values from the highest relative yield instance of the Core Topology 12 implementation with the highest median (see Fig. 2.5). The coloring of the lines indicates the percent rank within the 2000 instances, as measured by relative yield. The first row shows the concentration over time of the aptazyme ligand for each control node ( $p$ -ACA in each case). The second row shows the relative (v. static) concentrations of the pertinent folded proteins (PapA, PapB, PapC, shown with different line types; LAAO; Efflux Pump, respectively) for each control node. B) The third row shows the relative levels of initial input, chorismate, and final output,  $p$ -AS, over time.

## 2.5 | Modular Modeling with PyMDC

Much of the code written and used in this paper was developed in an ad-hoc fashion. To create a more user-friendly codebase for future modeling efforts –

organized, scalable, documented – PyMDC was developed. PyMDC is written in Python and built on top of LibSBML. The principal idea of PyMDC is that, when creating large number of similar models, much of the models are repeated. These repeated elements, such as transcription, translation, regulation, are modules in PyMDC, and these modules can be connected by their inputs and outputs to create a model. If elements are commonly reused and/or always modeled the same way, this saves a lot of time in model generation and allows for easy creation of large combinatorial sets of models. Figure 2.7 shows the base modules of PyMDC. A model is written in Python then translated automatically into a PySCeS model for simulation. A CSV file of all parameters is created so that parameter values or ranges can be specified, and users can create a template to automate this process.



**Figure 2.7.** Base module hierarchy of PyMDC. Primitive modules, such as addSpecies, addReaction, and addLinearKineticLaw, are used to develop more complex modules, which can then be used to develop even more complex modules. By combining many modules, the buildProtein module adds transcription and translation reactions along with all necessary species and reactions and rates – all with one line of code.

## 2.6 | Conclusions and Future Work

Our work on mechanistic modeling of metabolic pathways and genetic feedback controllers led to the development of PyMDC, a tool for easily building combinatorial sets of models out of modular model components. This strategy was used for developing a combinatorial set of RNA-based genetic feedback controller models. We then simulated each model using 2,000 parameter sets to create output distributions that allowed us to assess how the genetic feedback controllers impacted pathway titers. Our conclusions indicate that mostly the positive feedback-based controllers outperform no-feedback controls and negative feedback is only beneficial with very weak negative feedback connections. These results suggests that, in most cases, product toxicity is not enough to prohibit the strategy of making more enzyme to improve titers. Furthermore, it suggests that product toxicity is not enough to encourage the strategy of reducing enzyme levels to reduce product toxicity levels. The accuracy of these conclusions is difficult to evaluate without experimental measurements of product levels inside of cells and associated toxicity.

The predictive power of a model is predicated on the accuracy of that model. It is thus vital to fully understand and identify any assumptions made when creating a model. Ideally, these assumptions would then be tested experimentally to ensure their validity. In this case, neither was done sufficiently. In particular, the inaccuracy of assumptions made regarding toxicity and growth detracts from the

utility of the results obtained. As expounded on in Chapter 3, the effects of enzyme expression toxicity and dynamics play a large role in cell growth, expression, and enzyme catalysis. None of these effects are accounted for in our model. The work in Chapter 3 led to an understanding that inducer concentration in a cell can change rapidly as cells work to expel the inducer, which we find is possibly exacerbated by expression burden. This was not accounted for in our model, nor was its capacity to potentially cause escape subpopulations with reduced enzyme production. Furthermore, we modeled culture growth as a continuous – instead of batch – culture, which hinders the ability of the model to predict cell population dynamics in a batch culture and can lead to a poor estimation of how time-dependent processes can function. It is therefore also important to understand the time dynamics of dynamic controllers and metabolic production. More experimental data is required to model the accumulation of metabolites inside of cells to concentrations that are able to be sensed. This will enable better modeling of the applicability of particular instantiations of dynamic control and predicting what metabolite sensitivities are required for control to be successful. The requirements for cells to accumulate metabolite and mount a useful dynamic feedback response – all before the culture reaches stationary phase – are still unknown.

Many of these shortcomings could not have been anticipated at the time of modeling, though it was clear that PAL2 toxicity was poorly understood. Instead of waiting for more experimental evidence of our assumptions, our model contains

inaccurate assumptions, which render the model powerless to make accurate predictions for the real-life system under study. This underscores the importance of experimentally validating crucial assumptions of a model before embarking on an effort to make actionable predictions. Going forward, if the system is to be re-modeled, the aforementioned missing elements, along with recent work on ribosome allocation and protein cost [17,26,27,125], could be integrated into the model.

In addition to improving the model, experiments to narrow the ranges of sampled parameters, in particular the enzymatic rates and toxicity, would make statistical analysis easier by reducing the potential for parameters to be sampled in ranges that turn out to be unrealistic. When working with upwards of 100 parameters, even 2,000 samples is still a sparse sampling. Focusing the parameter space as much as possible will therefore improve sampling quality. When doing Partial Rank Correlation analysis, the enzymatic rates were always the most important with respect to titer, which is sensible given that the enzymes directly produce flux. Fixing these rates or severely narrowing the sampling range would facilitate observing effects of other parameters under study.

Additionally, the RNA-based genetic controllers that were studied in our simulation analysis have not been as tractable as anticipated. Indeed, our lab has not, as yet, seen any *in vivo* functionality from 4-AF 5' UTR aptazymes (aREDs) after several design iterations (see Chapter 4 for more information). Furthermore, because aREDs require some level of basal mRNA expression and have limited

expected dynamic range (2-3-fold), their utility as a means to implement genetic feedback using a transcription factor or small RNA actuator is questionable, as that feedback would have to be always present at a basal level. It is therefore recommended that any further computational studies into dynamic feedback control eschew the use of aREs in favor of alternative ligand-based control systems, such as riboswitches or ligand-activated CRISPR guide RNAs.

Given our recent work in burden and autonomous induction (see Chapter 3), one important question to answer is: In what context is dynamic feedback control useful? It seems possible that the only important dynamic control necessary is control of expression timing. If expression occurs at the optimal time, at the optimal rate, negative feedback may be superfluous and counterproductive. It might be tempting to see negative feedback as a means for finding the optimal rate of expression, but RBS screens may be easier than tuning a negative feedback regulator, which potentially involves both screening regulators and engineering their expression via RBS tuning. The question of the utility of dynamic control may be amenable to computational analysis, if the model contains the necessary physiological phenomena as discussed above.



# Chapter 3 | Programming Enzyme Expression Dynamics to Reduce Cellular Burden and Improve Expression and *In Vivo* Catalysis

## Abstract

Engineering metabolic pathways requires expressing large quantities of enzymes. This places a heavy burden on cells and can dramatically lower pathway productivity. How the dynamics of enzyme expression impact burden and its manifestations is not well understood, however. Here, we study burden as a function of enzyme expression dynamics using an *Arabidopsis thaliana* phenylalanine ammonia lyase (PAL) enzyme fused to superfolder GFP (PAL2-sfGFP), expressed in *Escherichia coli*. We show how the timing and level of manual induction impact PAL2-sfGFP expression burden. A high level of induction of PAL2-sfGFP can lead to as much as 80% less growth compared to uninduced cells. By controlling the timing of induction, we eliminate growth reductions due to burden while simultaneously improving enzyme expression. Interestingly, we observe that burden can manifest in unexpected ways not reflected in culture growth. PAL2-sfGFP burden can lead to bimodal levels of enzyme expression and reductions in enzyme-catalyzed conversion. Controlling both induction timing and level can mitigate the effects of both manifestations. We then show that stationary phase promoters can autonomously express PAL2-sfGFP at levels similar to

manually induced levels and, despite similar enzyme levels, generate more *in vivo* catalysis than manually induced cases – all without noticeable burden. Our work demonstrates the importance of considering burden as a dynamic phenomenon and considering how enzyme expression dynamics influence burden. Doing so can elucidate manifestations of burden and suggest strategies for mitigation in order to improve production from engineered metabolic pathways.

### **3.1 | Introduction**

The pursuit of high production titers from engineered metabolic pathways requires cellular hosts to produce large quantities of enzymes. It's been well established that expression of high levels of heterologous protein is deleterious to a growing cell culture, however [16,21,33,126–129]. Resources, such as ribosomes and ATP, that could be allocated to cell growth must instead be allocated to heterologous protein production [16]. Indeed, a model of ribosome allocation can be used to predict growth rate changes in response to protein overexpression [16], suggesting that ribosome allocation is a major contributor to the deleterious impacts of high levels of heterologous protein expression. Additionally, changing cellular conditions under the strain of high levels of protein expression in many cases triggers a stress response (e.g., heat-shock response, acid response) [33,37–39,83,130,131]. This can lead to proteolysis [132] and further reductions in culture growth. Understanding and mitigating the burden of high enzyme expression levels is thus critical for optimizing production from engineered metabolic pathways.

The notion of a two-stage production has been widely adopted to reduce the impact of expression on growth [28,133]. During the first stage, cells prioritize growth and produce little or no protein. During the second stage, cells prioritize protein production, by expressing protein and sometimes simultaneously down-regulating growth-related processes or competing pathways [134]. To implement a system under this two-stage framework, the dynamics of pathway enzyme production in the second stage need to be programmed along two axes: time and rate.

The time at which the cells shift stages from growth to production is a powerful point of control. Small changes in induction time can dramatically impact protein production [135,136] and pathway titers [49]. Many studies indicate that the best time to induce is in mid-to-late exponential phase [28,30,137,138], or even later [139]. A delayed induction is thought to be beneficial at least partly due to the accumulation of ribosomes and other expression infrastructure during exponential growth in new media [27,140]. A higher concentration of ribosomes and resources creates a lower protein cost, which is defined as the negative impact of expression on growth rate [27].

At a given time, switching from growth to production can be triggered either manually or autonomously. Manual induction of promoters offers a high level of control over induction timing and transcription rate, but numerous pitfalls (e.g., high inducer cost) limit its utility on an industrial scale [ref]. Alternative, autonomous induction systems have shown promise as a means to control protein

expression and improve pathway production without inducer molecules. Several groups have used quorum-sensing components to create dynamic “metabolic valves” that turn on at high cell densities to autonomously express heterologous pathway enzymes and re-direct flux away from growth toward enzyme production by degrading or downregulating growth-related genes [53,87,97]. Other groups have used quorum sensing components to autoinduce enzyme expression without explicitly altering flux [91–96]. A similar effect can be achieved by using promoters that require alternative sigma factors that are only expressed during stress situations or stationary phase, though many of these promoters suffer from low levels of expression [54]. For example, stress- and nutrient-sensitive promoters have been used to delay induction of pathway enzyme expression until cells near stationary phase [82–87], and other stationary phase promoters have been used to control protein expression in several studies [88–91]. A library of synthetic stationary phase promoters has also been characterized [57]. Additional means of autoinducing enzyme expression include autoinducing media compositions often used in conjunction with the T7 promoter system [31,141–143] and, more recently, SILEX [144].

When cells switch to the production stage, protein production occurs at some rate over time. Many tuning knobs exist for controlling protein production rate, including the promoter system and its induction level, plasmid copy number, the ribosome binding site (RBS), mRNA stability, and others [145]. Unfortunately, maximum strength on all counts is not a fruitful strategy. To wit, the phage T7

promoter-polymerase system often leads to severe complications [31,146], thought to stem from its high transcription rate [147]. Slow induction of the *trc* promoter was shown to reduce protease activity and increase levels of soluble protein compared to a quick, pulsed induction [148]. And recent work suggests that strong RBSs can lead to inefficient protein expression [17]. Thus, it seems there is a balance to be struck with protein production dynamics so as to not overload cellular capacity and thereby reduce burden. Much work remains to be done to enable predictably finding this balance.

Many studies track some measure of burden from protein expression. Often this measure is related to growth, e.g., final OD600 [32], growth rate [17,33], or time-course OD600 [17,27,33]. Other measures include expression capacity, i.e., the ability for cells to constitutively produce a protein [17]; cell proliferation in a competitive culture environment [149,150]; and mRNA levels of the *rrsG* ribosomal RNA [84], which may be responsive to levels of the stress alarmone ppGpp [151]. However, most studies neglect either the time or rate axis when measuring burden; that is, burden is not assessed as a function of both expression level and expression timing. And how autonomous induction can potentially mitigate burden is not well studied. Thus, the relationship between enzyme expression dynamics and enzyme expression burden remains poorly understood, as does how to use this relationship to engineer better autonomous induction.

Phenylalanine Ammonia-Lyase (PAL, EC 4.3.1.24) enzymes natively convert L-phenylalanine to *trans*-cinnamic acid [152]. One isozyme, PAL4 from *A. thaliana*,

has been shown to perform the same reaction using 4-amino-L-phenylalanine (4-AF) as substrate, producing 4-amino-cinnamic acid (4-ACA) as product [13], albeit at a much lower rate [14]. Elsewhere, PAL2 from *A. thaliana* was shown to have higher activity than other isozymes on L-phenylalanine [9,153,154]. We thus sought to study the use of PAL2 to convert 4-AF to 4-ACA, with the goal of ultimately producing an engineered metabolic pathway to produce 4-aminostyrene (4-AS) from glucose in *E. coli* [155]. Preliminary experiments with PAL2 showed that PAL2 expression imposed severe burden on *E. coli* cells (data not shown), suggesting it could be a model system for studying burden in *E. coli*.

We created a C-terminal fusion [156] of PAL2 to superfolder GFP (sfGFP) [157], PAL2-sfGFP, to enable protein expression tracking. PAL2-sfGFP was placed under the control of a Tn10 pA tet promoter (pTet) and the strong BBa\_B0030 RBS from the pBbE2A BglBrick plasmid [158] to create plasmid pPAL2.1 (Figure 1a). As a point of comparison, we created pSFGFP.1 (Figure 1b), which consists of pTet controlling sfGFP expression, with a strong, designed RBS [58,159] in place of BBa\_B0030.

In this work, we study enzyme expression dynamics and burden with *A. thaliana* PAL2, expressed using both manual and autonomous induction systems. We show how manual induction timing and increasing enzyme expression burden impact cell growth, enzyme accumulation, and *in vivo* enzyme activity. We elucidate a relationship between induction timing and bimodal enzyme expression levels in the population, wherein, presumed escape pressure due to enzyme

expression burden leads to a population of low-expressing cells. A delayed induction reduces the proportion of cells in this low-expressing population. We find that enzyme abundance does not always correlate with enzymatic activity, suggesting that the dynamics of enzyme expression plays an important role in producing enzyme that is active *in vivo*. We lastly show that stationary phase promoters can recapitulate and even exceed the best characteristics of manual induction, which we suggest can be attributed to improved expression dynamics compared to manual induction, and which supports their potential utility as a simple yet effective means to operate a “metabolic valve.” We hope this work serves to reinforce the importance of enzyme expression dynamics in metabolic engineering and furthers our understanding of how to achieve optimal dynamics.

## **3.2 | Materials and Methods**

### Construct assembly

All DNA constructs were assembled using Circular Polymerase Extension Cloning (CPEC) [160]. Primers were designed manually to have binding Tms and overlap Tms of at least 70 C and minimal homodimer  $\Delta G$ . Linear fragments were amplified with a 50 uL PCR reaction using Q5 high-fidelity DNA polymerase (New England Biolabs). Fragments were then gel-extracted using Qiagen kit reagents. All fragments were assembled with a 20 uL CPEC reaction. The resulting CPEC mixture was used directly to transform competent cells.

### E. coli transformation

Chemically competent cells are mixed 1:1 with 50 uL 1X KCM buffer and incubated on ice with at least 1 ng of miniprep DNA or 5 uL of CPEC reaction mixture in a 14 mL polypropylene culture tube for 30 minutes. Cells are then heat-shocked for 20 seconds at 42 C. 200-400 uL of SOC is then added and cells are shaken at 200 rpm at 37 C for at least one hour. All of the mixture is then transferred to an LB-Miller plate with appropriate antibiotics, inverted, and stored at 37 C for at 12-18 hours, or until colonies are clearly visible. Plates are then transferred to 4 C for storage. Plates are typically used within one week.

### E. coli strains used

All cloning and assembly procedures were performed using DH10b (Invitrogen) cells. All PAL2-sfGFP-related experiments were performed using MG1655 ( $\Delta$ recA  $\Delta$ endA) (Addgene) cells.

### Time-course measurement of PAL2-sfGFP expression

An overnight culture is grown by selecting around five colonies with a pipette tip and adding to 1 ml of LB-Miller media with appropriate antibiotics, then left to grow overnight (typically 12-18 hours) at 37 C with shaking at 200 rpm. The following morning, overnight cultures are diluted 1:100 into 1 ml LB-Miller media with antibiotics in a 96-deep-well plate with round-bottom 2 ml wells (Axygen). A Breathe-Easier membrane (Diversified Biotech) is placed on top of the plate for



sterility and oxygen permeability. Cultures are grown at 37 C with shaking at 900 rpm. Cells are induced at indicated optical densities or times using indicated concentrations of anhydrotetracycline (Fisherbrand). For fluorescence and optical density measurements, 25 uL of culture is added to 100 uL 1x PBS, and briefly mixed by pipetting up and down, in a 96-well, black-side, clear-bottom plate (Corning). Bubbles are removed before measurements are taken. Measurements are performed with a Biotek Synergy HTX plate reader. Absorbance is measured at 600 nm. Fluorescence is measured with a 485/528 nm filter using a bottom read with a gain setting of 40. All operations involving the primary growing culture are performed near a lit bunsen burner to maintain sterility.

#### Measurement of 4-AF to 4-ACA conversion

Cultures are grown as described in the “Time-course measurement PAL2-sfGFP expression” section. At induction, 50 uL of 100 mM 4-amino-L-phenylalanine (4-AF) (Alfa Aesar, CAS 943-80-6) in Milli-Q H<sub>2</sub>O is added to cultures along with inducer. At 24-hours post-inoculation, 500 uL of culture is spun-down at 14k rpm for 2 minutes in 1.5 ml microcentrifuge tubes (USA Scientific). 300 uL of culture supernatant is then transferred to an Amicon 10 kDa centrifuge filter and centrifuged at 14k rpm for 20 min, or until enough volume has been filtered. 98 uL of culture with 2 uL 10% TFA (i.e., 0.2% TFA) is then used for HPLC analysis.

### HPLC quantification of 4-ACA

The column used for all HPLC analysis is an Agilent ZORBAX Eclipse Plus Phenyl-Hexyl, 4.6 x 250 mm, with 5  $\mu$ M particle size. HPLC is performed on an Agilent 1200 series. The program for 4-ACA detection is as follows. With Solution A of Milli-Q H<sub>2</sub>O + 0.2% TFA and Solution B of Methanol + 0.2% TFA: 100% A for 4 min, gradient to 70% B for 4 minutes, gradient to 95% B for 4 minutes, 95% B for 4 minutes, 100% A for 4 min.

### Flow cytometry of PAL2-sfGFP expression

At indicated times, 1  $\mu$ L of culture (already diluted 1:5 into 1x PBS for plate reader measurements) is added to 200  $\mu$ L 1x PBS in a 96-well, black-side, clear-bottom plate (Corning). Flow cytometry is performed with a Milltenyi MACSQuant flow cytometer. 10,000 events are read with a low flow rate and medium mixing. FSC is set to log<sub>2</sub>, 550 nm. SSC is set to log<sub>2</sub>, 350 nm. B1 is set to log<sub>5</sub>, 350 nm. Triggering is set to SSC, with a threshold of 15 nm.


### Data analysis

All data analysis was performed with R in RStudio, with ggplot2 for visualizations and ggcyto for cytometry data analysis. T-tests were performed with the t.test() method in R.

### 3.3 | Results

#### PAL2-sfGFP expression burden can be attenuated by a delayed induction


To assess the burden that PAL2-sfGFP and sfGFP alone impose on cells, pPAL2.1 and pSFGFP.1 were expressed in *E. coli* MG1655 ( $\Delta$ recA  $\Delta$ endA) cells. Overnight cultures were diluted 1:100 and the resulting cultures were induced at nine distinct induction times (each culture being induced once) along the growth curve and grown in LB-Miller media at 37 C in 96-deep-well plates. To monitor both protein expression and growth, fluorescence and OD600 were measured at regular intervals using a plate reader. Flow cytometry was performed at 8 hours and 24 hours with all samples to measure per-cell fluorescence (Fig 3.1c).



**Figure 3.1.** Construct and experimental designs. A) pPAL2.1: pTet controls expression of PAL2 fused to sfGFP (PAL2-sfGFP) on ColE1 plasmid. B) pSFGFP.1: pTet controls expression of sfGFP on ColE1 plasmid. C) Experimental design. Overnight cultures are inoculated 1:100 into fresh media in 96-deep-well plates. For the first 8 hours, every 30 minutes, 25  $\mu$ L of culture is extracted and mixed with 100  $\mu$ L PBS to measure OD600 and fluorescence in a plate reader. Measurements are also taken at 10 and 24 hours. At regular intervals (0, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5 hours post-inoculation), inducer is added to cultures. For conversion experiments, 4-AF is added at the time of induction. At 24 hours post-inoculation, *in vivo* conversion of 4-AF to 4-ACA is measured with HPLC. At 8 hours and 24 hours post-inoculation, single-cell fluorescence measurements are taken by a flow cytometer. For further details, please refer to Methods and Materials.

We find that PAL2-sfGFP expression at all tested aTc induction levels can lead to a reduction, often severe, in growth, when observed at three hours following induction (Table SI.3.1). At three hours post-induction, the growth rate

(over those three hours) can be as low as 22% of that of an uninduced culture (Fig 3.2a). However, for medium and high induction levels, the reduction in growth is attenuated with an extra hour of induction delay, up to an induction time of 2.5 hours (Table SI.3.2). In contrast, sfGFP expression at the highest level appears to only cause a slight reduction in growth (Fig 3.2a), despite potentially more fluorescence (Fig 3.2b), indicating that the culture may be able to accumulate higher levels of sfGFP than PAL2-sfGFP before growth attenuation occurs. This is likely explained by the four-fold size disparity between the proteins (239 amino acids for sfGFP v 973 amino acids for PAL2-sfGFP), differences in rare codon abundance, or other reasons. The enzymatic activity of PAL2 does not noticeably contribute to burden: an enzymatically dead PAL2 mutant (S204A) [161] led to similar levels of expression and growth attenuation as the wild-type PAL2 (Table SI.3.3).



**Figure 3.2.** Measurements of burden and expression of PAL2-sfGFP and sfGFP. Induction levels: low (10 nM), medium (25 nM), high (100 nM). All fluorescence and rate values were normalized to a maximum of 100 for each panel. A) % uninduced (UI) growth rate at 3 hours post-induction, where wild-type is uninduced cells. A

lower growth rate indicates slower growth due to PAL2-sfGFP expression burden. A darker red color symbolizes a lower growth rate compared to wild-type. B) Per-cell fluorescence measurements using flow cytometry. A darker green color indicates higher fluorescence. Values are the average of 2-3 independent biological replicates.


#### PAL2-sfGFP expression level can increase with a delayed induction

Along with the decrease in growth attenuation with a delayed induction, per-cell mean enzyme expression levels, as measured by flow cytometry, can increase with an extra hour of induction time, up to an induction time of 3 hours, for medium- and high-level inductions (Fig 3.2b, Table SI.3.4). Lower expression levels at the latest induction times (Table SI.3.4) are expected to be due to a reduced nutrient pool for making protein as cells near stationary phase.

#### PAL2-sfGFP expression can result in bimodal fluorescence levels

Per-cell expression levels at 24 hours (Fig 3.3a) form a bimodal distribution in the cases of high and medium induction levels of PAL2-sfGFP. Distributions are unimodal for all sfGFP induction levels and the low induction level of PAL2-sfGFP. Comparing the 8-hour and 24-hour measurements (Fig 3.3b) shows that reductions in mean expression, for the high induction levels of PAL2-sfGFP, occur over the sixteen hours between measurements (Table SI.3.5). For the medium induction level, the proportion of cells in the low-fluorescence population does not change significantly from 8 to 24 hours for almost all induction times (Table SI.3.5),

suggesting that the low-fluorescence population arises more quickly for the medium induction level case.



**Figure 3.3.** Flow cytometry measurements. A) 10,000 fluorescence intensity events grouped into 200 bins. The darker blue the bin color, the higher the number of events in that bin, and thus the proportion of cells with that level of fluorescence. Two distinct bands of dark blue indicate a bimodal population. B)  $\frac{Fluor_{24h}}{Fluor_{8h}}$ : mean fluorescence at 24 hours divided by mean fluorescence at 8 hours. This demonstrates the change in mean fluorescence from the 8 hour timepoint to the 24 hour timepoint. Redder color symbolizes more low-fluorescence cells at 24 hours than at 8 hours. C) Fraction of cells expressing pPAL2.1 (i.e., pTet : PAL2-sfGFP) in the high-fluorescence population at the indicated timepoint. A darker red color symbolizes more low-fluorescence cells. Values are the average of 2-3 independent biological replicates.

This reduction is especially dramatic (up to 69%) for the high induction level of PAL2-sfGFP, and the reduction diminishes with an extra hour delay in induction, for induction times between one and three hours (Table SI.3.6). The reduction in the aforementioned mean expression levels corresponds with a reduction in the fraction of cells present in the high-expression subpopulation (Fig 3.3c). Thus, we suggest that changes in population dynamics may be largely responsible for the increase in mean culture expression seen with delayed induction timing.


### Bimodal fluorescence levels are due to a non-genetic process

The time-dependent nature of the bimodality observed in expression suggests two hypotheses. The first is that enzyme expression burden exerts mutational pressure on the population; thus, slow-growing enzyme-expressers are out-competed by cells with expression-reducing mutations that confer a fitness advantage. The second is that enzyme expression burden exerts a pressure to increase efflux and/or decrease influx of the aTc inducer molecule, potentially by overexpressing



AcrAB, which happens to some degree regardless of expression burden [52]. In both cases, there is an advantage to inducing later, which gives “cheater” cells fewer possible cell divisions, before nutrients are exhausted, with which to overtake the population.

To test the mutation hypothesis, we plated cells harboring pPAL2.1 that had been induced at 2 and 3.5 hours with a high-level aTc induction then grown for 24 hours. Flow cytometry data indicate that roughly 60% and 20% of cells should be in the low-fluorescence population for the 2- and 3.5-hour inductions, respectively (Fig 3b). Under the mutation hypothesis, we would expect 60% and 20% of cells to have genetic changes that confer a fitness advantage leading to faster growth in the presence of inducer. However, when ten colonies from each plate (i.e., the 2- and 3.5-hour inductions) were grown in the presence of high-level aTc, all cultures appeared to grow at similar rates that were not different from a typical 0-hour induction (data not shown). Furthermore, the 5' UTR, a likely target for loss-of-function mutations [17], of all colonies were sequenced and no mutations were found. Thus, we reject the mutation hypothesis. The population dynamics observed are not due to a genetic change but instead a transient change.



**Figure 3.4.** Induction times relative to uninduced culture growth rate. The gray line is the mean of uninduced cultures with pPAL2.1. Points and the numbers above them indicate the time at which cultures were induced. The gray line thus shows the culture growth rate at the induction times used in this study. Values are the average of 2-3 independent biological replicates; error bars are standard deviations.


PAL2-sfGFP expression burden is minimized with an induction near stationary phase

By looking at the culture growth rates that correspond to induction times, we can start to understand how culture conditions influence burden. Cultures containing uninduced pPAL2.1 have a maximal growth rate in the 1.5-2.5 hour region (Fig 3.4), which is consistent with expectations for growth in LB [162]. As growth rate nears its maximum, i.e., during exponential phase, cellular ribosome concentration increases, then plateaus following maximal growth rate [27,140]. Accordingly, protein production cost is expected to decrease as growth rate increases, then plateau following maximal growth rate [27]. This would imply that maximal

production levels and rates should occur with induction times of 2 and 2.5 hours for the system under study. However, most maximums for sfGFP are at 3.5 hour inductions, and for PAL2-sfGFP are at 4 or 4.5 hour inductions (Fig 3.2). These times coincide with very late exponential or early stationary phase (Fig 3.4).

PAL2-sfGFP *in vivo* catalysis can be improved with a delayed induction


With the goal of improving production from metabolic pathways containing the PAL2 enzyme, we turned to measuring *in vivo* catalysis from cells expressing PAL2-sfGFP. Cells were grown and induced as described above, plus 5 mM 4-AF was added at the time of induction. Conversion of 4-AF to 4-ACA after 24 hours post-inoculation was measured using HPLC.



**Figure 3.5.** *In vivo* conversion of 4-AF to 4-ACA at 24 hours post-inoculation. Comparison of conversion from medium and high induction levels of PAL2-sfGFP. Bluer color symbolizes higher conversion. A darker blue color symbolizes higher conversion. Color is on the same scale as the high pulsed induction level. Values are the average of 2-3 independent biological replicates.

Contrary to expectations, maximal conversion is likely seen not with a high induction level but with a medium induction level (Fig 3.5, Table SI.3.7). This is

despite significantly lower per-cell enzyme levels (Table SI.3.8) and potentially larger escape population fractions (Fig 3.3c) compared to the high-induction case. As with expression level and growth rate, there appears to be an improvement in conversion with induction time (Fig 3.5).



**Figure 3.6.** Comparison of tet and  $\sigma 38$  promoters. Induction levels: high (100 nM). All fluorescence and rate values were normalized to a maximum of 100 per panel. A) Mean per-cell fluorescence at 24 hours. A darker green color indicates high fluorescence. B) Mean fraction of cells in high-fluorescence population. A darker red color indicates a large fraction of low-producing cells. C) Mean conversion of 5 mM 4-AF to 4-ACA at 24 hours post-inoculation. A darker blue color indicates higher conversion. Values are the average of 2-3 independent biological replicates.

### Expression dynamics of stationary phase promoters can improve *in vivo* catalysis and reduce expression burden

We lastly sought to develop an autonomous induction system that would perform as well as the best cases of manual induction with pTet. We hypothesized that this would require an induction time of around 4 hours and levels of expression in between the medium- and high-level manual inductions. An RpoS ( $\sigma 38$ ) promoter

consensus sequence [54,163] (SP1) and two of the highest-expressing synthetic promoters from the Miksch, et al.  $\sigma$  38 promoter library [57] (SP2, SP3), paired with a strong, designed RBS, were used to drive expression of PAL2-sfGFP.

We find that per-cell expression levels are between the medium and high induction levels (Fig 3.6a, Tables SI.3.9 and SI.3.10), and nearly all cells are in the high-expression population (Fig 3.6b). Cells with the s38 promoters achieved higher levels (up to 50-80%) of *in vivo* conversion of 4-AF to 4-ACA compared to a manual, pulsed induction of the tet promoter (Fig 3.6c, Tables SI.3.11-13). We expect that much of the improvement in conversion is due to the expression level being in-between the medium and high induction levels. This result indicates that stationary phase promoters could potentially be used to drive high levels of enzyme expression in an autonomous fashion.

### **3.5 | Discussion**

In this work, we examine the impact of expression dynamics on burden from overexpressing PAL2-sfGFP. We see, consistent with previous research, that delaying induction can lead to increased protein expression and faster growth. Prior research [27] suggests that much of this benefit arises from decreasing protein cost as cells reach maximal growth rate and ribosome concentration. Our work suggests that high levels of enzyme expression burden can introduce another factor, namely, a subpopulation that escapes the negative effects of burden by producing less enzyme. We see two populations: one with high levels of

PAL2-sfGFP expression and one with low levels of expression. The low-expression population appears to be enabled not by a genetic change but by a transient one.

We suspect this transient change is an upregulation of aTc efflux by the AcrAB pump [52], which leads to population splitting as follows. In the initial population of cells that are induced, there will be a distribution of AcrAB expression. Cells with more AcrAB will pump out more aTc and produce less PAL2-sfGFP. Less PAL2-sfGFP leads to faster growth and more expression capacity to express more AcrAB in response to aTc accumulation. With this positive feedback loop producing more AcrAB and less PAL2-sfGFP, this subpopulation will be able to grow much faster than the cells that had, initially, lower levels of AcrAB expression, and overtake the culture, leading to a split population. Our observation that a larger proportion of escape cells occurs with a medium-level induction compared to a high-level induction can be explained, counterintuitively, by the lower burden from a medium-level induction. The lower level of burden enables a larger fraction of cells to start the AcrAB expression positive feedback loop, and these cells will have less aTc to pump out compared to a high-level induction. With higher induction, there is more aTc to pump out and more burden; thus, the fraction that can escape decreases and escape takes longer.

The benefit of later induction thus appears to be two-fold, in this case. Firstly, protein cost is lower, due to higher ribosome concentration; secondly, there are fewer division cycles left for “cheater” cells to overtake the population. Given the explanation above, it seems possible that most protein accumulation occurs in

the cells present at the time of induction, as any new cells likely arise from cells that are growing quickly and not producing much protein. Therefore, maximizing the number of cells present at the time of induction would maximize culture protein accumulation, provided induction is done while there are sufficient nutritional resources for protein production.

While these observations are specific to aTc efflux and the pTet promoter system, inducer efflux has been seen with IPTG [50,51] and arabinose [51], suggesting that burden could impact these systems in a similar fashion. If indeed all manual induction systems suffer from the possibility of large inducer-effluxing subpopulations, strains with pump knockouts or autonomous induction systems would appear to be a solution to this problem, as they allow no inducer escape and obviate the need for an inducer, respectively. Our data shows that population enzyme expression bimodality does not occur with our autonomous induction systems, and that high levels of protein expression are achievable, on par with a manual induction with a tet promoter. Higher levels of protein expression are potentially achievable, but will depend on the limiting resource. In the cases of limiting nutrient availability or limiting  $\sigma 38$  in the sigma factor pool, expressing additional  $\sigma 38$  with a stationary phase promoter could lead to both earlier expression and a faster expression rate, as there would be more  $\sigma 38$  to compete against  $\sigma 70$  for RNA polymerases.

Our results show the highest levels of 4-AF to 4-ACA conversion from  $\sigma 38$  promoters expressing PAL2-sfGFP. We see  $\sigma 38$  promoters generating mean

per-cell PAL2-sfGFP levels at around 60-70% the level of the high-induction case, and roughly twice as much as the medium-induction case. With this level of PAL2-sfGFP expression, we see roughly 50% and 80% increases in conversion compared to the best medium- and high-induction cases, respectively. There are several interpretations of this data. Firstly, it is possible that the increase in PAL2-sfGFP compared to the medium-induction case is mostly properly folded protein than can convert 4-AF to 4-ACA, and thus explains the improvement in conversion. This would imply that being at 60-70% the level of PAL2-sfGFP from a high-level induction avoids the negative effects of overloading the cell, which leads to decreases in conversion and active enzyme in the high-induction case. It is also possible that the rate of enzyme expression in cells with a  $\sigma 38$  promoter construct is lower than in cells with a tet promoter, and that this lower rate allows cells to avoid overloading the cell's capacity to create active enzyme. Lastly, it is possible that substrate is limiting, and that higher levels of burden lead to lower levels of substrate influx, and thus less substrate for PAL2 to convert. Further experiments are necessary to deconvolute the potential contributions from these mechanisms.

Our work shows that induced cells exhibit growth similar to an uninduced control when induction is sufficiently delayed. Protein cost and inducer efflux can explain why an earlier induction leads to reduced growth, but these effects are not eliminated with a later induction, though growth is indistinguishable from an uninduced control. This would lead one to believe that burden has been eliminated. It is more likely that, instead, using growth as a proxy for burden breaks down in



this case. While reduction in growth is important to mitigate, there are other manifestations of burden that may be important to account for.

Expression capacity is one alternative measure of burden, though it is unclear how much expression capacity is necessary in the context of a late-exponential-phase induction of metabolic pathway enzymes, where the end goal is to produce as much functional enzyme as possible. It may therefore be more profitable to measure not the cellular capacity for expressing enzyme, but rather the cellular capacity for creating enzymes that are functional. Our results seem to indicate that a high level of expression can lead to less functional enzyme than a lower level of expression. A real-time measure of misfolding or aggregation would allow for monitoring when cells are being pushed past their ability to create functional enzyme. This measure would allow for understanding the utility of modulating enzyme expression rate in order to stay within the cellular capacity to create functional enzyme.

For a culture of cells expressing metabolic pathway enzymes, there is an optimal function of enzyme expression rate over time. To understand what this function looks like, we need to study how modulating the timing of enzyme expression and the rate of enzyme expression impacts cell fitness and pathway performance. We hope our results will serve to inform these efforts and point toward fruitful further studies.

## **3.6 | Supplementary Information**

### **Statistics Tables**

induction_time	induction_level	rate_induced	rate_uninduced	p_value	t_value
0	High	c(0.018, 0.007, 0.007)	c(0.059, 0.039, 0.054)	0.00410	-5.700
1	High	c(0.026, 0.022, 0.021)	c(0.111, 0.102, 0.116)	0.00037	-20.000
2	High	c(0.055, 0.057, 0.057)	c(0.153, 0.159, 0.135)	0.00280	-13.000
2.5	High	c(0.083, 0.087, 0.1)	c(0.156, 0.172, 0.149)	0.00086	-8.100
3	High	c(0.123, 0.129, 0.12)	c(0.143, 0.185, 0.131)	0.11000	-1.700
3.5	High	c(0.138, 0.161, 0.135)	c(0.131, 0.172, 0.117)	0.59000	0.250
4	High	c(0.152, 0.177, 0.136)	c(0.119, 0.165, 0.098)	0.84000	1.200
4.5	High	c(0.154, 0.199)	c(0.136, 0.189)	0.64000	0.400
5	High	c(0.143, 0.171, 0.099)	c(0.122, 0.158, 0.091)	0.68000	0.490
0	Medium	c(0.017, 0.016, 0.017)	c(0.048, 0.034, 0.052)	0.01800	-5.100
1	Medium	c(0.048, 0.052, 0.054)	c(0.103, 0.096, 0.117)	0.00430	-8.400
2	Medium	c(0.082, 0.068, 0.104)	c(0.143, 0.153, 0.136)	0.00820	-5.100
2.5	Medium	c(0.115, 0.113, 0.128)	c(0.144, 0.16, 0.146)	0.00530	-4.500
3	Medium	c(0.134, 0.148, 0.132)	c(0.133, 0.164, 0.135)	0.32000	-0.540
3.5	Medium	c(0.123, 0.162, 0.124)	c(0.128, 0.162, 0.126)	0.45000	-0.130
4	Medium	c(0.147, 0.158, 0.113)	c(0.126, 0.153, 0.097)	0.73000	0.660
4.5	Medium	c(0.14, 0.159)	c(0.136, 0.162)	0.51000	0.031
5	Medium	c(0.12, 0.139, 0.111)	c(0.11, 0.123, 0.094)	0.85000	1.200
0	Low	c(0.046, 0.033, 0.03)	c(0.054, 0.046, 0.051)	0.04300	-2.600
1	Low	c(0.099, 0.087)	c(0.135, 0.101)	0.18000	-1.400
2	Low	c(0.149, 0.129, 0.129)	c(0.154, 0.131, 0.135)	0.34000	-0.450
2.5	Low	c(0.153, 0.145, 0.135)	c(0.157, 0.141, 0.141)	0.40000	-0.270
3	Low	c(0.154, 0.136, 0.136)	c(0.161, 0.134, 0.129)	0.52000	0.057
3.5	Low	c(0.133, 0.137, 0.124)	c(0.141, 0.133, 0.128)	0.32000	-0.490
4	Low	c(0.12, 0.11, 0.116)	c(0.111, 0.114, 0.11)	0.83000	1.200
4.5	Low	c(0.097, 0.106)	c(0.108, 0.107)	0.20000	-1.300
5	Low	c(0.095, 0.101, 0.093)	c(0.092, 0.099, 0.087)	0.78000	0.870

**Table SI.3.1.** Comparisons of induced v uninduced growth rates at 3 hours post-induction. Shown are sets of induced and uninduced growth rates at each induction time for each induction level of PAL2-sfGFP from pTet. P-values and t-values are obtained by performing a one-sided t-test with the alternative hypothesis that induced rate is lower than the uninduced rate.

induction_level	comparison	first	second	p_value	t_value
High	0 to 1	c(0.305, 0.179, 0.13)	c(0.234, 0.216, 0.181)	0.4600	-0.10
High	1 to 2	c(0.234, 0.216, 0.181)	c(0.359, 0.358, 0.422)	0.0020	-6.40
High	2 to 3	c(0.359, 0.358, 0.422)	c(0.86, 0.697, 0.916)	0.0071	-6.40
High	2.5 to 3.5	c(0.532, 0.506, 0.671)	c(1.05, 0.936, 1.15)	0.0023	-5.90
High	3 to 4	c(0.86, 0.697, 0.916)	c(1.28, 1.07, 1.39)	0.0130	-3.70
High	3.5 to 4.5	c(1.05, 0.936, 1.15)	c(1.13, 1.05)	0.2900	-0.61
High	4 to 5	c(1.28, 1.07, 1.39)	c(1.17, 1.08, 1.09)	0.8600	1.40
Medium	0 to 1	c(0.354, 0.471, 0.327)	c(0.466, 0.542, 0.462)	0.0620	-2.10
Medium	1 to 2	c(0.466, 0.542, 0.462)	c(0.573, 0.444, 0.765)	0.1900	-1.10
Medium	2 to 3	c(0.573, 0.444, 0.765)	c(1.01, 0.902, 0.978)	0.0230	-3.70
Medium	2.5 to 3.5	c(0.799, 0.706, 0.877)	c(0.961, 1, 0.984)	0.0280	-3.70
Medium	3 to 4	c(1.01, 0.902, 0.978)	c(1.17, 1.03, 1.16)	0.0270	-2.80
Medium	3.5 to 4.5	c(0.961, 1, 0.984)	c(1.03, 0.981)	0.2500	-0.88
Medium	4 to 5	c(1.17, 1.03, 1.16)	c(1.09, 1.13, 1.18)	0.4100	-0.26
Low	0 to 1	c(0.852, 0.717, 0.588)	c(0.733, 0.861)	0.2500	-0.78
Low	1 to 2	c(0.733, 0.861)	c(0.968, 0.985, 0.956)	0.1100	-2.70
Low	2 to 3	c(0.968, 0.985, 0.956)	c(0.957, 1.01, 1.05)	0.1600	-1.30
Low	2.5 to 3.5	c(0.975, 1.03, 0.957)	c(0.943, 1.03, 0.969)	0.5700	0.20
Low	3 to 4	c(0.957, 1.01, 1.05)	c(1.08, 0.965, 1.05)	0.2900	-0.59
Low	3.5 to 4.5	c(0.943, 1.03, 0.969)	c(0.898, 0.991)	0.7100	0.68
Low	4 to 5	c(1.08, 0.965, 1.05)	c(1.03, 1.02, 1.07)	0.4200	-0.22

**Table SI.3.2.** Comparisons of differences in growth rate at induction times one hour apart. Shown are sets of growth rate differences (induced rate / uninduced rate) for two induction times, the first and second, of PAL2-sfGFP from pTet. For a comparison, the first (e.g., 0-hour) induction time set is compared to the second (e.g., 1-hour), to see how growth rate difference changes with induction time. P-values and t-values are obtained by performing a one-sided t-test with the alternative hypothesis that the first growth rate difference is lower than the second.

induction_time	induction_level	pTet : PAL2mut-sfGFP	pTet : PAL2-sfGFP	p_value	t_value
0	High	c(0.173, 0.17)	c(0.305, 0.179, 0.13)	0.780	-0.30
1	High	c(0.174, 0.214)	c(0.234, 0.216, 0.181)	0.850	0.20
2	High	c(0.424, 0.432)	c(0.359, 0.358, 0.422)	0.390	-0.94
2.5	High	c(0.611, 0.542)	c(0.532, 0.506, 0.671)	0.500	-0.73
3	High	c(0.962, 0.851)	c(0.86, 0.697, 0.916)	0.410	-0.87
3.5	High	c(1.13, 1.12)	c(1.05, 0.936, 1.15)	0.130	-1.70
4	High	c(1.29, 1.46)	c(1.28, 1.07, 1.39)	0.500	-0.71
4.5	High	c(1.31, 1.21)	c(1.13, 1.05)	0.700	-0.41
5	High	c(0.843, 1.07)	c(1.17, 1.08, 1.09)	0.054	2.80
0	Medium	c(0.558, 0.404)	c(0.354, 0.471, 0.327)	0.780	-0.30
1	Medium	c(0.436, 0.495)	c(0.466, 0.542, 0.462)	0.850	0.20
2	Medium	c(0.784, 0.746)	c(0.573, 0.444, 0.765)	0.390	-0.94
2.5	Medium	c(0.967, 0.993)	c(0.799, 0.706, 0.877)	0.500	-0.73
3	Medium	c(0.981, 0.971)	c(1.01, 0.902, 0.978)	0.410	-0.87
3.5	Medium	c(1.06, 1.02)	c(0.961, 1, 0.984)	0.130	-1.70
4	Medium	c(1.09, 1.17)	c(1.17, 1.03, 1.16)	0.500	-0.71
4.5	Medium	c(0.905, 0.938)	c(1.03, 0.981)	0.700	-0.41
5	Medium	c(1.04, 0.915)	c(1.09, 1.13, 1.18)	0.054	2.80

**Table SI.3.3.** Comparisons of PAL2 v dead PAL2 differences in growth rate. Shown are sets of growth rate differences (induced rate / uninduced rate) for regular PAL2-sfGFP and a catalytically dead PAL2-sfGFP, PAL2mut-sfGFP, for each induction time and induction level. Comparisons between the two sets will determine if there is a significant difference between the growth rate differences for the two populations. P-values and t-values are obtained by performing a two-sided t-test.

induction_level	timepoint	comparison	first	second	p_value	t_value
High	8 hours	0 to 1	c(14056, 12842, 14333)	c(16385, 14103, 15157)	0.0750	-1.800
High	8 hours	1 to 2	c(16385, 14103, 15157)	c(19898, 17731, 19381)	0.0075	-4.100
High	8 hours	2 to 3	c(19898, 17731, 19381)	c(20558, 14644, 21432)	0.5200	0.056
High	8 hours	2.5 to 3.5	c(20459, 13019, 18748)	c(19879, 24112, 20425)	0.1100	-1.600
High	8 hours	3 to 4	c(20558, 14644, 21432)	c(18521, 16805, 18082)	0.6700	0.490
High	8 hours	3.5 to 4.5	c(19879, 24112, 20425)	c(13325, 6460.4, 10648)	0.9900	4.700
High	8 hours	4 to 5	c(18521, 16805, 18082)	c(8246, 4445.3, 6305.8)	1.0000	9.500
Medium	8 hours	0 to 1	c(2448, 1231.6, 1771.9)	c(2343.4, 1245.2, 2121.9)	0.4300	-0.180
Medium	8 hours	1 to 2	c(2343.4, 1245.2, 2121.9)	c(2715.7, 1732.7, 3211.4)	0.1500	-1.200
Medium	8 hours	2 to 3	c(2715.7, 1732.7, 3211.4)	c(3099.7, 1862.4, 3879.7)	0.3100	-0.540
Medium	8 hours	2.5 to 3.5	c(3729.4, 1663.3, 3051.9)	c(3415.1, 2770.4, 4649.1)	0.1900	-0.970
Medium	8 hours	3 to 4	c(3099.7, 1862.4, 3879.7)	c(5133, 3625.9, 7548.9)	0.0740	-1.900
Medium	8 hours	3.5 to 4.5	c(3415.1, 2770.4, 4649.1)	c(5990.6, 2147.3, 4421.8)	0.3400	-0.460
Medium	8 hours	4 to 5	c(5133, 3625.9, 7548.9)	c(3610, 1563.4, 3036.4)	0.9400	2.100
Low	8 hours	0 to 1	c(475.07, 633.74, 449.62)	c(747.29, 1207.9, 584.12)	0.1100	-1.700
Low	8 hours	1 to 2	c(747.29, 1207.9, 584.12)	c(844.58, 775.03, 672.37)	0.6500	0.430
Low	8 hours	2 to 3	c(844.58, 775.03, 672.37)	c(1015.4, 943.19, 742.5)	0.1200	-1.400
Low	8 hours	2.5 to 3.5	c(911.52, 896.61, 731.61)	c(1209, 987.12, 958.51)	0.0550	-2.100
Low	8 hours	3 to 4	c(1015.4, 943.19, 742.5)	c(1421.4, 1278.5, 1009)	0.0460	-2.300
Low	8 hours	3.5 to 4.5	c(1209, 987.12, 958.51)	c(785.92, 900.04, 800.08)	0.9600	2.600
Low	8 hours	4 to 5	c(1421.4, 1278.5, 1009)	c(733.98, 794.38, 700.92)	0.9800	4.000
High	24 hours	0 to 1	c(4426.4, 4213.7, 3962.3)	c(5890.9, 4262.4, 4980.8)	0.1000	-1.700
High	24 hours	1 to 2	c(5890.9, 4262.4, 4980.8)	c(8409.2, 6219.2, 6234.6)	0.0520	-2.200
High	24 hours	2 to 3	c(8409.2, 6219.2, 6234.6)	c(9958.9, 7927, 10888)	0.0420	-2.300
High	24 hours	2.5 to 3.5	c(7288.1, 5342.3, 7181.4)	c(14588, 18288, 17236)	0.0017	-8.000
High	24 hours	3 to 4	c(9958.9, 7927, 10888)	c(15870, 13410, 19679)	0.0240	-3.300
High	24 hours	3.5 to 4.5	c(14588, 18288, 17236)	c(10104, 5462.5, 9159.7)	0.9900	4.700
High	24 hours	4 to 5	c(15870, 13410, 19679)	c(6503, 4170.9, 4732)	0.9900	5.700
Medium	24 hours	0 to 1	c(1516.1, 1105.7, 1231)	c(1590.5, 1111.4, 1437.5)	0.3200	-0.510
Medium	24 hours	1 to 2	c(1590.5, 1111.4, 1437.5)	c(1965.7, 1492.7, 2092.2)	0.0580	-2.000
Medium	24 hours	2 to 3	c(1965.7, 1492.7, 2092.2)	c(2362.2, 1706.6, 2360.9)	0.1800	-1.000
Medium	24 hours	2.5 to 3.5	c(2490.8, 1589.9, 1919)	c(2561.5, 2427.2, 2822)	0.0670	-2.100
Medium	24 hours	3 to 4	c(2362.2, 1706.6, 2360.9)	c(3473.5, 3103.5, 4514.2)	0.0230	-3.300
Medium	24 hours	3.5 to 4.5	c(2561.5, 2427.2, 2822)	c(3763.9, 1969.9, 3001.1)	0.3100	-0.580
Medium	24 hours	4 to 5	c(3473.5, 3103.5, 4514.2)	c(2827.1, 1464.5, 2435.1)	0.9700	2.500
Low	24 hours	0 to 1	c(396.93, 600.17, 329.42)	c(672.65, 1098.1, 427.14)	0.1400	-1.400
Low	24 hours	1 to 2	c(672.65, 1098.1, 427.14)	c(701.84, 782.98, 486.28)	0.6200	0.350
Low	24 hours	2 to 3	c(701.84, 782.98, 486.28)	c(916.59, 865.99, 517.39)	0.2600	-0.710
Low	24 hours	2.5 to 3.5	c(817.16, 838.7, 546.82)	c(1097.7, 911.64, 677.68)	0.1800	-1.100
Low	24 hours	3 to 4	c(916.59, 865.99, 517.39)	c(1206.7, 1204.5, 739.59)	0.1200	-1.400
Low	24 hours	3.5 to 4.5	c(1097.7, 911.64, 677.68)	c(722.72, 825.99, 561.2)	0.8700	1.300
Low	24 hours	4 to 5	c(1206.7, 1204.5, 739.59)	c(649.65, 757.04, 510.59)	0.9500	2.400

**Table SI.3.4.** Comparisons of mean RFU from high and medium induction levels at induction times one hour apart. Shown are sets of mean RFU from flow cytometry runs (comprised of 10,000 events) for two induction times, the first and second, of pTet : PAL2-sfGFP for each induction level and timepoint. For a comparison, the first (e.g., 0-hour) induction time set is compared to the second (e.g., 1-hour), to see how mean RFU changes with induction time. P-values and t-values are obtained by performing a one-sided t-test with the alternative hypothesis that the first mean RFU is lower than the second.

induction_level	induction_time	8 hours	24 hours	p_value	t_value
High	0	c(0.90288, 0.87762, 0.9246)	c(0.27102, 0.2836, 0.24585)	0.0000025	36.00
High	1	c(0.91992, 0.8863, 0.92812)	c(0.30815, 0.26166, 0.30175)	0.0000033	32.00
High	2	c(0.94318, 0.89177, 0.94968)	c(0.41751, 0.35223, 0.33234)	0.0000600	18.00
High	2.5	c(0.94723, 0.81717, 0.95448)	c(0.42506, 0.37613, 0.43705)	0.0016000	10.00
High	3	c(0.92891, 0.80819, 0.92902)	c(0.56972, 0.53549, 0.64104)	0.0023000	6.00
High	3.5	c(0.90407, 0.85968, 0.90655)	c(0.79112, 0.79541, 0.84825)	0.0160000	3.30
High	4	c(0.87201, 0.85981, 0.88021)	c(0.77893, 0.81595, 0.87146)	0.1000000	1.80
High	4.5	c(0.89863, 0.86312, 0.88373)	c(0.81705, 0.82502, 0.82215)	0.0120000	5.70
High	5	c(0.91454, 0.85382, 0.87991)	c(0.80132, 0.84531, 0.75089)	0.0360000	2.60
Medium	0	c(0.23722, 0.099721, 0.20259)	c(0.12818, 0.10569, 0.12489)	0.1400000	1.40
Medium	1	c(0.2079, 0.10717, 0.2222)	c(0.12916, 0.10435, 0.13805)	0.1300000	1.50
Medium	2	c(0.19759, 0.13705, 0.24855)	c(0.13743, 0.13448, 0.16136)	0.1300000	1.50
Medium	2.5	c(0.31091, 0.18485, 0.30901)	c(0.20583, 0.19439, 0.19561)	0.1200000	1.70
Medium	3	c(0.35311, 0.24944, 0.42126)	c(0.27252, 0.25382, 0.26581)	0.1300000	1.50
Medium	3.5	c(0.45187, 0.45971, 0.5692)	c(0.3527, 0.43821, 0.37881)	0.0470000	2.30
Medium	4	c(0.70482, 0.67463, 0.83688)	c(0.5425, 0.60899, 0.63643)	0.0420000	2.50
Medium	4.5	c(0.84521, 0.47482, 0.78761)	c(0.64766, 0.38093, 0.59777)	0.1600000	1.10
Medium	5	c(0.77917, 0.19721, 0.73015)	c(0.61922, 0.1671, 0.57436)	0.3300000	0.49

**Table SI.3.5.** Comparisons of fraction of cells in the high-RFU population at 8 v 24 hours. Shown are sets of proportions of cells with an RFU (as determined by flow cytometry) from pTet : PAL2-sfGFP in the high-RFU population for each induction time and level at two timepoints, 8 hours and 24 hours. For a comparison, the 8-hour set is compared to the 24-hour set, to see how high-RFU proportion changes with time. P-values and t-values are obtained by performing a one-sided t-test with the alternative hypothesis that the 8-hour proportion is lower than the 24-hour proportion.

induction_level	timepoint	comparison	first	second	p_value	t_value
High	8 hours	0 to 1	c(0.9, 0.88, 0.92)	c(0.92, 0.89, 0.93)	0.230000	-0.80
High	8 hours	1 to 2	c(0.92, 0.89, 0.93)	c(0.94, 0.89, 0.95)	0.290000	-0.60
High	8 hours	2 to 3	c(0.94, 0.89, 0.95)	c(0.93, 0.81, 0.93)	0.760000	0.83
High	8 hours	2.5 to 3.5	c(0.95, 0.82, 0.95)	c(0.9, 0.86, 0.91)	0.630000	0.36
High	8 hours	3 to 4	c(0.93, 0.81, 0.93)	c(0.87, 0.86, 0.88)	0.670000	0.49
High	8 hours	3.5 to 4.5	c(0.9, 0.86, 0.91)	c(0.9, 0.86, 0.88)	0.680000	0.52
High	8 hours	4 to 5	c(0.87, 0.86, 0.88)	c(0.91, 0.85, 0.88)	0.310000	-0.55
Medium	8 hours	0 to 1	c(0.24, 0.1, 0.2)	c(0.21, 0.11, 0.22)	0.500000	0.00
Medium	8 hours	1 to 2	c(0.21, 0.11, 0.22)	c(0.2, 0.14, 0.25)	0.370000	-0.35
Medium	8 hours	2 to 3	c(0.2, 0.14, 0.25)	c(0.35, 0.25, 0.42)	0.041000	-2.40
Medium	8 hours	2.5 to 3.5	c(0.31, 0.18, 0.31)	c(0.45, 0.46, 0.57)	0.008900	-3.90
Medium	8 hours	3 to 4	c(0.35, 0.25, 0.42)	c(0.7, 0.67, 0.84)	0.002700	-5.50
Medium	8 hours	3.5 to 4.5	c(0.45, 0.46, 0.57)	c(0.85, 0.47, 0.79)	0.110000	-1.70
Medium	8 hours	4 to 5	c(0.7, 0.67, 0.84)	c(0.78, 0.2, 0.73)	0.770000	0.86
High	24 hours	0 to 1	c(0.27, 0.28, 0.25)	c(0.31, 0.26, 0.3)	0.140000	-1.30
High	24 hours	1 to 2	c(0.31, 0.26, 0.3)	c(0.42, 0.35, 0.33)	0.044000	-2.50
High	24 hours	2 to 3	c(0.42, 0.35, 0.33)	c(0.57, 0.54, 0.64)	0.002900	-5.40
High	24 hours	2.5 to 3.5	c(0.43, 0.38, 0.44)	c(0.79, 0.8, 0.85)	0.000056	-15.00
High	24 hours	3 to 4	c(0.57, 0.54, 0.64)	c(0.78, 0.82, 0.87)	0.001900	-6.10
High	24 hours	3.5 to 4.5	c(0.79, 0.8, 0.85)	c(0.82, 0.83, 0.82)	0.320000	-0.53
High	24 hours	4 to 5	c(0.78, 0.82, 0.87)	c(0.8, 0.85, 0.75)	0.710000	0.60
Medium	24 hours	0 to 1	c(0.13, 0.11, 0.12)	c(0.13, 0.1, 0.14)	0.410000	-0.25
Medium	24 hours	1 to 2	c(0.13, 0.1, 0.14)	c(0.14, 0.13, 0.16)	0.130000	-1.30
Medium	24 hours	2 to 3	c(0.14, 0.13, 0.16)	c(0.27, 0.25, 0.27)	0.000300	-11.00
Medium	24 hours	2.5 to 3.5	c(0.21, 0.19, 0.2)	c(0.35, 0.44, 0.38)	0.007700	-7.00
Medium	24 hours	3 to 4	c(0.27, 0.25, 0.27)	c(0.54, 0.61, 0.64)	0.002900	-11.00
Medium	24 hours	3.5 to 4.5	c(0.35, 0.44, 0.38)	c(0.65, 0.38, 0.6)	0.099000	-1.80
Medium	24 hours	4 to 5	c(0.54, 0.61, 0.64)	c(0.62, 0.17, 0.57)	0.790000	0.99

**Table SI.3.6.** Comparisons of fraction of cells in the high-RFU population at induction times one hour apart. Shown are sets of proportions of cells with an RFU (as determined by flow cytometry) from pTet : PAL2-sfGFP in the high-RFU population for each induction level and timepoint at two induction times, first and second. For a comparison, the first (e.g., 0-hour) induction time set is compared to the second (e.g., 1-hour), to see how high-RFU proportion changes with induction time. P-values and t-values are obtained by performing a one-sided t-test with the alternative hypothesis that the first set proportion is lower than the second set.

induction_time	High Induction	Medium Induction	p_value	t_value
0	c(0.000966, 0.0012)	c(0.00355, 0.0029)	0.03400	-6.20
1	c(0.00128, 0.00133)	c(0.0033, 0.00332)	0.00120	-74.00
2	c(0.00154, 0.0016)	c(0.0035, 0.00353)	0.00095	-58.00
2.5	c(0.00374, 0.00378)	c(0.00416, 0.00412)	0.00270	-13.00
3	c(0.00537, 0.00518)	c(0.00543, 0.00487)	0.63000	0.42
3.5	c(0.0047, 0.00473)	c(0.00784, 0.00675)	0.06600	-4.70
4	c(0.00499, 0.00447, 0.0038)	c(0.00513, 0.00515)	0.08600	-2.10
4.5	c(0.00568, 0.00638, 0.00652)	c(0.0041, 0.0045)	0.99000	5.80
5	c(0.00546, 0.00601, 0.00547)	c(0.0034, 0.00367)	1.00000	9.30

**Table SI.3.7.** Comparison of conversion from medium and high induction levels. Shown are fractional levels of conversion (where 0.01 = 1%) of 5 mM 4-AF to 4-ACA from medium and high induction levels of PAL2-sfGFP from pTet at each induction time. P-values and t-values are obtained by performing a one-sided t-test with the alternative hypothesis that the high-level induction conversion is lower than the medium-level conversion.



induction_time	timepoint	High	Medium	p_value	t_value
0	8 hours	c(14056, 12842, 14333)	c(2448, 1231.6, 1771.9)	0.0089000	3.4
1	8 hours	c(16385, 14103, 15157)	c(2343.4, 1245.2, 2121.9)	0.0070000	3.7
2	8 hours	c(19898, 17731, 19381)	c(2715.7, 1732.7, 3211.4)	0.0053000	3.9
2.5	8 hours	c(20459, 13019, 18748)	c(3729.4, 1663.3, 3051.9)	0.0072000	3.6
3	8 hours	c(20558, 14644, 21432)	c(3099.7, 1862.4, 3879.7)	0.0018000	5.0
3.5	8 hours	c(19879, 24112, 20425)	c(3415.1, 2770.4, 4649.1)	0.0000170	12.0
4	8 hours	c(18521, 16805, 18082)	c(5133, 3625.9, 7548.9)	0.0000006	11.0
4.5	8 hours	c(13325, 6460.4, 10648)	c(5990.6, 2147.3, 4421.8)	0.0016000	4.2
5	8 hours	c(8246, 4445.3, 6305.8)	c(3610, 1563.4, 3036.4)	0.0012000	4.5
0	24 hours	c(4426.4, 4213.7, 3962.3)	c(1516.1, 1105.7, 1231)	0.0089000	3.4
1	24 hours	c(5890.9, 4262.4, 4980.8)	c(1590.5, 1111.4, 1437.5)	0.0070000	3.7
2	24 hours	c(8409.2, 6219.2, 6234.6)	c(1965.7, 1492.7, 2092.2)	0.0053000	3.9
2.5	24 hours	c(7288.1, 5342.3, 7181.4)	c(2490.8, 1589.9, 1919)	0.0072000	3.6
3	24 hours	c(9958.9, 7927, 10888)	c(2362.2, 1706.6, 2360.9)	0.0018000	5.0
3.5	24 hours	c(14588, 18288, 17236)	c(2561.5, 2427.2, 2822)	0.0000170	12.0
4	24 hours	c(15870, 13410, 19679)	c(3473.5, 3103.5, 4514.2)	0.0000006	11.0
4.5	24 hours	c(10104, 5462.5, 9159.7)	c(3763.9, 1969.9, 3001.1)	0.0016000	4.2
5	24 hours	c(6503, 4170.9, 4732)	c(2827.1, 1464.5, 2435.1)	0.0012000	4.5

**Table SI.3.8.** Comparisons of mean RFU from medium and high induction levels. Shown are mean RFU levels, as measured by flow cytometry from 10,000 events, for medium and high induction levels of PAL2-sfGFP from pTet at each induction time and timepoint. P-values and t-values are obtained by performing a one-sided t-test with the alternative hypothesis that the medium-level induction RFU is lower than the high-level conversion.

induction_time	timepoint	pTet	pS38	p_value	t_value
SP1	8 hours	c(18521, 16805, 18082)	c(8238, 8762)	0.00038	16.0
SP2	8 hours	c(18521, 16805, 18082)	c(8984, 9424.8)	0.00061	15.0
SP3	8 hours	c(18521, 16805, 18082)	c(9441.5, 10394)	0.00100	11.0
SP1	24 hours	c(15870, 13410, 19679)	c(9584.6, 10756)	0.03400	3.2
SP2	24 hours	c(15870, 13410, 19679)	c(10755, 11139)	0.04800	2.9
SP3	24 hours	c(15870, 13410, 19679)	c(11399, 11786)	0.06000	2.6

**Table SI.3.9.** Comparisons of RFU from stationary phase promoters against high induction level. Shown are sets of mean RFU from flow cytometry runs (comprised of 10,000 events) for a high induction level of PAL2-sfGFP from pTet at the best induction time, and each stationary phase promoter. P-values and t-values are obtained by performing a one-sided t-test with the alternative hypothesis that the stationary phase mean RFU is lower than the high-level induction.

induction_time	timepoint	pTet	pS38	p_value	t_value
SP1	8 hours	c(5133, 3625.9, 7548.9)	c(8238, 8762)	0.05500	-2.6
SP2	8 hours	c(5133, 3625.9, 7548.9)	c(8984, 9424.8)	0.03800	-3.2
SP3	8 hours	c(5133, 3625.9, 7548.9)	c(9441.5, 10394)	0.02300	-3.6
SP1	24 hours	c(3473.5, 3103.5, 4514.2)	c(9584.6, 10756)	0.00580	-9.0
SP2	24 hours	c(3473.5, 3103.5, 4514.2)	c(10755, 11139)	0.00052	-16.0
SP3	24 hours	c(3473.5, 3103.5, 4514.2)	c(11399, 11786)	0.00041	-17.0

**Table SI.3.10.** Comparisons of RFU from stationary phase promoters against medium induction level. Shown are sets of mean RFU from flow cytometry runs (comprised of 10,000 events) for a medium induction level of PAL2-sfGFP from pTet at the best induction time at each timepoint, and each stationary phase promoter. P-values and t-values are obtained by performing a one-sided t-test with the alternative hypothesis that the medium-level mean RFU is lower than the stationary phase induction.

induction_time	Medium Induction	SP1	p_value	t_value
0	c(0.00355, 0.0029)	c(0.00956, 0.0101, 0.0143)	0.014	-5.3
1	c(0.0033, 0.00332)	c(0.00956, 0.0101, 0.0143)	0.017	-5.3
2	c(0.0035, 0.00353)	c(0.00956, 0.0101, 0.0143)	0.017	-5.2
2.5	c(0.00416, 0.00412)	c(0.00956, 0.0101, 0.0143)	0.020	-4.8
3	c(0.00543, 0.00487)	c(0.00956, 0.0101, 0.0143)	0.025	-4.0
3.5	c(0.00784, 0.00675)	c(0.00956, 0.0101, 0.0143)	0.052	-2.5
4	c(0.00513, 0.00515)	c(0.00956, 0.0101, 0.0143)	0.027	-4.1
4.5	c(0.0041, 0.0045)	c(0.00956, 0.0101, 0.0143)	0.020	-4.6
5	c(0.0034, 0.00367)	c(0.00956, 0.0101, 0.0143)	0.017	-5.2

**Table SI.3.11.** Comparison of conversion from medium induction level and stationary phase promoter SP1. Shown are fractional levels of conversion (where 0.01 = 1%) of 5 mM 4-AF to 4-ACA from a medium induction level of PAL2-sfGFP from pTet and the SP1 stationary phase promoter at each induction time. P-values and t-values are obtained by performing a one-sided t-test with the alternative hypothesis that the medium induction level conversion is lower than the SP1 conversion.

induction_time	Medium Induction	SP2	p_value	t_value
0	c(0.00355, 0.0029)	c(0.00861, 0.00884, 0.0104)	0.0015	-9.3
1	c(0.0033, 0.00332)	c(0.00861, 0.00884, 0.0104)	0.0044	-11.0
2	c(0.0035, 0.00353)	c(0.00861, 0.00884, 0.0104)	0.0047	-10.0
2.5	c(0.00416, 0.00412)	c(0.00861, 0.00884, 0.0104)	0.0058	-9.1
3	c(0.00543, 0.00487)	c(0.00861, 0.00884, 0.0104)	0.0045	-6.6
3.5	c(0.00784, 0.00675)	c(0.00861, 0.00884, 0.0104)	0.0470	-2.5
4	c(0.00513, 0.00515)	c(0.00861, 0.00884, 0.0104)	0.0089	-7.4
4.5	c(0.0041, 0.0045)	c(0.00861, 0.00884, 0.0104)	0.0036	-8.4
5	c(0.0034, 0.00367)	c(0.00861, 0.00884, 0.0104)	0.0035	-9.9

**Table SI.3.12.** Comparison of conversion from medium induction level and stationary phase promoter SP2. Shown are fractional levels of conversion (where 0.01 = 1%) of 5 mM 4-AF to 4-ACA from a medium induction level of PAL2-sfGFP from pTet and the SP2 stationary phase promoter at each induction time. P-values and t-values are obtained by performing a one-sided t-test with the alternative hypothesis that the medium induction level conversion is lower than the SP2 conversion.

induction_time	Medium Induction	SP3	p_value	t_value
0	c(0.00355, 0.0029)	c(0.00867, 0.00856)	0.0170	-16.0
1	c(0.0033, 0.00332)	c(0.00867, 0.00856)	0.0025	-95.0
2	c(0.0035, 0.00353)	c(0.00867, 0.00856)	0.0019	-89.0
2.5	c(0.00416, 0.00412)	c(0.00867, 0.00856)	0.0014	-76.0
3	c(0.00543, 0.00487)	c(0.00867, 0.00856)	0.0220	-12.0
3.5	c(0.00784, 0.00675)	c(0.00867, 0.00856)	0.1200	-2.4
4	c(0.00513, 0.00515)	c(0.00867, 0.00856)	0.0040	-62.0
4.5	c(0.0041, 0.0045)	c(0.00867, 0.00856)	0.0100	-21.0
5	c(0.0034, 0.00367)	c(0.00867, 0.00856)	0.0032	-35.0

**Table SI.3.13.** Comparison of conversion from medium induction level and stationary phase promoter SP3. Shown are fractional levels of conversion (where 0.01 = 1%) of 5 mM 4-AF to 4-ACA from a medium induction level of PAL2-sfGFP from pTet and the SP3 stationary phase promoter at each induction time. P-values and t-values are obtained by performing a one-sided t-test with the alternative hypothesis that the medium induction level conversion is lower than the SP3 conversion.

# Chapter 4 | Production of 4-aminocinnamic Acid from Glucose with *E. coli*

## Abstract


This chapter describes work toward developing a biosynthetic pathway for producing 4-aminocinnamic acid (4-ACA) in *E. coli*. To do so, we developed a biosynthetic pathway for producing 4-aminophenylalanine (4-AF), the immediate upstream precursor to 4-ACA, and HPLC methods for 4-AF detection. Titrers in the range of 100 mg/L were achieved in test-tube cultures, and suggestions are provided to increase titers further and extend the pathway to produce 4-ACA. Also discussed are attempts to use 4-AF-responsive aptazymes in the 5' mRNA untranslated region (UTR) to dynamically control gene expression, and the use of *in vitro* RNA-based biosensors to detect 4-AF concentrations in *E. coli* culture supernatants. The chapter ends with a discussion of lessons from this work and future directions.

## 4.1 | Introduction

4-aminocinnamic acid (4-ACA) is a high-value aromatic compound amenable for use in advanced polymers [13]. 4-ACA has not been produced from glucose in microbes, though it has been produced by addition of 4-amino-phenylalanine (4-AF) to resting *E. coli* cells expressing AtPAL4, a phenylalanine ammonia lyase

enzyme from *A. thaliana* [13]. 4-ACA is presumed to be a challenging compound to produce at high levels in microbes due to its toxicity (see Fig SI.2.2a). The toxicity makes this pathway an attractive testbed for studying toxicity mitigation as a means to improve pathway production. Furthermore, our lab has developed ligand-responsive self-cleaving RNA ribozymes, or aptazymes, that respond to 4-AF, the precursor to 4-ACA, that could be used to regulate pathway gene expression to mitigate toxicity. Hence, this pathway is of great interest to our lab.






**Figure 4.1.** Biosynthesis pathway for chorismate from D-erythrose-4-phosphate (E4P). Enzymes catalyzing the shown reactions are indicated next to reaction arrows. Created using the BioCyc Pathway Collage tool.

The pathway to produce 4-ACA from glucose is comprised of 19 or 20 enzymes, most of which are part of the native *E. coli* pathway to produce aromatic amino acids. Two pathways, comprised of eight or seven genes, convert glucose to phosphoenolpyruvate (PEP), as part of glycolysis, and glucose to erythrose-4-phosphate (E4P), as part of the pentose-phosphate pathway. Either

PEP or E4P can be used to create shikimate with four enzymes, and chorismate with an additional three (Fig. 4.1). A further three enzymes, the PapABC operon (PapA, PapB, and PapC) can convert chorismate to 4-aminophenyl pyruvate (4-APPA) (Figure 4.2). Functional PapABC operons have been taken from the genomes of *Streptomyces venezuelae* [10,11,13] and *Pseudomonas fluorescens* [12]. A transaminase enzyme from *E. coli*, likely TyrB [10,164], then converts 4-APPA to 4-aminophenylalanine (4-AF). A final enzyme, PAL, can convert 4-AF to 4-ACA (Fig. 4.2).

Attempts to overproduce 4-AF have focused on increasing flux through the aromatic amino acid pathway and reducing flux to the amino acids themselves. Much of this can be accomplished through the use of the strain NST37 [5], which was developed to overproduce L-phenylalanine. It does this by nonfunctionalizing TyrR, which eliminates negative feedback on AroG and AroL; deleting TrpE and TyrA, which prevents tryptophan and tyrosine biosynthesis; and overexpressing aroF, aroG, and pheA, which increases flux to chorismate and then L-phenylalanine. By deleting pheA [12], much of the metabolic pull on chorismate is eliminated and can be redirected to 4-AF production.



**Figure 4.2.** Biosynthesis of 4-ACA from chorismate. Five-gene biosynthesis pathway for 4-ACA (at right) from chorismate (at left), by way of 4-AF (middle). PapA, PapB, and PapC comprise the PapABC operon. PAL2 is the specific phenylalanine ammonia lyase under study in Chapter 3.

## 4.2 | Materials and Methods

### Construct assembly

All DNA constructs were assembled using Circular Polymerase Extension Cloning (CPEC) [160]. Primers were designed manually to have binding Tms and overlap Tms of at least 70 C and minimal homodimer  $\Delta G$ . Linear fragments were amplified with a 50  $\mu$ L PCR reaction using Q5 high-fidelity DNA polymerase (New England Biolabs). Fragments were then gel-extracted using Qiagen kit reagents. All fragments were assembled with a 20  $\mu$ L CPEC reaction. The resulting CPEC mixture was used directly to transform competent cells.

### *E. coli* transformation

Chemically competent cells are mixed 1:1 with 50  $\mu$ L 1X KCM buffer and incubated on ice with at least 1 ng of miniprep DNA or 5  $\mu$ L of CPEC reaction mixture in a 14 mL polypropylene culture tube for 30 minutes. Cells are then heat-shocked for

20 seconds at 42 C. 200–400 uL of SOC is then added and cells are shaken at 200 rpm at 37 C for at least one hour. All of the mixture is then transferred to an LB-Miller plate with appropriate antibiotics, inverted, and stored at 37 C for at 12–18 hours, or until colonies are clearly visible. Plates are then transferred to 4 C for storage. Plates are typically used within one week.

### *E. coli* strains used

All cloning and assembly procedures were performed using either DH10b (Invitrogen) or 10  $\beta$  (New England Biolabs) cells. 4-AF production experiments were performed using either MG1655 ( $\Delta$ recA  $\Delta$ endA) (Addgene), NST37 (ATCC), or DH10b (Invitrogen) cells. Aptazyme experiments were performed using T7 Express (New England Biolabs) cells.

### Shikimate production in *E. coli*

An overnight culture is grown by selecting around five colonies with a pipette tip and adding to 1 ml of LB-Miller media with appropriate antibiotics, then left to grow overnight (typically 12–18 hours) at 37 C with shaking at 200 rpm. The following morning, overnight cultures are diluted 1:100 into 2 ml MOPS EZ-Rich defined media (Teknova). At an OD600 of around 0.4 (as measured using 150 uL culture in 300 uL well in plate reader), cultures are induced with indicated concentrations of IPTG. Cultures are grown at 37 C with shaking at 200 rpm. At 24-hours post-inoculation, 500 uL of culture is spun-down at 14k rpm for 2 minutes in 1.5 ml

microcentrifuge tubes (USA Scientific). 300 uL of culture supernatant is then transferred to an Amicon 10 kDa centrifuge filter and centrifuged at 14k rpm for 20 min, or until enough volume has been filtered. 99 uL of culture with 1 uL 10% TFA (i.e., 0.1% TFA) is then used for HPLC analysis.

#### 4-AF production in *E. coli*

An overnight culture is grown by selecting around five colonies with a pipette tip and adding to 1 ml of LB-Miller media with appropriate antibiotics, then left to grow overnight (typically 12-18 hours) at 37 C with shaking at 200 rpm. The following morning, overnight cultures are diluted 1:100 into 2 ml MOPS EZ-Rich defined media (Teknova) with 10% LB-Miller media with antibiotics in a 14 ml polypropylene culture tube and grown at 37 C with shaking at 200 rpm. Optical densities are occasionally sampled using a Biotek Synergy HTX plate reader: 150 uL of culture is placed into a well on a black-side, clear-bottom 96-well plate and absorbance at 600 nm is measured. Cells are induced at indicated optical densities using indicated concentrations of anhydrotetracycline (aTc, Fisherbrand). After induction, cells are transferred to a 30 C shaker or left shaking at 37 C, as indicated. At 24-hours post-inoculation, 500 uL of culture is spun-down at 14k rpm for 2 minutes in 1.5 ml microcentrifuge tubes (USA Scientific). 300 uL of culture supernatant is then transferred to an Amicon 10 kDa centrifuge filter and centrifuged at 14k rpm for 20 min, or until enough volume has been filtered. 98 uL of culture with 2 uL 10% TFA

(i.e., 0.2% TFA) is then used for HPLC analysis. Culture without TFA is used for RNA aptamer ribosensor assays.

#### Aptazyme experiments in *E. coli*

An overnight culture is grown by selecting around five colonies with a pipette tip and adding to 1 ml of LB-Miller media with appropriate antibiotics, then left to grow overnight (typically 12-18 hours) at 37 C with shaking at 200 rpm. The following morning, overnight cultures are diluted 1:100 into 2 ml LB-Miller media or MOPS EZ-Rich defined media (Teknova), as indicated, with antibiotics in a 14 ml polypropylene culture tube and grown at 37 C with shaking at 200 rpm. Cells are induced at indicated optical densities using indicated concentrations of IPTG. Optical densities and fluorescence measurements are sampled as indicated using a Biotek Synergy HTX plate reader: 150 uL of culture is placed into a well on a black-side, clear-bottom 96-well plate. Absorbance is measured at 600 nm. Fluorescence is measured with a 485/528 nm filter using a bottom read with a gain setting of 40.

#### HPLC quantification of shikimate and 4-AF

The column used for all HPLC analysis is an Agilent ZORBAX Eclipse Plus Phenyl-Hexyl, 4.6 x 250 mm, with 5 uM particle size. HPLC is performed on an Agilent 1200 series. The program for 4-AF detection is as follows. With Solution A of Milli-Q H<sub>2</sub>O + 0.2% TFA and Solution B of Methanol + 0.2% TFA: 100% A for 4 min,

gradient to 100% B for 14 minutes, 100% A for 4 minutes. The program for shikimate detection is as follows. With Solution A of Milli-Q H<sub>2</sub>O + 0.1% TFA and Solution B of Methanol + 0.1% TFA: 100% A for 4 min, gradient to 70% B for 4 minutes, gradient to 95% B for 4 minutes, 95% B for 4 minutes, 100% A for 4 min.

### 4.3 | Shikimate Production

As shikimate is an important intermediate in the 4-ACA pathway, and its production the subject of much study [6], we attempted to produce high levels of shikimate using a construct, pS4, from Juminaga, et al. [112]. pS4 is a large plasmid with six enzymes from the shikimate biosynthesis pathway. Two, *tktA* and *ppsA*, are upstream of E4P and PEP, respectively, and thus are expected to increase accumulation of these precursors. The other four convert E4P and PEP to shikimate. One, *aroG*, a 3-Deoxy-D-arabinoheptulosonate 7-phosphate (DAHP) synthase, is a feedback-resistant version (termed *aroG<sup>fbr</sup>*) of the initial step that converts E4P and PEP to DAHP. Without feedback on *aroG*, a pathway bottleneck is eliminated. The paper reports low protein expression levels and low promoter inducibility, but indicates that this construct can produce shikimate titers in excess of 700 mg/L in shake flasks after 24 hours.

Attempts to produce high levels of shikimate with pS4 and pS3, a construct similar to pS4, failed to recapitulate the published results, however. HPLC analysis of *E. coli* cultures growing with pS3 or pS4 in DH10b cells in similar conditions to Juminaga, et al. (See Methods) for 24 hours showed titers of 55-57 mg/L of

shikimate regardless of induction (Table 4.1). While the cause of the discrepancy in titers is unclear, it seemed that expressing the full seven genes to convert PEP and E4P to chorismate would be unnecessary to reach high levels of 4-AF production [12]. A feedback-resistant DAHP synthase, *aroG<sup>fbr</sup>*, was reported to contribute the most to high 4-AF levels.

Inducer level	Plasmid pS3	Plasmid pS4	pS4 + 10 mM shikimate
0 $\mu$ M IPTG	26 / 0.32 mM / 56 mg/L (3.55 min)	no data	no data
100 $\mu$ M IPTG	26.5 / 0.33 mM / 57 mg/L (3.52 min)	no data	no data
1000 $\mu$ M IPTG	no data	25.4 / 0.31 mM / 55 mg/L (3.56 min)	837 / 10.31 mM / 1790 mg/L (3.55 min)

**Table 4.1.** Shikimate production data. Format: Shikimate HPLC peak area / concentration in mM / concentration in mg/L. Peaks were observed at 3.6 min. Retention times are in parentheses. Measurements were taken at 260 nm. n=1.

#### 4.4 | HPLC Detection of 4-AF

Concurrent with the work described in Sections 4.5 and 4.6, an HPLC program to detect 4-AF was developed. The high polarity of 4-AF leads to low retention when using common, polar HPLC mobile phases such as acetonitrile and methanol, and a common, polar stationary phase, such as water. Moreover, the molecule can adopt several protonation states, leading to a strong pH-dependence of retention. When the supernatant of a culture grown in unbuffered LB is used, the 4-AF peak elutes



when running only water through a phenyl-hexyl column, and moreover is unresolvable amongst other peaks. This low retention is partly due to low pH caused by the addition of 0.1% TFA, a common additive that improves peak resolution. Using a buffered media, such as MOPS EZ-Rich, and 0.2% TFA, the 4-AF peak is retained longer and is resolvable amongst nearby peaks. This concentration of TFA, while it reduces the pH, does not reduce it past the buffered range, and leads to a pH of around 7. A similar strategy is used by Masuo, et al., who use potassium phosphate at pH 7 as their stationary phase. Thus, a pH in the 7 range is expected to result in a lower-polarity state of 4-AF, allowing it to retain longer than the low-pH-protonation-state 4-AF and enable it to be detected more easily.

To detect 4-AF, we initially looked at the 280 nm wavelength, as 4-AF has an absorbance peak in the 280 nm range, similar to other aromatics. However, the limit of detection is lower with a 210 nm wavelength, as used by Masuo, et al. In fact, in all cases of 4-AF production detected with HPLC (see next section), including a control with 1 mM 4-AF, 4-AF was seen only at 210 nm and 220 nm and not at 280 nm.

#### **4.5 | 4-AF Production Using *S. venezuelae* Operon**

Initial attempts to produce 4-AF from glucose in *E. coli* were performed using a plasmid containing a PapABC operon from *S. venezuelae*, which was derived from pJC9A from Carothers, et al. [7], which was itself derived from pLASC-lacpw from Mehl, et al. [10]. This operon was codon-optimized and placed in front of a pBAD

arabinose-inducible promoter to create plasmid pJTS16. This construct was never seen to produce any 4-AF, using methods similar to those described in Methods and grown at 37 C. Subsequent analysis of the original papA sequence in the plasmid map PapABC operon showed many sequence deviations from the genomic sequence (91% amino acid identity) from which it was obtained, *S. venezuelae* (ATCC 10712) [10], including a single-base frameshift deletion. This deletion was fixed, the papA gene re-codon-optimized, and the promoter replaced with a Tn10 pA tet promoter, creating plasmid pJTS76D. This construct was also never seen to produce any 4-AF. SDS-PAGE analysis showed undetectable bands for all PapABC enzymes amongst whole-cell lysate. Designed RBSs [159] were introduced to improve expression of the enzymes, which SDS-PAGE confirmed. Additionally, the original papB sequence (in the obtained plasmid map) was analyzed against the genomic sequence and found to have a frameshift deletion, so the papB gene was replaced with the genomic version. (Note: papC is equivalent to the genomic version.) Plasmids with the genomic papB sequence include pJTS76W, pJTS76X, and pJTS76Y, with optimized RBSs for papA and papB, papA and papB and papC, and papA, respectively. Despite these many changes, no 4-AF production was observed. While it was not surprising that all constructs and conditions tested prior to finding and fixing the two frameshift deletions produced no 4-AF, it was surprising to see no 4-AF subsequently. It is expected that the differences remaining in the papA gene compared to the genomic version may create a nonfunctional PapA protein. A

fully genomic PapABC has not been tested.

#### **4.6 | 4-AF Production Using *P. fluorescens* Operon**

As an alternative to the *S. venezuelae* operon described in Section 4.5, the PapABC operon from *P. fluorescens* SBW25, described in Masuo, et al., was used. The papABC genes were placed downstream of a Tn10 pA tet promoter, and all RBS sequences were computationally designed for maximal expression using the RBS Calculator (v2) [58], to create plasmid pJTS123. Following the methods described in Methods, 4-AF was produced and detected via HPLC. Maximum titers observed using pJTS123 in strain NST37 were 57 mg/L. Potentially higher titers were observed using a two-plasmid system: pJTS123 and pJTS111. pJTS111 contains *aroG<sup>fbr</sup>* and *aroL*, the two genes downregulated by *tyrR*, under control of the Tn10 pA tet promoter. With both pJTS123 and pJTS111 in DH10b (notably, a common cloning strain), titers of 104 mg/L were reached. A plasmid combining papABC and *aroG<sup>fbr</sup>* and *aroL* into one five-gene operon controlled by pTet, plasmid pJTS128, yielded a maximum of 45 mg/L in the NST37 strain. We thus expect that there is a disadvantage to having a long, five-gene mRNA, and that smaller operons lead to improved expression, perhaps due to increased mRNA stability. Table 4.2 shows a construct list with associated maximum titers and conditions.

Plasmid(s)	123	128	123 + 111
Cell Strain	NST37	NST37	DH10b
[aTc] in nM	40	60	60
Induction OD600	0.26	0.1	0.4
Growth Temp.	30	30	30
Peak Area	2584	2007	4686
[4-AF] in uM	229	178	415
[4-AF] in mg/L	57	45	104

**Table 4.2.** Highest observed 4-AF titers for the constructs shown. n=1, though similar conditions have been studied (different induction levels and times), which gives us confidence in the general trend of these results.

The impact of temperature on pathway titers was studied by growing cells with both pJTS123 and pJTS111, as described in Methods, identically up until induction, then growing one tube at 30 C and one at 37 C. As Table 4.3 shows, a 37 C post-induction growth appears to lead to a reduction of pathway titer, with approximately 11% of the 4-AF made compared to the 30 C tube. This indicates that the 4-AF enzymes are likely more active at 30 C than 37 C. While 30 C appears to be better for 4-AF production, the *A. thaliana* PAL2 enzyme that converts 4-AF to 4-ACA has been shown to have optimal turnover at 48 C [152]. Thus, this may indicate that a pathway comprised of papABC and PAL2 may require a temperature such as 37 C to find a balance between the opposing optimal temperatures for these enzymes.

We also assessed the impact of induction time on pathway performance. The data in Chapter 3 suggests that induction time may have a large impact on pathway

titer, and that delaying induction could improve titer. We saw that a delay from an OD600 of 0.1 to OD600 of 0.4 led to titers of 57 and 104 mg/L, respectively (Table 4.4). This suggests that an induction delay may improve titer.

<b>Construct</b>	<b>123 + 111</b>	<b>123 + 111</b>
<b>Cell Strain</b>	DH10b	DH10b
<b>[aTc] in nM</b>	40	40
<b>Induction OD</b>	0.4	0.4
<b>Growth Temp.</b>	<b>30</b>	<b>37</b>
<b>Peak Area</b>	3958	429
<b>[pAF] in uM</b>	350	38
<b>[pAF] in mg/L</b>	88	10

**Table 4.3.** Impact of growth temperature on 4-AF titer. Growing at 30 C post-induction results in titers nearly 9 times higher than post-induction growth at 37 C. n=1.

There are numerous potential explanations for the discrepancy between our 4-AF titers and those observed in Masuo, et al. Perhaps the most important is differences in media composition. They saw best performance in MOPS-M9 medium with what is essentially 40% LB added: 2 g/L yeast extract + 5 g/L tryptone + 4 g/L ammonium chloride. We used MOPS EZ-Rich medium, which contains around 0.5 g/L ammonium chloride, with 10% LB: 0.5 g/L yeast extract + 1 g/L tryptone. Of at least equal importance are presumed differences in expression and/or enzyme stoichiometry. They split the papABC operon in two, putting papA and papBC on separate plasmids, which improved titers around 25% from a one-plasmid papBAC operon. The gene order of papBAC v. our papABC gene order

could potentially lead to higher titers and better enzyme stoichiometry [112]. Lastly, their NST37 strain had an additional knockout of pheLA (pheL being the pheA leader peptide), which resulted in a 50% improvement in titer for them.


Construct	123 + 111	123 + 111
Cell Strain	DH10b	DH10b
[aTc] in nM	60	60
Induction OD600	0.1	0.4
Growth Temp.	30	30
Peak Area	2543	4686
[4-AF] in uM	225	415
[4-AF] in mg/L	57	104

**Table 4.4.** Impact of induction time on pathway titer. Delaying induction from an OD600 of 0.1 to 0.4 resulted in an almost two-fold increase of 4-AF production. n=1.

#### 4.7 | 4-AF-responsive Dynamic Control of Gene Expression

A new frontier of dynamic control in metabolic pathways is using RNA-based sensors instead of protein-based transcription factors. RNA aptazymes have been proposed as a means for achieving this [7]. Aptazymes contain an aptamer domain that can bind a metabolite of interest. When this aptamer domain is bound, it leads to a structural rearrangement that causes the aptazyme's ribozyme domain to self-cleave. When placed in the 5' UTR of an mRNA, this self-cleavage event leaves a 5'-OH. In *E. coli*, this 5'-OH instead of the typical 5'-PPP is thought to prevent RNase E binding at the 5' end, thus extending the lifespan of the mRNA. Different amounts of mRNA longevity improvement from a 5'-OH have been reported


[68,165], and one group has shown very context-specific effects of 5' UTR ribozyme cleavage on gene expression [166], including decreases in gene expression. In any case, it seems possible to develop metabolite-responsive changes in gene expression with 5' UTR aptazymes.



**Figure 4.3.** 4-AF-HCl effect on expression from 5' UTR aRED constructs. T7 Express (lacIq/LysY) cells with pDSY2F were grown for 2.5 hours then induced with 200  $\mu$ M IPTG and the indicated amount of Tris, Tris + pAF, Tris + pAF-HCl, and nothing (null) was added. Only the case with pAF-HCl shows an increase in fluorescence above the control, indicating that HCl is needed for the increase in fluorescence, and that 4-AF alone does not increase fluorescence. n=1.

Our lab's work to-date, however, has not led to the development of a 4-AF-responsive aptazyme that is capable of modulating gene expression in *E. coli*, though cleavage has been demonstrated *in vitro*. We have shown, however, a possible relationship between pH and presumed aptazyme cleavage (i.e., by seeing increased fluorescence) that suggests a strong need to perform aptazyme

experiments in buffered conditions. The 4-AF used in initial experiments was 4-AF-HCl, the HCl being for solubility, which is a common commercial formulation. With an aptazyme in the 5' UTR of superfolder GFP (sfGFP), in plasmid pDSY2F, the addition of 10 mM 4-AF-HCl solubilized in 10 mM Tris potentially leads to greater *in vivo* fluorescence levels when cells were grown in unbuffered LB-Miller media. However, 10 mM 4-AF without HCl leads to potentially no improvement in expression (Fig. 4.3). A similar improvement in fluorescence to that seen with 4-AF-HCl addition can possibly be achieved with the addition of 10 mM HCl alone (Fig. 4.4), further suggesting that HCl and the concomitant decrease in pH is the agent causing the increase in expression.



**Figure 4.4.** HCl effect on expression from 5' UTR aRED constructs. T7 Express (lacIq/LysY) cells with pDSY2F were grown for 2.5 hours then induced with 200  $\mu$ M IPTG and the indicated amount of HCl. Fluorescence normalized to OD600 for the HCl+ case very quickly overtakes the HCl- case, ending around 3 times higher. Note that OD600 of the culture converges at 6 hours post-induction (not shown). n=1.



## 4.8 | Detecting 4-AF Using RNA Aptamer Ribosensors *In Vitro*

One of the bottlenecks in developing a high-titer metabolic pathway is screening production of many pathway variants. Often this is done with high-throughput chromatography, such as ultra performance liquid chromatography or gas chromatography, which limits screening throughput to around 1000 samples per instrument per day. The combinatorial explosion that can result from changes to pathway enzymes and culture conditions can result in millions of variants to screen, however. While design-of-experiment-based sampling can reduce the number of necessary variants, screening remains a costly and time-intensive endeavour. To address this challenge, our lab developed a methodology for creating RNA aptamer-based ribosensors that can be used for inexpensive, multiplexed, *in vitro* quantitative detection of metabolites for strain screening [167]. These ribosensors work by a strand-displacement reaction that occurs when the metabolite-of-interest binds the RNA aptamer and causes a structural rearrangement of the ribosensor. The rearranged ribosensor can then displace a strand of the output RNA duplex, freeing a fluorophore, which will then fluoresce for detection.

A proof-of-concept ribosensor sensitive to 4-AF was developed using a previously characterized 4-AF aptamer [168]. After a set of ambiguous HPLC results with *S. venezuelae* papABC pathway constructs (it was unclear if 4-AF was present), we tested these culture samples with the 4-AF ribosensors. As noted in Burke, et al.,

the ribosensors showed outputs consistent with titers in the 100 mg/L range. Subsequent analysis of the HPLC results, in addition to subsequent production experiments and HPLC analysis, confirmed that these strains do not produce 4-AF in observable quantities. It must then be concluded that the ribosensors did not detect 4-AF but instead detected another compound, likely similar in structure, that was generated from pathway induction. This false positive illustrates a potential limitation of RNA aptamer-based sensors for use with cell cultures containing a milieu of metabolites. It is difficult to ascertain which metabolite the ribosensors bound and thus which counterselection could have been done in order to prevent this.

## **4.9 | Conclusions and Future Directions**

In this work, we produced shikimate and 4-AF in *E. coli* using previously developed components. We also developed a protocol for detection of 4-AF using HPLC. This work lays a foundation for developing a 4-AF and 4-ACA production platform, which could be used as a testbed to study how enzyme expression burden and product toxicity can be mitigated by controlling genetic expression.

There are several easy improvements to the 4-AF production pathway, outlined at the end of Section 4.6, that are expected to improve titers substantially, and there are many others that are worth noting. As an alternative to creating a NST37 ( $\Delta$ pheLA) strain would be to use CRISPRi or small RNA (sRNA) to knock down expression of pheLA in the NST37 strain, or to knock down expression of tyrA, trpE,

pheA, and tyrR simultaneously in an MG1655 strain. The latter would presumably lead to better cell growth and not require supplementary amino acids to overcome auxotrophy. The timing of the CRISPRi or sRNA knockdown could be optimized for strain productivity. In addition to the knockdown program, cells would express papABC and aroG<sup>fb</sup>r and possibly aroL and/or tktA. Masuo, et al. showed an improvement with tktA expression but have not examined expression of aroL. It is unclear if a one-plasmid system is inherently worse than a two-plasmid system in terms of reaching a high level of gene expression. Therefore, it will be necessary to construct and test sets of the 4-AF pathway genes in one-plasmid and two-plasmid configurations using various operon sizes and thus 2-4 different promoters and terminators. To further maximize titers, all sets of genes will need to be screened using RBSs of differing strengths in order to balance enzyme expression.

The primary barrier to high 4-ACA titers is the activity of the PAL enzyme. We have seen a maximum of around 1% conversion of extracellular 4-AF after 24 hours using the *A. thaliana* PAL2 isozyme. Others have reported similarly poor conversion with other isozymes [14]. Therefore, even with 1 or 2 g/L 4-AF, we would expect around 10-20 mg/L of 4-ACA. A priority for improving production should therefore be finding isozymes with greater specificity for 4-AF, potentially PAL/TAL or TAL (tyrosine ammonia lyase) enzymes that would be more likely to tolerate the *para*-position amine. Beyond that, either rational modifications or directed evolution could be used to create an enzyme more tolerant of said amine.

Together, the aforementioned strategies could lead to 4-ACA titers high enough to lead to product toxicity, though this hinges on finding a better PAL isozyme or engineering/evolving one. Alternative pathways, such as one for producing styrene [9] or 4-hydroxystyrene [8], have properties similar to the 4-ACA production pathway. That is, they require expression of a PAL or TAL enzyme, which could be used to study enzyme expression burden, and lead to production of a toxic compound, which could be used to study product toxicity. While it is convenient that RNA aptamer ribosensors exist to detect 4-AF, a rough cost-benefit analysis would indicate that the amount of effort required to develop a 4-ACA pathway into a testbed for studying both enzyme expression toxicity and product toxicity outweighs the benefit of having such a testbed. As mentioned, other pathways exist with these qualities, and it would likely be better to develop RNA-based sensors and gene expression controllers tailored to a pathway with desired properties that already exists.

## Chapter 5 | Conclusions

The work in this dissertation is focused on the issue of toxicity and burden in engineered metabolic pathways, with the aims of better understanding why toxicity and burden occur, and how to mitigate negative impacts on pathway titers. While many outstanding questions remain, this work has substantively advanced the study of pathway dynamic control modeling and enzyme burden mitigation, and suggests fruitful further work.

In Chapter 2, we developed a computational framework for generating and analyzing large combinatorial sets of genetic feedback controllers that control enzyme expression in an engineered metabolic pathway with product toxicity. This framework could be used to generate and analyze large sets of kinetic genetic network models for virtually any area of synthetic biology.

In Chapter 3, we performed an in-depth experimental analysis of enzyme expression burden from one enzyme, PAL2. This work recapitulates previous results demonstrating the importance of expression timing and expression dynamics. Cell cultures with delayed expression have increased enzyme expression levels and substrate conversion levels, and also show better growth. Our work shows that burden from enzyme expression can induce large changes in population dynamics and encourage escape phenotypes, which may be a result of upregulated inducer efflux. We find that stationary phase promoters are capable of high levels of expression similar to a tet promoter, but also create less burden and facilitate

better enzyme conversion activity, which may result from slower enzyme expression rates. This work suggests new considerations and areas of inquiry with respect to burden in metabolic pathways, namely, how burden exacerbates inducer efflux; the relationship between enzyme expression rate, burden, and protein folding; and the utility of strong stationary phase promoters in metabolic engineering.

In Chapter 4, we demonstrated production and HPLC detection of roughly 100 mg/L of 4-AF in *E. coli*, recapitulating previously reported levels of production. Studies with PAL2 suggest roughly a 1% conversion *in vivo* of 4-AF to 4-ACA is possible. It thus seems likely that a pathway in *E. coli* to produce levels of 4-ACA relevant for the study of product toxicity is out of reach without finding or engineering a PAL isozyme with a higher conversion rate. The 4-AF pathway could still be useful as a testbed for development of RNA aptamer-based biosensors, however.

Going forward, this work suggests that perhaps the most fruitful area of further study surrounds the questions raised in Chapter 3. Namely, what is the relationship between enzyme expression rate, burden, and protein folding? Can we use strong stationary phase promoters to express large metabolic pathways? What does the optimal curve of enzyme expression rate over time look like, and how do we engineer that curve? These questions should provide the basis for much impactful research in the future.

## References

1. Nielsen J, Keasling JD. Engineering Cellular Metabolism. *Cell*. 2016;164: 1185–1197.
2. Prather KLJ, Martin CH. De novo biosynthetic pathways: rational design of microbial chemical factories. *Curr Opin Biotechnol*. 2008;19: 468–474.
3. Tsuge Y, Kawaguchi H, Sasaki K, Kondo A. Engineering cell factories for producing building block chemicals for bio-polymer synthesis. *Microb Cell Fact*. 2016;15: 19.
4. Ger YM, Chen SL, Chiang HJ, Shiuan D. A single Ser-180 mutation desensitizes feedback inhibition of the phenylalanine-sensitive 3-deoxy-D-arabino-heptulosonate 7-phosphate (DAHP) synthetase in *Escherichia coli*. *J Biochem*. 1994;116: 986–990.
5. Tribe DE. Novel microorganism and method [Internet]. US Patent. 4681852, 1987. Available: <https://www.google.com/patents/US4681852>
6. Gu P, Fan X, Liang Q, Qi Q, Li Q. Novel technologies combined with traditional metabolic engineering strategies facilitate the construction of shikimate-producing *Escherichia coli*. *Microb Cell Fact*. 2017;16: 167.
7. Carothers JM, Goler JA, Juminaga D, Keasling JD. Model-driven engineering of RNA devices to quantitatively program gene expression. *Science*. 2011;334: 1716–1719.
8. Qi WW, Vannelli T, Breinig S, Ben-Bassat A, Gatenby AA, Haynie SL, et al. Functional expression of prokaryotic and eukaryotic genes in *Escherichia coli* for conversion of glucose to p-hydroxystyrene. *Metab Eng*. 2007;9: 268–276.
9. McKenna R, Nielsen DR. Styrene biosynthesis from glucose by engineered *E. coli*. *Metab Eng*. 2011;13: 544–554.
10. Mehl RA, Anderson JC, Santoro SW, Wang L, Martin AB, King DS, et al. Generation of a bacterium with a 21 amino acid genetic code. *J Am Chem Soc*. 2003;125: 935–939.
11. Yanai K, Sumida N, Okakura K, Moriya T, Watanabe M, Murakami T. Para-position derivatives of fungal anthelmintic cyclodepsipeptides engineered with *Streptomyces venezuelae* antibiotic biosynthetic genes. *Nat Biotechnol*. 2004;22: 848–855.
12. Masuo S, Zhou S, Kaneko T, Takaya N. Bacterial fermentation platform for

- producing artificial aromatic amines. *Sci Rep*. 2016;6: 25764.
13. Suvannasara P, Tateyama S, Miyasato A, Matsumura K, Shimoda T, Ito T, et al. Biobased Polyimides from 4-Aminocinnamic Acid Photodimer. *Macromolecules*. 2014;47: 1586–1593.
  14. Konishi K, Takaya N, Masuo S, Zhou S. 4-AMINO CINNAMIC ACID PRODUCTION METHOD USING ENZYME [Internet]. US Patent. 20160362711, 2016. Available: <http://www.freepatentsonline.com/y2016/0362711.html>
  15. Konishi K, Takaya N, Masuo S. Method for producing aniline derivative by fermentation from carbon source. US Patent. 2017; Available: <https://www.google.com/patents/US20170022528>
  16. Scott M, Gunderson CW, Mateescu EM, Zhang Z, Hwa T. Interdependence of cell growth and gene expression: origins and consequences. *Science*. 2010;330: 1099–1102.
  17. Ceroni F, Algar R, Stan G-B, Ellis T. Quantifying cellular capacity identifies gene expression designs with reduced burden. *Nat Methods*. 2015;12: 415–418.
  18. Mingardon F, Clement C, Hirano K, Nhan M, Luning EG, Chanal A, et al. Improving olefin tolerance and production in *E. coli* using native and evolved AcrB. *Biotechnol Bioeng*. 2015;112: 879–888.
  19. Mukhopadhyay A. Tolerance engineering in bacteria for the production of advanced biofuels and chemicals. *Trends Microbiol*. 2015;23: 498–508.
  20. Borkowski O, Ceroni F, Stan G-B, Ellis T. Overloaded and stressed: whole-cell considerations for bacterial synthetic biology. *Curr Opin Microbiol*. 2016;33: 123–130.
  21. Wu G, Yan Q, Jones JA, Tang YJ, Fong SS, Koffas MAG. Metabolic Burden: Cornerstones in Synthetic Biology and Metabolic Engineering Applications. *Trends Biotechnol*. 2016;34: 652–664.
  22. Dunlop MJ, Dossani ZY, Szmidsztal HL, Chu HC, Lee TS, Keasling JD, et al. Engineering microbial biofuel tolerance and export using efflux pumps. *Mol Syst Biol*. 2011;7: 487.
  23. Fisher MA, Boyarskiy S, Yamada MR, Kong N, Bauer S, Tullman-Ercek D. Enhancing tolerance to short-chain alcohols by engineering the *Escherichia coli* AcrB efflux pump to secrete the non-native substrate n-butanol. *ACS Synth Biol*. 2014;3: 30–40.
  24. Bruce LJ, Daugulis AJ. Solvent selection strategies for extractive biocatalysis.



- Biotechnol Prog. Wiley Online Library; 1991;7: 116–124.
25. Dunlop MJ. Engineering microbes for tolerance to next-generation biofuels. *Biotechnol Biofuels*. 2011;4: 32.
  26. Weiße AY, Oyarzún DA, Danos V, Swain PS. Mechanistic links between cellular trade-offs, gene expression, and growth. *Proc Natl Acad Sci U S A*. 2015;112: E1038–47.
  27. Shachrai I, Zaslaver A, Alon U, Dekel E. Cost of unneeded proteins in *E. coli* is reduced after several generations in exponential growth. *Mol Cell*. 2010;38: 758–767.
  28. Donovan RS, Robinson CW, Glick BR. Review: Optimizing inducer and culture conditions for expression of foreign proteins under the control of the lac promoter. *J Ind Microbiol*. Springer-Verlag; 1996;16: 145–154.
  29. Jones JA, Koffas MAG. Chapter Eight - Optimizing Metabolic Pathways for the Improved Production of Natural Products. In: Sarah E. O'Connor, editor. *Methods in Enzymology*. Academic Press; 2016. pp. 179–193.
  30. Galloway CA, Sowden MP, Smith HC. Increasing the yield of soluble recombinant protein expressed in *E. coli* by induction during late log phase. *Biotechniques*. 2003;34: 524–6, 528, 530.
  31. Lee SK, Keasling JD. Heterologous protein production in *Escherichia coli* using the propionate-inducible pPro system by conventional and auto-induction methods. *Protein Expr Purif*. 2008;61: 197–203.
  32. Liu D, Xiao Y, Evans BS, Zhang F. Negative feedback regulation of fatty acid production based on a malonyl-CoA sensor-actuator. *ACS Synth Biol*. 2015;4: 132–140.
  33. Dong H, Nilsson L, Kurland CG. Gratuitous overexpression of genes in *Escherichia coli* leads to growth inhibition and ribosome destruction. *J Bacteriol*. 1995;177: 1497–1504.
  34. Gyorgy A, Jiménez JI, Yazbek J, Huang H-H, Chung H, Weiss R, et al. Isocost Lines Describe the Cellular Economy of Genetic Circuits. *Biophys J*. Elsevier; 2015;109: 639–646.
  35. Cookson NA, Mather WH, Danino T, Mondragón-Palomino O, Williams RJ, Tsimring LS, et al. Queueing up for enzymatic processing: correlated signaling through coupled degradation. *Mol Syst Biol*. 2011;7: 561.
  36. Goff SA, Casson LP, Goldberg AL. Heat shock regulatory gene *htpR* influences rates of protein degradation and expression of the *lon* gene in *Escherichia coli*.

- Proc Natl Acad Sci U S A. 1984;81: 6647–6651.
37. Gill RT, Valdes JJ, Bentley WE. A comparative study of global stress gene regulation in response to overexpression of recombinant proteins in *Escherichia coli*. *Metab Eng.* 2000;2: 178–189.
  38. Oh MK, Liao JC. DNA microarray detection of metabolic responses to protein overproduction in *Escherichia coli*. *Metab Eng.* 2000;2: 201–209.
  39. Kanemori M, Mori H, Yura T. Induction of heat shock proteins by abnormal proteins results from stabilization and not increased synthesis of sigma 32 in *Escherichia coli*. *J Bacteriol.* 1994;176: 5648–5653.
  40. Liberek K, Georgopoulos C. Autoregulation of the *Escherichia coli* heat shock response by the DnaK and DnaJ heat shock proteins. *Proc Natl Acad Sci U S A.* 1993;90: 11019–11023.
  41. Tomoyasu T, Ogura T, Tatsuta T, Bukau B. Levels of DnaK and DnaJ provide tight control of heat shock gene expression and protein repair in *Escherichia coli*. *Mol Microbiol.* 1998;30: 567–581.
  42. Guisbert E, Herman C, Lu CZ, Gross CA. A chaperone network controls the heat shock response in *E. coli*. *Genes Dev.* 2004;18: 2812–2821.
  43. Harcum SW, Bentley WE. Response dynamics of 26-, 34-, 39-, 54-, and 80-kDa proteases in induced cultures of recombinant *Escherichia coli*. *Biotechnol Bioeng.* 1993;42: 675–685.
  44. Harcum SW, Bentley WE. Heat-shock and stringent responses have overlapping protease activity in *Escherichia coli*. *Appl Biochem Biotechnol. Humana Press;* 1999;80: 23–37.
  45. Yu H, Shi Y, Sun X, Luo H, Shen Z. Effect of poly(beta-hydroxybutyrate) accumulation on the stability of a recombinant plasmid in *Escherichia coli*. *J Biosci Bioeng.* 2003;96: 179–183.
  46. Lau BTC, Malkus P, Paulsson J. New quantitative methods for measuring plasmid loss rates reveal unexpected stability. *Plasmid.* 2013;70: 353–361.
  47. Chen Y-J, Liu P, Nielsen AAK, Brophy JAN, Clancy K, Peterson T, et al. Characterization of 582 natural and synthetic terminators and quantification of their design constraints. *Nat Methods.* 2013;10: 659–664.
  48. Sleight SC, Bartley BA, Lieviant JA, Sauro HM. Designing and engineering evolutionary robust genetic circuits. *J Biol Eng.* 2010;4: 12.
  49. Andrew Jones J, Vernacchio VR, Lachance DM, Lebovich M, Fu L, Shirke AN, et

- al. ePathOptimize: A Combinatorial Approach for Transcriptional Balancing of Metabolic Pathways. *Sci Rep. Nature Publishing Group*; 2015;5: 11301.
50. Bohn C, Bouloc P. The *Escherichia coli* *cmlA* gene encodes the multidrug efflux pump Cmr/MdfA and is responsible for isopropyl-beta-D-thiogalactopyranoside exclusion and spectinomycin sensitivity. *J Bacteriol.* 1998;180: 6072–6075.
  51. Carolé S, Pichoff S, Bouch JP. *Escherichia coli* gene *ydeA* encodes a major facilitator pump which exports L-arabinose and isopropyl-beta-D-thiogalactopyranoside. *J Bacteriol.* 1999;181: 5123–5125.
  52. Le TT, Emonet T, Harlepp S, Guet CC, Cluzel P. Dynamical determinants of drug-inducible gene expression in a single bacterium. *Biophys J.* 2006;90: 3315–3321.
  53. Gupta A, Reizman IMB, Reisch CR, Prather KLJ. Dynamic regulation of metabolic flux in engineered bacteria using a pathway-independent quorum-sensing circuit. *Nat Biotechnol.* 2017;35: 273–279.
  54. Hsiao V. Synthetic Circuits for Feedback and Detection in Bacteria. Murray RM, editor. Ph.D., Caltech. 2016.
  55. Chubukov V, Sauer U. Environmental dependence of stationary-phase metabolism in *Bacillus subtilis* and *Escherichia coli*. *Appl Environ Microbiol.* 2014;80: 2901–2909.
  56. Gefen O, Fridman O, Ronin I, Balaban NQ. Direct observation of single stationary-phase bacteria reveals a surprisingly long period of constant protein production activity. *Proc Natl Acad Sci U S A.* 2014;111: 556–561.
  57. Miksch G, Bettenworth F, Friehs K, Flaschel E, Saalbach A, Twellmann T, et al. Libraries of synthetic stationary-phase and stress promoters as a tool for fine-tuning of expression of recombinant proteins in *Escherichia coli*. *J Biotechnol.* 2005;120: 25–37.
  58. Espah Borujeni A, Channarasappa AS, Salis HM. Translation rate is controlled by coupled trade-offs between site accessibility, selective RNA unfolding and sliding at upstream standby sites. *Nucleic Acids Res.* 2014;42: 2646–2659.
  59. Zelcbuch L, Antonovsky N, Bar-Even A, Levin-Karp A, Barenholz U, Dayagi M, et al. Spanning high-dimensional expression space using ribosome-binding site combinatorics. *Nucleic Acids Res.* 2013;41: e98.
  60. Jeschek M, Gerngross D, Panke S. Rationally reduced libraries for combinatorial pathway optimization minimizing experimental effort. *Nat Commun.* 2016;7:

11163.

61. Chen H, Shiroguchi K, Ge H, Xie XS. Genome-wide study of mRNA degradation and transcript elongation in *Escherichia coli*. *Mol Syst Biol*. 2015;11: 781.
62. Anderson KL, Dunman PM. Messenger RNA Turnover Processes in *Escherichia coli*, *Bacillus subtilis*, and Emerging Studies in *Staphylococcus aureus*. *Int J Microbiol*. 2009;2009: 525491.
63. Carpousis AJ. The RNA degradosome of *Escherichia coli*: an mRNA-degrading machine assembled on RNase E. *Annu Rev Microbiol*. 2007;61: 71–87.
64. Górna MW, Carpousis AJ, Luisi BF. From conformational chaos to robust regulation: the structure and function of the multi-enzyme RNA degradosome. *Q Rev Biophys*. 2012;45: 105–145.
65. Bandyra KJ, Bouvier M, Carpousis AJ, Luisi BF. The social fabric of the RNA degradosome. *Biochim Biophys Acta*. 2013;1829: 514–522.
66. Kaberdin VR, Lin-Chao S. Unraveling new roles for minor components of the *E. coli* RNA degradosome. *RNA Biol*. 2009;6: 402–405.
67. Mackie GA. RNase E: at the interface of bacterial RNA processing and decay. *Nat Rev Microbiol*. 2013;11: 45–57.
68. Celesnik H, Deana A, Belasco JG. Initiation of RNA decay in *Escherichia coli* by 5' pyrophosphate removal. *Mol Cell*. 2007;27: 79–90.
69. Deana A, Celesnik H, Belasco JG. The bacterial enzyme RppH triggers messenger RNA degradation by 5' pyrophosphate removal. *Nature*. 2008;451: 355–358.
70. Wong HC, Chang S. Identification of a positive retroregulator that stabilizes mRNAs in bacteria. *Proc Natl Acad Sci U S A*. 1986;83: 3233–3237.
71. Lopez PJ, Dreyfus M. The *lacZ* mRNA can be stabilised by the T7 late mRNA leader in *E. coli*. *Biochimie*. 1996;78: 408–415.
72. Carrier TA, Keasling JD. Engineering mRNA stability in *E. coli* by the addition of synthetic hairpins using a 5' cassette system. *Biotechnol Bioeng*. 1997;55: 577–580.
73. Blum E, Carpousis AJ, Higgins CF. Polyadenylation promotes degradation of 3'-structured RNA by the *Escherichia coli* mRNA degradosome in vitro. *J Biol Chem*. 1999;274: 4009–4016.
74. Smolke CD, Carrier TA, Keasling JD. Coordinated, differential expression of two

- genes through directed mRNA cleavage and stabilization by secondary structures. *Appl Environ Microbiol.* 2000;66: 5399–5405.
75. Man S, Cheng R, Miao C, Gong Q, Gu Y, Lu X, et al. Artificial trans-encoded small non-coding RNAs specifically silence the selected gene expression in bacteria. *Nucleic Acids Res.* 2011;39: e50.
  76. Sharma V, Yamamura A, Yokobayashi Y. Engineering artificial small RNAs for conditional gene silencing in *Escherichia coli*. *ACS Synth Biol.* 2012;1: 6–13.
  77. Mutalik VK, Qi L, Guimaraes JC, Lucks JB, Arkin AP. Rationally designed families of orthogonal RNA regulators of translation. *Nat Chem Biol.* 2012;8: 447–454.
  78. Na D, Yoo SM, Chung H, Park H, Park JH, Lee SY. Metabolic engineering of *Escherichia coli* using synthetic small regulatory RNAs. *Nat Biotechnol.* 2013;31: 170–174.
  79. Park H, Bak G, Kim SC, Lee Y. Exploring sRNA-mediated gene silencing mechanisms using artificial small RNAs derived from a natural RNA scaffold in *Escherichia coli*. *Nucleic Acids Res.* 2013;41: 3787–3804.
  80. Zhang F, Carothers JM, Keasling JD. Design of a dynamic sensor-regulator system for production of chemicals and fuels derived from fatty acids. *Nat Biotechnol.* 2012;30: 354–359.
  81. Xu P, Li L, Zhang F, Stephanopoulos G, Koffas M. Improving fatty acids production by engineering dynamic pathway regulation and metabolic control. *Proc Natl Acad Sci U S A.* 2014;111: 11299–11304.
  82. Farmer WR, Liao JC. Improving lycopene production in *Escherichia coli* by engineering metabolic control. *Nat Biotechnol.* 2000;18: 533–537.
  83. Dahl RH, Zhang F, Alonso-Gutierrez J, Baidoo E, Batth TS, Redding-Johanson AM, et al. Engineering dynamic pathway regulation using stress-response promoters. *Nat Biotechnol.* 2013;31: 1039–1046.
  84. Lo T-M, Chng SH, Teo WS, Cho H-S, Chang MW. A Two-Layer Gene Circuit for Decoupling Cell Growth from Metabolite Production. *Cell Syst.* 2016;3: 133–143.
  85. Bothfeld WH, Kapov G, Tyo K. A glucose-sensing toggle switch for autonomous, high productivity genetic control. *ACS Synth Biol.* 2017; doi:10.1021/acssynbio.6b00257
  86. Doroshenko VG, Tsyrenzhapova IS, Krylov AA, Kiseleva EM, Ermishev VY, Kazakova SM, et al. Pho regulon promoter-mediated transcription of the key pathway gene *aroGFbr* improves the performance of an L-phenylalanine-producing *Escherichia coli* strain. *Appl Microbiol Biotechnol.*

2010;88: 1287–1295.

87. Liao H, Mercogliano CP, Wolter TR, Louie MTM, Ribble WK, Lipscomb T, et al. CONTROL OF GROWTH-INDUCTION-PRODUCTION PHASES [Internet]. US Patent. 20150057465, 2015. Available: <http://www.freepatentsonline.com/y2015/0057465.html>
88. Beshay U, Miksch G, Friehs K, Flaschel E. Increasing the secretion ability of the *kil* gene for recombinant proteins in *Escherichia coli* by using a strong stationary-phase promoter. *Biotechnol Lett.* 2007;29: 1893–1901.
89. Kang Z, Wang Q, Zhang H, Qi Q. Construction of a stress-induced system in *Escherichia coli* for efficient polyhydroxyalkanoates production. *Appl Microbiol Biotechnol.* 2008;79: 203–208.
90. Cao Y, Xian M. Production of phloroglucinol by *Escherichia coli* using a stationary-phase promoter. *Biotechnol Lett.* 2011;33: 1853–1858.
91. He X, Chen Y, Liang Q, Qi Q. Autoinduced AND Gate Controls Metabolic Pathway Dynamically in Response to Microbial Communities and Cell Physiological State. *ACS Synth Biol.* 2016; doi:10.1021/acssynbio.6b00177
92. Thomas MD, van Tilburg A. Overexpression of foreign proteins using the *Vibrio fischeri* lux control system. *Methods Enzymol.* 2000;305: 315–329.
93. Tsao C-Y, Hooshangi S, Wu H-C, Valdes JJ, Bentley WE. Autonomous induction of recombinant proteins by minimally rewiring native quorum sensing regulon of *E. coli*. *Metab Eng.* 2010;12: 291–297.
94. Liu H, Lu T. Autonomous production of 1,4-butanediol via a de novo biosynthesis pathway in engineered *Escherichia coli*. *Metab Eng.* 2015;29: 135–141.
95. Ben R, Jiying F, Jian'an S, Tu TN, Jing S, Jingsong Z, et al. An auto-inducible expression system based on the RhII-RhIR quorum-sensing regulon for recombinant protein production in *E. coli*. *Biotechnol Bioprocess Eng. The Korean Society for Biotechnology and Bioengineering;* 2016;21: 160–168.
96. Kim E-M, Min Woo H, Tian T, Yilmaz S, Javidpour P, Keasling JD, et al. Autonomous control of metabolic state by a quorum sensing (QS)-mediated regulator for bisabolene production in engineered *E. coli*. *Metab Eng.* 2017; doi:10.1016/j.ymben.2017.11.004
97. Soma Y, Hanai T. Self-induced metabolic state switching by a tunable cell density sensor for microbial isopropanol production. *Metab Eng.* 2015;30: 7–15.
98. Martínez-Antonio A, Janga SC, Salgado H, Collado-Vides J. Internal-sensing

machinery directs the activity of the regulatory network in *Escherichia coli*. *Trends Microbiol.* 2006;14: 22–27.

99. Carothers JM, Goler JA, Keasling JD. Chemical synthesis using synthetic biology. *Curr Opin Biotechnol.* 2009;20: 498–503.
100. Harrison ME, Dunlop MJ. Synthetic feedback loop model for increasing microbial biofuel production using a biosensor. *Front Microbiol.* 2012;3: 360.
101. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. *Nature.* 1990;346: 818–822.
102. Chen YY, Jensen MC, Smolke CD. Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems. *Proc Natl Acad Sci U S A.* 2010;107: 8531–8536.
103. Michener JK, Smolke CD. High-throughput enzyme evolution in *Saccharomyces cerevisiae* using a synthetic RNA switch. *Metab Eng.* 2012;14: 306–316.
104. Win MN, Smolke CD. Higher-order cellular information processing with synthetic RNA devices. *Science.* 2008;322: 456–460.
105. Yang J, Seo SW, Jang S, Shin S-I, Lim CH, Roh T-Y, et al. Synthetic RNA devices to expedite the evolution of metabolite-producing microbes. *Nat Commun. nature.com;* 2013;4: 1413.
106. Goikhman MY, Yevlampieva NP, Kamanina NV, Podeshvo IV, Gofman IV, Mil'tsov SA, et al. New polyamides with main-chain cyanine chromophores. *Polym Sci Series A. Springer;* 2011;53: 457–468.
107. Orth JD, Thiele I, Palsson BØ. What is flux balance analysis? *Nat Biotechnol.* 2010;28: 245–248.
108. Schuster S. Use and limitations of modular metabolic control analysis in medicine and biotechnology. *Metab Eng.* 1999;1: 232–242.
109. Chiang AWT, Hwang M-J. A computational pipeline for identifying kinetic motifs to aid in the design and improvement of synthetic gene circuits. *BMC Bioinformatics.* 2013;14 Suppl 16: S5.
110. Davis JH, Rubin AJ, Sauer RT. Design, construction and characterization of a set of insulated bacterial promoters. *Nucleic Acids Res.* 2011;39: 1131–1141.
111. Seo SW, Yang J-S, Cho H-S, Yang J, Kim SC, Park JM, et al. Predictive combinatorial design of mRNA translation initiation regions for systematic

- optimization of gene expression levels. *Sci Rep.* ncbi.nlm.nih.gov; 2014;4: 4515.
112. Juminaga D, Baidoo EEK, Redding-Johanson AM, Batth TS, Burd H, Mukhopadhyay A, et al. Modular engineering of L-tyrosine production in *Escherichia coli*. *Appl Environ Microbiol.* 2012;78: 89–98.
  113. Olivier BG, Rohwer JM, Hofmeyr J-HS. Modelling cellular systems with PySCeS. *Bioinformatics.* 2005;21: 560–561.
  114. Hindmarsh AC. ODEPACK, A Systematized Collection of ODE Solvers , R. S. Stepleman et al. (eds.), North-Holland, Amsterdam, (vol. 1 of ), pp. 55-64. *IMACS Transactions on Scientific Computation. Scientific Computing;* 1983;1: 55–64.
  115. McKay MD, Beckman RJ, Conover WJ. Comparison of Three Methods for Selecting Values of Input Variables in the Analysis of Output from a Computer Code. *Technometrics.* Taylor & Francis; 1979;21: 239–245.
  116. Elowitz MB, Leibler S. A synthetic oscillatory network of transcriptional regulators. *Nature.* 2000;403: 335–338.
  117. Bintu L, Buchler NE, Garcia HG, Gerland U, Hwa T, Kondev J, et al. Transcriptional regulation by the numbers: models. *Curr Opin Genet Dev.* 2005;15: 116–124.
  118. De Lay N, Schu DJ, Gottesman S. Bacterial small RNA-based negative regulation: Hfq and its accomplices. *J Biol Chem.* 2013;288: 7996–8003.
  119. Bintu L, Buchler NE, Garcia HG, Gerland U, Hwa T, Kondev J, et al. Transcriptional regulation by the numbers: applications. *Curr Opin Genet Dev.* 2005;15: 125–135.
  120. Link KH, Guo L, Ames TD, Yen L, Mulligan RC, Breaker RR. Engineering high-speed allosteric hammerhead ribozymes. *Biol Chem.* 2007;388: 779–786.
  121. Thimmaiah T, Voje WE Jr, Carothers JM. Computational design of RNA parts, devices, and transcripts with kinetic folding algorithms implemented on multiprocessor clusters. *Methods Mol Biol.* 2015;1244: 45–61.
  122. Sparkman-Yager D, Correa-Rojas RA, Carothers JM. Kinetic folding design of aptazyme-regulated expression devices as riboswitches for metabolic engineering. *Methods Enzymol.* 2015;550: 321–340.
  123. Goler JA, Carothers JM, Keasling JD. Dual-selection for evolution of in vivo functional aptazymes as riboswitch parts. *Methods Mol Biol.* 2014;1111: 221–235.
  124. Alon U. Network motifs: theory and experimental approaches. *Nat Rev Genet.*



2007;8: 450–461.

125. Liao C, Blanchard AE, Lu T. An integrative circuit-host modelling framework for predicting synthetic gene network behaviours. *Nat Microbiol.* 2017; doi:10.1038/s41564-017-0022-5
126. Betenbaugh MJ, Beaty C, Dhurjati P. Effects of plasmid amplification and recombinant gene expression on the growth kinetics of recombinant *E. coli*. *Biotechnol Bioeng.* 1989;33: 1425–1436.
127. Glick BR. Metabolic load and heterologous gene expression. *Biotechnol Adv.* 1995;13: 247–261.
128. Bienick MS, Young KW, Klesmith JR, Detwiler EE, Tomek KJ, Whitehead TA. The interrelationship between promoter strength, gene expression, and growth rate. *PLoS One.* 2014;9: e109105.
129. Borkowski O, Ceroni F, Stan G-B, Ellis T. Overloaded and stressed: whole-cell considerations for bacterial synthetic biology. *Curr Opin Microbiol.* 2016;33: 123–130.
130. Goff SA, Goldberg AL. Production of abnormal proteins in *E. coli* stimulates transcription of *lon* and other heat shock genes. *Cell.* 1985;41: 587–595.
131. Dürschmid K, Reischer H, Schmidt-Heck W, Hrebicek T, Guthke R, Rizzi A, et al. Monitoring of transcriptome and proteome profiles to investigate the cellular response of *E. coli* towards recombinant protein expression under defined chemostat conditions. *J Biotechnol.* 2008;135: 34–44.
132. Gottesman S. Minimizing proteolysis in *Escherichia coli*: genetic solutions. *Methods Enzymol.* 1990;185: 119–129.
133. Burg JM, Cooper CB, Ye Z, Reed BR, Moreb EA, Lynch MD. Large-scale bioprocess competitiveness: the potential of dynamic metabolic control in two-stage fermentations. *Curr Opin Chem Eng.* 2016;14: 121–136.
134. Solomon KV, Prather KLJ. The zero-sum game of pathway optimization: emerging paradigms for tuning gene expression. *Biotechnol J.* 2011;6: 1064–1070.
135. Neubauer P, Hofmann K, Holst O, Mattiasson B, Kruschke P. Maximizing the expression of a recombinant gene in *Escherichia coli* by manipulation of induction time using lactose as inducer. *Appl Microbiol Biotechnol.* 1992;36: 739–744.
136. Huber R, Roth S, Rahmen N, Büchs J. Utilizing high-throughput experimentation to enhance specific productivity of an *E. coli* T7 expression

- system by phosphate limitation. *BMC Biotechnol.* 2011;11: 22.
137. Structural Genomics Consortium, China Structural Genomics Consortium, Northeast Structural Genomics Consortium, Gräslund S, Nordlund P, Weigelt J, et al. Protein production and purification. *Nat Methods.* 2008;5: 135–146.
  138. Mühlmann M, Forsten E, Noack S, Büchs J. Optimizing recombinant protein expression via automated induction profiling in microtiter plates at different temperatures. *Microb Cell Fact.* 2017;16: 220.
  139. Ou J, Wang L, Ding X, Du J, Zhang Y, Chen H, et al. Stationary phase protein overproduction is a fundamental capability of *Escherichia coli*. *Biochem Biophys Res Commun.* 2004;314: 174–180.
  140. Failmezger J, Ludwig J, Nieß A, Siemann-Herzberg M. Quantifying ribosome dynamics in *Escherichia coli* using fluorescence. *FEMS Microbiol Lett.* academic.oup.com; 2017;364. doi:10.1093/femsle/fnx055
  141. Studier FW. Protein production by auto-induction in high density shaking cultures. *Protein Expr Purif.* 2005;41: 207–234.
  142. Li Z, Kessler W, van den Heuvel J, Rinas U. Simple defined autoinduction medium for high-level recombinant protein production using T7-based *Escherichia coli* expression systems. *Appl Microbiol Biotechnol.* 2011;91: 1203–1213.
  143. William Studier F. Stable Expression Clones and Auto-Induction for Protein Production in *E. coli*. In: Chen YW, editor. *Structural Genomics.* Humana Press; 2013. pp. 17–32.
  144. Briand L, Marcion G, Kriznik A, Heydel JM, Artur Y, Garrido C, et al. A self-inducible heterologous protein expression system in *Escherichia coli*. *Sci Rep.* 2016;6: 33037.
  145. Rosano GL, Ceccarelli EA. Recombinant protein expression in *Escherichia coli*: advances and challenges. *Front Microbiol.* 2014;5: 172.
  146. Tan C, Marguet P, You L. Emergent bistability by a growth-modulating positive feedback circuit. *Nat Chem Biol.* 2009;5: 842–848.
  147. Segall-Shapiro TH, Meyer AJ, Ellington AD, Sontag ED, Voigt CA. A “resource allocator” for transcription based on a highly fragmented T7 RNA polymerase. *Mol Syst Biol.* 2014;10: 742.
  148. Ramírez DM, Bentley WE. Fed-batch feeding and induction policies that improve foreign protein synthesis and stability by avoiding stress responses.

- Biotechnol Bioeng. 1995;47: 596–608.
149. Frumkin I, Schirman D, Rotman A, Li F, Zahavi L, Mordret E, et al. Gene Architectures that Minimize Cost of Gene Expression. *Mol Cell*. 2016; doi:10.1016/j.molcel.2016.11.007
  150. Stoebel DM, Dean AM, Dykhuizen DE. The cost of expression of *Escherichia coli* lac operon proteins is in the process, not in the products. *Genetics*. 2008;178: 1653–1660.
  151. Murray HD, Schneider DA, Gourse RL. Control of rRNA expression by small molecules is dynamic and nonredundant. *Mol Cell*. 2003;12: 125–134.
  152. Cochrane FC, Davin LB, Lewis NG. The *Arabidopsis* phenylalanine ammonia lyase gene family: kinetic characterization of the four PAL isoforms. *Phytochemistry*. 2004;65: 1557–1564.
  153. Dreßen A, Hilberath T, Mackfeld U, Billmeier A, Rudat J, Pohl M. Phenylalanine ammonia lyase from *Arabidopsis thaliana* (AtPAL2): a potent enzyme for the synthesis of non-canonical aromatic alpha-amino acids: Part I: Comparative characterization to the enzymes from *Petroselinum crispum* (PcPAL1) and *Rhodospiridium toruloides* (RtPAL). *J Biotechnol*. 2017; doi:10.1016/j.jbiotec.2017.04.005
  154. Liu C, Men X, Chen H, Li M, Ding Z, Chen G, et al. A systematic optimization of styrene biosynthesis in *Escherichia coli* BL21(DE3). *Biotechnol Biofuels*. *biotechnologyforbiofuels ...*; 2018;11: 14.
  155. Stevens JT, Carothers JM. Designing RNA-based genetic control systems for efficient production from engineered metabolic pathways. *ACS Synth Biol*. 2015;4: 107–115.
  156. Chen X, Zaro JL, Shen W-C. Fusion protein linkers: property, design and functionality. *Adv Drug Deliv Rev*. 2013;65: 1357–1369.
  157. Pédelacq J-D, Cabantous S, Tran T, Terwilliger TC, Waldo GS. Engineering and characterization of a superfolder green fluorescent protein. *Nat Biotechnol*. 2006;24: 79–88.
  158. Lee TS, Krupa RA, Zhang F, Hajimorad M, Holtz WJ, Prasad N, et al. BglBrick vectors and datasheets: A synthetic biology platform for gene expression. *J Biol Eng*. 2011;5: 12.
  159. Salis HM, Mirsky EA, Voigt CA. Automated design of synthetic ribosome binding sites to control protein expression. *Nat Biotechnol*. 2009;27: 946–950.
  160. Quan J, Tian J. Circular polymerase extension cloning of complex gene

- libraries and pathways. PLoS One. 2009;4: e6441.
161. Schuster B, Rétey J. Serine-202 is the putative precursor of the active site dehydroalanine of phenylalanine ammonia lyase Site-directed mutagenesis studies on the enzyme from parsley (*Petroselinum crispum* L.) - ScienceDirect [Internet]. [cited 8 Feb 2017]. Available: <http://www.sciencedirect.com/science/article/pii/0014579394006814>
  162. Sezonov G, Joseleau-Petit D, D'Ari R. Escherichia coli physiology in Luria-Bertani broth. J Bacteriol. 2007;189: 8746–8749.
  163. Lee SJ, Gralla JD. Sigma38 (rpoS) RNA polymerase promoter engagement via -10 region nucleotides. J Biol Chem. 2001;276: 30064–30071.
  164. Tateyama S, Masuo S, Suvannasara P, Oka Y, Miyazato A, Yasaki K, et al. Ultrastrong, Transparent Polytruxillamides Derived from Microbial Photodimers. Macromolecules. American Chemical Society; 2016;49: 3336–3342.
  165. Qi L, Haurwitz RE, Shao W, Doudna JA, Arkin AP. RNA processing enables predictable programming of gene expression. Nat Biotechnol. 2012;30: 1002–1006.
  166. Wurmthaler LA, Klauser B, Hartig JS. Highly motif- and organism-dependent effects of naturally occurring hammerhead ribozyme sequences on gene expression. RNA Biol. 2017; 0.
  167. Burke CR, Sparkman-Yager D, Carothers JM. Multi-state design of kinetically-controlled RNA aptamer ribosensors [Internet]. bioRxiv. 2017. p. 213538. doi:10.1101/213538
  168. Carothers JM, Goler JA, Kapoor Y, Lara L, Keasling JD. Selecting RNA aptamers for synthetic biology: investigating magnesium dependence and predicting binding affinity. Nucleic Acids Res. 2010;38: 2736–2747.

# Appendix A | Genetic Sequences

## pPAL2.1

LOCUS pPAL2.1 5731 bp ds-DNA circular 05-FEB-2018

DEFINITION .

FEATURES Location/Qualifiers

protein\_bind 698..714  
/label="Q2"  
misc\_feature 3674..3802  
/label="dbl term"  
CDS complement(20..646)  
/label="tetR"  
promoter 647..719  
/label="tet promoter region"  
misc\_feature complement(4759..5614)  
/label="Amp"  
CDS 755..2905  
/label="A. thaliana PAL2"  
rep\_origin complement(3936..4618)  
/label="colE1 origin"  
misc\_feature 3712..3782  
/label="recombined out"  
misc\_feature 2906..2956  
/label="A(EAAAK) 3A linker"  
CDS 2957..3673  
/label="sfGFP"  
terminator 4624..4729  
/label="T0"  
RBS 735..754  
/label="B0030 RBS"  
protein\_bind 668..686  
/label="Q1"

ORIGIN

```
1 AAAAGTGCCA CCTGACGTCT TAAGACCCAC TTTCACATTT AAGTTGTTTT TCTAATCCGC
61 ATATGATCAA TTCAAGGCCG AATAAGAAGG CTGGCTCTGC ACCTTGGTGA TCAAATAATT
121 CGATAGCTTG TCGTAATAAT GCGGCATAC TATCAGTAGT AGGTGTTTCC CTTTCTTCTT
181 TAGCGACTTG ATGCTCTTGA TCTTCCAATA CGCAACCTAA AGTAAAATGC CCCACAGCGC
241 TGAGTGCATA TAATGCATTC TCTAGTGA AAAACCTTGTTG GCATAAAAAG GCTAATTGAT
301 TTTTCGAGAGT TTCATACTGT TTTTCTGTAG GCCGTGTACC TAAATGTACT TTTGCTCCAT
361 CCGGATGACT TAGTAAAGCA CATCTAAAAC TTTTAGCGTT ATTACGTAAA AAATCTTGCC
421 AGCTTTCCCC TTCTAAAGGG CAAAAGTGAG TATGGTGCCT ATCTAACATC TCAATGGCTA
481 AGGCGTTCGAG CAAAGCCCGC TTATTTTTTA CATGCCAATA CAATGTAGGC TGCTCTACAC
541 CTAGCTTCTG GCGGAGTTTA CGGGTGTTA AACCTTCGAT TCCGACCTCA TTAAGCAGCT
601 CTAATGCGCT GTTAATCACT TTACTTTTAT CTAATCTAGA CATCATTAAT TCCTAATTTT
661 TGTGACACT CTATCGTTGA TAGAGTTAT TTACCACTCC CTATCAGTGA TAGAGAAAAG
721 AATTCAAAAAG ATCTTTTAAAG AAGGAGATAT ACATATGGAT CAAATCGAAG CAATGTTGTG
781 CCGCGGAGGA GAGAAGACAA AAGTGGCGGT TACTACGAAG ACTTTGGCAG ATCCATTGAA
841 TTGGGGTTTA GCAGCGGATC AAATGAAAGG AAGTCATTTA GATGAAGTGA AGAAGATGGT
901 CGAAGAGTAT CGTAGACCAG TCGTGAATCT TGGCGGAGAA AACTGACGA TCGGACAAGT
961 TGCTGCCATC TCCACCGTAG GAGGCGCGT TAAGTTGAG TTAGCGGAGA CTTC AAGAGC
1021 CCGTGTGAAA GCTAGCAGTG ATTGGGTTAT GGAGAGCATG AACAAAGGTA CTGACAGTTA
1081 CCGAGTCACC ACCGGCTTTG GTGCTACTTC TCACCGGAGA ACCAAAAACG GCACCGCATT
1141 ACAAAACGAA CTCATTAGAT TTTTGAACGC CGGAATATTC GGAACACGA AGGAGACATG
1201 TCACACACTG CCGCAATCCG CCACAAGAGC CGCCATGCTC GTCAGAGTCA AACTCTTCT
1261 CCAAGGATAC TCCGGGATCC GATTCGAGAT CCTCGAAGCG ATTACAAGTC TCCTCAACCA
1321 CAACATCTCT CCGTCACTAC CTCTCCGTGG AACCAATTACC GCCTCCGGCG ATCTCGTTCC
1381 TCTCTCTTAC ATCGCCGGAC TTCTCACC GGTCCTAAT TCCAAAGCCA CCGGTCCCGA
1441 CGGTGAATCG CTAACCGCA AAGAAGCTTT TGAGAAAGCC GGAATCAGTA CTGGATTCTT
1501 CGATTTACAA CCTAAGGAAG GTTTAGCTCT CGTTAATGGC ACGGCGGTTG GATCTGGAAT
1561 GCGCTCGATG GTTCTATTCG AAGCGAATGT CCAAGCGGTG TTAGCGGAGG TTTTATCAGC
1621 GATCTTCGCG GAGGTTATGA GCGGAAACC TGAGTTTACC GATCATCTGA CTCATCGTTT
```

1681 AAAACATCAT CCCGGACAAA TCGAAGCGGC GGCATAATG GAGCACATAC TCGACGGAAG  
1741 CTCATACATG AAATTAGCTC AAAAGGTTCA CGAGATGGAT CCATTGCAGA AACCAAAACA  
1801 AGATCGTTAC GCTCTTCGTA CATCTCCTCA ATGGCTAGGT CCTCAAATTG AAGTAATCCG  
1861 TCAAGCTACG AAATCGATAG AGCGTGAAT CAACTCCGTT AACGATAATC CGTTGATCGA  
1921 TGTTTTCGAGG AACAAAGCGA TTCACGGTGG TAACTTCCAA GGAACACCAA TCGGAGTTTC  
1981 TATGGATAAC ACGAGATTGG CGATTGCTGC GATTGGGAAG CTAATGTTTG CTCAATTCTC  
2041 TGAGCTTGTT AATGATTCTT ACAACAATGG ACTCCTTCG AATCTAACTG CTTGAGTAA  
2101 TCCAAGTTTG GATTATGGAT TCAAAGGAGC AGAGATTGCT ATGGCTTCTT ATTGTTCTGA  
2161 GCTTCAATAC TTGGCTAATC CAGTCACAAG CCATGTTCAA TCAGCTGAGC AACATAATCA  
2221 AGATGTGAAC TCTCTTGTT TGATCTCGTC TCGTAAAACA TCTGAAGCTG TGGATATTCT  
2281 TAAGCTAATG TCAACAACGT TCCTTGTGGG GATATGTCAA GCTGTTGATT TGAGACATTT  
2341 GGAGGAGAAT CTGAGACAAA CTGTGAAGAA CACAGTTTCT CAAGTTGCTA AGAAAGTGTT  
2401 AACCACCTGA ATCAACGGTG AGTTACATCC GTCAAGGTTT TGCAGAGAAG ACTTGCTTAA  
2461 GGTGTTGATG CGTGAGCAAG TGTTCACGTA TGTGGATGAT CCTTGTAGCG CTACGTACCC  
2521 GTTGATGCAG AGACTAAGAC AAGTTATTGT TGATCACGCT TTGTCCAACG GTGAGACTGA  
2581 GAAGAATGCA GTGACTTCGA TCTTTCAAAA GATTGGAGCT TTTGAAGAGG AGCTTAAGGC  
2641 TGTGCTTCCA AAGGAAGTTG AAGCGGCTAG AGCGGCTTAT GGGAAATGGAA CTGCGCCGAT  
2701 TCCTAACCGG ATTAAGGAAT GTAGGTCGTA TCCGTTGTAT AGGTTCTGTA GGGAAGAGCT  
2761 TGGAACGAAG TTGTTGACTG GAGAAAAGGT TGTGTCTCCG GGAGAGGAGT TTGATAAGGT  
2821 CTTCACTGCT ATGTGTGAAG GTAACTTAT TGATCCGTTG ATGGATTGTC TCAAGGAATG  
2881 GAACGGAGCT CCGATTCCGA TTTGCGCGGA AGCGGCGGCG AAAGAAGCGG CGGCGAAAGA  
2941 AGCGGCGGCG AAAGCGATGA GCAAAGGAGA AGAACTTTTC ACTGGAGTTG TCCCAATTCT  
3001 TGTTGAATTA GATGGTGATG TTAATGGGCA CAAATTTTCT GTCCGTGGAG AGGGTGAAGG  
3061 TGATGCTACA AACGGAAAAC TCACCCTTAA ATTTATTTGC ACTACTGGAA AACTACCTGT  
3121 TCCGTGGCCA ACACTTGTC TACTCTGAC CTATGGTGT CAATGCTTTT CCGGTTATCC  
3181 GGATCACATG AAACGGCATG ACTTTTTCAA GAGTGCCATG CCCGAAGGTT ATGTACAGGA  
3241 ACGCACTATA TCTTTCAAAG ATGACGGGAC CTACAAGACG CGTGCTGAAG TCAAGTTTGA  
3301 AGGTGATACC CTTGTTAATC GTATCGAGTT AAAGGGTATT GATTTTAAAG AAGATGGAAA  
3361 CATTCTTGGG CACAAACTCG AGTACAACCT TAACTCACAC AATGTATACA TCACGGCAGA  
3421 CAAACAAAAG AATGGAATCA AAGCTAACTT CAAAATTCGC CACAACGTTG AAGATGGTTC  
3481 CGTTCAACTA GCAGACCATT ATCAACAAAA TACTCCAATT GCGGATGGCC CTGTCTTTTT  
3541 ACCAGACAAC CATTACCTGT CGACACAATC TGTCTTTTCG AAAGATCCCA ACGAAAAGCG  
3601 TGACCACATG GTCCTTCTTG AGTTTGTAAC TGCTGCTGGG ATTACACATG GCATGGATGA  
3661 GCTCTACAAA TAACCAGGCA TCAATAAAAA CGAAAGGCTC AGTCGAAAAGA CTGGGCCTTT  
3721 CGTTTTATCT GTTGTGTTGTC GGTGAACGCT CTCTACTAGA GTCACACTGG CTCACCTTCG  
3781 GGTGGGCCTT TCTGCGTTA TACCTAGGGC GTTCGGCTGC GCGGAGCGGT ATCAGCTCAC  
3841 TCAAAGGCGG TAATACGGTT ATCCACAGAA TCAGGGGATA ACGCAGGAAA GAACATGTGA  
3901 GCAAAGGCC AGCAAAGGC CAGGAACCGT AAAAAGGCCG CGTTGCTGGC GTTTTTCCAT  
3961 AGGCTCCGCC CCCTGACGA GCATCACAAA AATCGACGCT CAAGTCAGAG GTGGCGAAAC  
4021 CCGACAGGAC TATAAGATA CCAGGCGTTC CCCCCTGGAA GCTCCCTCGT GCGCTCTCCT  
4081 GTTCCGACCC TGCCGCTTAC CGGATACCTG TCCGCCTTTC TCCCTTCGGG AAGCGTGGCG  
4141 CTTTCTCATA GCTCACGCTG TAGGTATCTC AGTTCGGTGT AGGTCGTTTC TCCAAGCTG  
4201 GGCTGTGTGC ACGAACCCCC CGTTCAGCCC GACCGCTGCG CTTATCCGG TAACTATCGT  
4261 CTTGAGTCCA ACCCGGTAAG ACACGACTTA TCGCCACTGG CAGCAGCCAC TGGTAAACAGG  
4321 ATTAGCAGAG CGAGGTATGT AGGCGGTGCT ACAGAGTTCT TGAAGTGGTG GCCTAACTAC  
4381 GGCTACACTA GAAGGACAGT ATTTGGTATC TGCGCTCTGC TGAAGCCAGT TACCTTCGGA  
4441 AAAAAGGTTG GTAGCTCTTG ATCCGGCAA CAAACCACCG CTGGTAGCGG TGGTTTTTTT  
4501 GTTTGCAAGC AGCAGATTAC GCGCAGAAAA AAAGGATCTC AAGAAGATCC TTTGATCTTT  
4561 TCTACGGGGT CTGACGCTCA GTGGAACGAA AACTCACGTT AAGGGATTTT GGTCATGACT  
4621 AGTGCTTGGG TTCTACCAA TAAAAACGCG CCGGCGGCAA CCGAGCGTTC TGAACAAATC  
4681 CAGATGGAGT TCTGAGGTCA TTAAGGATC TATCAACAGG AGTCCAAGCG AGCTCGTAAA  
4741 CTTGGTCTGA CAGTTACCAA TGCTTAATCA GTGAGGCACC TATCTCAGCG ATCTGTCTAT  
4801 TTCGTTTATC CATAGTTGCC TGACTCCCCG TCGTGATGAT AACTACGATA CGGGAGGGCT  
4861 TACCATCTGG CCCAGTGCT GCAATGATAC CGCGAGACCC ACGCTCACCG GCTCCAGATT  
4921 TATCAGCAAT AAACCAGCCA GCCGGAAGGG CCGAGCGCAG AAGTGGTCTT GCAACTTTAT  
4981 CCGCCTCCAT CCAGTCTATT AATTGTTGCC GGAAGCTAG AGTAAAGTAG TCGCCAGTTA  
5041 ATAGTTTGGC CAACGTTGTT GCCATTGCTA CAGGCATCGT GGTGTCACG TCGTCGTTTG  
5101 GTATGGCTTC ATTCAGCTCC GGTTCCTAAC GATCAAGGCG AGTTACATGA TCCCCCATGT  
5161 TGTGCAAAAA AGCGGTTAGC TCCTTCGGTC CTCCGATCGT TGTGAGAAGT AAGTTGGCCG  
5221 CAGTGTTATC ACTCATGGTT ATGGCAGCAC TGATAAATC TCTTACTGTC ATGCATCCG  
5281 TAAGATGCTT TTCTGTGACT GGTGAGTACT CAACCAAGTC ATTCTGAGAA TAGTGTATGC  
5341 GGCGACCGAG TTGCTCTTGC CCGGCGTCAA TACGGGATAA TACCGGCCA CATAGCAGAA  
5401 CTTTAAAGT GTCATCATT GGAAAACGTT CTTCGGGGCG AAAACTCTCA AGGATCTTAC  
5461 CGCTGTTGAG ATCCAGTTCG ATGTAACCCA CTCGTGCACC CAACTGATCT TCAGCATCTT  
5521 TTAATTTTAC CAGCGTTTCT GGGTGAGCAA AAACAGGAAG GCAAATGACC GCAAAAAAGG  
5581 GAATAAGGGC GACACGGAAA TGTGAATAC TCATACTCTT CCTTTTTCAA TATTATTGAA

```
5641 GCATTTATCA GGGTTATTGT CTCATGAGCG GATACATATT TGAATGTATT TAGAAAAATA
5701 AACAAATAGG GGTTCGCGC ACATTTCCCC G
//
```

# pSFGFP.1

LOCUS pSFGFP.1 3543 bp ds-DNA circular 09-OCT-2017

DEFINITION .

FEATURES Location/Qualifiers

CDS complement(136..762)  
/label="tetR"  
misc\_feature complement(2687..3542)  
/label="Amp"  
promoter 763..838  
/label="Tn10 TetA Promoter"  
rep\_origin complement(1864..2546)  
/label="colE1 origin"  
misc\_feature 803..808  
/label="-10"  
misc\_feature 1602..1730  
/label="dbl term"  
misc\_feature 779..784  
/label="-35"  
misc\_feature 851..872  
/label="sfGFP\_RBS1"  
CDS 873..1589  
/label="sfGFP"  
protein\_bind 814..832  
/label="TetO2"  
protein\_bind 784..802  
/label="TetO1"  
terminator 2552..2657  
/label="T0"

ORIGIN

```
1 CTCTTCCTTT TTCAATATTA TTGAAGCATT TATCAGGGTT ATTGTCTCAT GAGCGGATAC
61 ATATTTGAAT GTATTTAGAA AAATAAACAA ATAGGGGTTT CGCGCACATT TCCCCGAAAA
121 GTGCCACCTG ACGTCTTAAG ACCCACTTTC ACATTTAAGT TGTTTTTCTA ATCCGCATAT
181 GATCAATFCA AGCCCGAATA AGAAGGCTGG CTCTGCACCT TGGTGATCAA ATAATTCGAT
241 AGCTTGTCGT AATAATGGCG GCATACTATC AGTAGTAGGT GTTTCCCTTT CTTCCTTAGC
301 GACTTGATGC TCTTGATCTT CCAATACGCA ACCTAAAGTA AAATGCCCCA CAGCGCTGAG
361 TGCATATAAT GCATTCTCTA GTGAAAAACC TTGTTGGCAT AAAAAGGCTA ATTGATTTTC
421 GAGAGTTTCA TACTGTTTTT CTGTAGGCCG TGTACCTAAA TGTACTTTTG CTCCATCGCG
481 ATGACTTAGT AAAGCACATC TAAACTTTT AGCGTTATTA CGTAAAAAAT CTTGCCAGCT
541 TTCCCTTCT AAAGGGCAAA AGTGAGTATG GTGCCTATCT AACATCTCAA TGGCTAAGGC
601 GTCGAGCAA CCCCGCTTAT TTTTACATG CCAATACAAT GTAGGCTGCT CTACACCTAG
661 CTCTGGGCG AGTTACGGG TTGTTAAACC TTCGATTCCG ACCTCATTAA GCAGCTCTAA
721 TCGCCTGTTA ATCACTTTAC TTTTATCTAA TCTAGACATC ATTAATTCCT AATTTTGTG
781 GACACTCTAT CGTTGATAGA GTTATTTTAC CACTCCCTAT CAGTGATAGA GAAAAGAATT
841 CAAAAGATCT GGAATAATTA AGGAGGTATA AAATGAGCAA AGGAGAAGAA CTTTTCACTG
901 GAGTTGTCCC AATCTTGTG GAATTAGATG GTGATGTTAA TGGGCACAAA TTTTCTGTCC
961 GTGGAGAGGG TGAAGGTGAT GCTACAAACG GAAAACCTAC CCTTAAATTT ATTTGCACTA
1021 CTGAAAAACT ACCTGTTCGG TGGCCAACAC TTGTCACTAC TCTGACCTAT GGTGTTCAAT
1081 GCTTTTCCCG TTATCCGGAT CACATGAAAC GGCATGACTT TTTCAAGAGT GCCATGCCCG
1141 AAGGTTATGT ACAGGAACGC ACTATATCTT TCAAAGATGA CGGGACCTAC AAGACGCGTG
1201 CTGAAGTCAA GTTTGAAGGT GATACCCTTG TTAATCGTAT CGAGTTAAAG GGTATTGATT
1261 TTAAAGAAGA TGGAAACATT CTGGACACA AACTCGAGTA CAACTTTAAC TCACACAATG
1321 TATACATCAC GGCAGACAAA CAAAAGAATG GAATCAAAGC TAACCTCAA ATTCGCCACA
1381 ACGTTGAAGA TGTTCCGTT CAACTAGCAG ACCATTATCA ACAAATACT CCAATTGGCG
1441 ATGGCCCTGT CTTTTACCA GACAACCATT ACCTGTCGAC ACAATCTGTC CTTTCGAAAG
1501 ATCCCAACGA AAAGCGTGAC CACATGGTCC TTCTTGAGTT TGTAAGTCTGCT GCTGGGATTA
1561 CACATGGCAT GGATGAGTCT TACAATAAG AGTAAGGATC TCCAGGCATC AAATAAACG
1621 AAAGGCTCAG TCGAAAGACT GGCCTTTTCG TTTTATCTGT TGTGTCGG TGAACGCTCT
1681 CTAAGTAGAGT CACTAGGCT CACCTTCGGG TGGGCTTTC TCGGTTTATA CCTAGGGCGT
1741 TCGGCTGCGG CGAGCGGTAT CAGCTCAGTC AAAGGCGGTA ATACGGTTAT CCACAGAATC
1801 AGGGGATAAC GCAGGAAAGA ACATGTGAGC AAAAGGCCAG CAAAAGGCCA GGAACCGTAA
1861 AAAGCCCGG TTGCTGGCGT TTTTCCATAG GCTCCGCCCT CCTGACGAGC ATCACAATAA
1921 TCGACGCTCA AGTCAAGAGG GCGGAAACCC GACAGGACTA TAAAGATACC AGGCGTTTCC
1981 CCCTGGAAGC TCCCTCGTGC GCTCTCTGT TCCGACCCTG CCGCTTACCG GATACCTGTC
2041 GCCTTTCTC CTTTCGGGAA GCGTGGCGCT TTCTCATAGC TCACGCTGTA GGTATCTCAG
```



2101 TTCGGTGTAG GTCGTTGCT CCAAGCTGGG CTGTGTGCAC GAACCCCGG TTCAGCCCGA  
2161 CCGCTGCGCC TTATCCGGTA ACTATCGTCT TGAGTCCAAC CCGGTAAGAC ACGACTTATC  
2221 GCCACTGGCA GCAGCCACTG GTAACAGGAT TAGCAGAGCG AGGTATGTAG GCGGTGCTAC  
2281 AGAGTTCTTG AAGTGGTGGC CTAACACGG CTACACTAGA AGGACAGTAT TTGGTATCTG  
2341 CGCTCTGCTG AAGCCAGTTA CCTTCGGAAA AAGAGTTGGT AGCTCTTGAT CCGGCAAACA  
2401 AACCACCGCT GGTAGCGGTG GTTTTTTTGT TTGCAAGCAG CAGATTACGC GCAGAAAAAA  
2461 AGGATCTCAA GAAGATCCTT TGATCTTTTC TACGGGGTCT GACGCTCAGT GGAACGAAAA  
2521 CTCACGTAA GGGATTTTGG TCATGACTAG TGCTTGATT CTCACCAATA AAAAACGCCC  
2581 GCGGCAACC GAGCGTTCTG AACAAATCCA GATGGAGTTC TGAGGTCATT ACTGGATCTA  
2641 TCAACAGGAG TCCAAGCGAG CTCGTAAACT TGGTCTGACA GTTACCAATG CTTAATCAGT  
2701 GAGGCACCTA TCTCAGCGAT CTGTCTATTT CGTTCATCCA TAGTTGCCG ACTCCCCGTC  
2761 GTGTAGATAA CTACGATACG GGAGGGCTTA CCATCTGGCC CCAGTGCTGC AATGATACCG  
2821 CGAGACCCAC GTCACCCGGC TCCAGATTTA TCAGCAATAA ACCAGCCAGC CGGAAGGGCC  
2881 GAGCGCAGAA GTGGTCCTGC AACTTTATCC GCCTCCATCC AGTCTATTAA TTGTTGCCGG  
2941 GAAGCTAGAG TAAGTAGTTC GCCAGTTAAT AGTTTGCACA ACGTTGTTGC CATTGCTACA  
3001 GGCATCGTGG TGTCACGCTC GTCGTTTGGT ATGGCTTCAT TCAGCTCCGG TTCCCAACGA  
3061 TCAAGGCGAG TTACATGATC CCCCATGTTG TGCAAAAAAG CGGTTAGCTC CTTCCGGTCT  
3121 CCGATCGTTG TCAGAAGTAA GTTGGCCGCA GTGTTATCAC TCATGGTTAT GGCAGCACTG  
3181 CATAATTCTC TTAATGTCAT GCCATCCGTA AGATGCTTTT CTGTGACTGG TGAGTACTCA  
3241 ACCAAGTCAT TCTGAGAATA GTGTATGCGG CGACCGAGTT GCTCTTGCCC GGGTCAATA  
3301 CGGGATAATA CCGCGCCACA TAGCAGAACT TTA AAAAGTGC TCATCATTGG AAAACGTTCT  
3361 TCGGGGCGAA AACTCTCAAG GATCTTACCG CTGTTGAGAT CCAGTTCGAT GTAACCCACT  
3421 CGTGCACCCA ACTGATCTTC AGCATCTTTT ACTTTCACCA GCGTTTCTGG GTGAGCAAAA  
3481 ACAGGAAGGC AAAATGCCGC AAAAAGGGA ATAAGGGCGA CACGGAATG TTGAATACTC  
3541 ATA

//

## pJTS123

LOCUS pJTS123 6149 bp ds-DNA circular 09-OCT-2017

DEFINITION .

FEATURES Location/Qualifiers  
misc\_feature complement(138..993)  
/label="Amp"  
misc\_feature 3965..4306  
/label="pfPapB\_Opt"  
promoter 1757..1829  
/label="tet promoter region"  
misc\_feature 4307..4328  
/label="pfPapC\_RBS1"  
rep\_origin 5464..6146  
/label="ColE1"  
misc\_feature 1845..1869  
/label="pfPapA\_RBS1"  
misc\_feature 1870..3939  
/label="pfPapA\_Opt"  
CDS complement(1130..1756)  
/label="tetR"  
protein\_bind 1778..1796  
/label="Q1"  
misc\_feature 3940..3964  
/label="pfPapB\_RBS1"  
terminator 3..108  
/label="T0"  
misc\_feature 4329..5201  
/label="pfPapC\_Opt"  
terminator 5202..5330  
/label="dbl\_terminator"  
protein\_bind 1808..1824  
/label="Q2"

ORIGIN

```
1 GTGCTTGGAT TCTCACCAAT AAAAAACGCC CGGCGGCAAC CGAGCGTTCT GAACAAATCC
61 AGATGGAGTT CTGAGGTCAT TACTGGATCT ATCAACAGGA GTCCAAGCGA GTCGCTAAAC
121 TTGGTCTGAC AGTTACCAAT GCTTAATCAG TGAGGCACCT ATCTCAGCGA TCTGTCTATT
181 TCGTTCATCC ATAGTTGCCCT GACTCCCCGT CGTGTAGATA ACTACGATAC GGGAGGGCTT
241 ACCATCTGGC CCCAGTGCTG CAATGATACC GCGAGACCCA CGCTCACCGG CTCCAGATTT
301 ATCAGCAATA AACCAGCCAG CCGGAAGGGC CGAGCGCAGA AGTGGTCCCTG CAACTTTATC
361 CGCCTCCATC CAGTCTATTA ATTGTTGCCG GGAAGCTAGA GTAAGTAGTT CGCCAGTTAA
421 TAGTTTGGCG AACGTTGTTG CCATTGCTAC AGGCATCGTG GTGTCACGCT CGTCGTTTGG
481 TATGGCTTCA TTCAGCTCCG GTTCCCAACG ATCAAGGCGA GTTACATGAT CCCCATGTT
541 GTGCAAAAAA GCGGTTAGCT CCTTCGGTCC TCCGATCGTT GTCAGAAGTA AGTTGGCCGC
601 AGTGTATCA CTCATGGTTA TGGCAGCACT GCATAATTCT CTTACTGTCA TGCCATCCGT
661 AAGATGCTTT TCTGTGACTG GTGAGTACTC AACCAAGTCA TTCTGAGAAT AGTGTATGCG
721 GCACCCGAGT TGTCTTGCC CGGCGTCAAT ACGGGATAAT ACCGCGCCAC ATAGCAGAAC
781 TTTAAAAGTG CTCATCATTG GAAAACGTTT TTCGGGGCGA AACTCTCAA GGATCTTACC
841 GCTGTTGAGA TCCAGTTCGA TGTAACCCAC TCGTGCACCC AACTGATCTT CAGCATCTTT
901 TACTTTCACC AGCGTTTCTG GGTGAGCAAA AACAGGAAGG CAAAATGCCG CAAAAAGGG
961 AATAAGGGCG ACACGGAAAT GTTGAATACT CATACTCTTC CTTTTTCAAT ATTATTGAAG
1021 CATTTATCAG GGTATTGTC TCATGAGCGG ATACATATTT GAATGTATTT AGAAAAATAA
1081 ACAAATAGGG GTTCCGCGCA CATTTCCCG AAAAGTGCCA CTGACGTCT TAAGACCCAC
1141 TTCACATTT AAGTTGTTTT TCTAATCCGC ATATGATCAA TTCAGGCCG AATAAGAAGG
```

1201 CTGGCTCTGC ACCTTGGTGA TCAAATAATT CGATAGCTTG TCGTAATAAT GGCGGCATAC  
1261 TATCAGTAGT AGGTGTTTTCC CTTTCTTCTT TAGCGACTTG ATGCTCTTGA TCTTCCAATA  
1321 CGCAACCTAA AGTAAAAATGC CCCACAGCGC TGAGTGCATA TAATGCATTC TCTAGTGAAA  
1381 AACCTTGTG GCATAAAAAAG GCTAATTGAT TTTCGAGAGT TTCATACTGT TTTTCTGTAG  
1441 GCCGTGTACC TAAATGTACT TTTGCTCCAT CGCGATGACT TAGTAAAGCA CATCTAAAAC  
1501 TTTTAGCGTT ATTACGTAAA AAATCTTGCC AGCTTTCCCC TTCTAAAGGG CAAAAGTGAG  
1561 TATGGTGCCT ATCTAACATC TCAATGGCCTA AGGCGTCGAG CAAAGCCCGC TTATTTTTTA  
1621 CATGCCAATA CAATGTAGGC TGCTCTACAC CTAGCTTCTG GCGGAGTTTA CGGGTTGTTA  
1681 AACCTTCGAT TCCGACCTCA TTAAGCAGCT CTAATGCGCT GTTAATCACT TTACTTTTAT  
1741 CTAACTAGA CATCATTAAAT TCCTAATTTT TGTGACTACT CTATCGTTGA TAGAGTTATT  
1801 TTACCACTCC CTATCAGTGA TAGAGAAAAG AATTCAAAAG ATCTAACTGG TAATTTGAGG  
1861 AGGTAATTTA TGAAGATCCT GCTGATCGAT AACTTTGATA GCTTCACCCA GAATATTGCC  
1921 CAGTATCTGT ATGAAGTTAC CGGTATTTGT GCCGATATTG TTACCAATAC CGTGACCTAT  
1981 GAACATCTGC AAATCGAACA GTATGATGCC GTTGTCTGA GCCCTGGTCC GGGTCATCCG  
2041 GGTGAATATC TGGATTTTGG TGTGTGTGGT CAGGTGATTC TGCATAGTCC GGTCCGCTG  
2101 CTGGGTATTT GTCTGGGTCA TCAGGGTATT GCACAGTTT TAGGTGGCAC CGTTGGTCAT  
2161 GCACCGACAC CGGTTTCATGG TTATCGTAGC AAAATTACCC ATAGCGGTAG CGGTCTGTTT  
2221 CGTGATCTGC CGGAACAGTT TGAAGTTGTT CGTTATCATA GCCTGATGTG TACCCATCTG  
2281 CCGCAAGAAC TCGGTTGTAC CGCATGGACC GAAGAGGGTG TTGTATGGC AATGAACAT  
2341 GAAAGCCGTC CGATTTGGGG TGTTACGTTT CATCCGAAA GCATTGATAG CGAATATGGT  
2401 CATGCCCTGC TGAGCAACTT TATTGGTATG GCCATCGAAC ATAATGGCAA TCATCGTACC  
2461 AGCGCAACCC AGAATCCGGA TGCAAGCGCA AGCGCCAATG AACATTATCG TGCAAGTTGGT  
2521 GGTCTGTGTA ATATGCAGCT GGCTATCGT ACCTATCCGG GTCCGTTTGA TCCGCTGGCA  
2581 CTGTTTACCC AGCGTTATGC ACAGGATCAT CATGCATTTT GGCTGGATAG CGAAAAAGC  
2641 GAACGTCCGA ATGCACGTTA TAGCATTATG GGTAGTGGTC AGGCACAGGG TAGCATTCTG  
2701 CTGACATATG ATGTTAATAG CGAAAGTCTG ACCCTGGCAG GTCCGAAAGG TAGCCGTATT  
2761 GTGACCGGTG ATTTTTTAC CCGTTTTAGC CAGATTGTTG AAAGCGTTAA TGTGTCAGTT  
2821 CCGCAGTATC TGCCGTTTGA GTTAAAGGT GGTTTTGTGG GTTATATGGG CTATGAACTG  
2881 AAAGCACTGA CCGGTGGTAA TAAAGTGTAT CGTAGCGGTC AGCCGGATGC AGGTTTTATG  
2941 TTTGCACCGC ATTTTTTTGT GTTCGATCAT CACGATCAGA CCGTGTATGA GTGCATGATT  
3001 AGCGCAACCG GTCAGAGTCC GCAGTGGCCT CAGCTGCTGA CCAGCATGAC CACTGAAT  
3061 AATGCAACCG ATCGTCGTCC GTTGTTCCT GGTGCAGTTG ATGAACTGGA ACTGAGCCTG  
3121 GAAGATGGTC CGGATGATTA TATTCGTAAA GTTAAACAGA GCCTGCAGTA TATTACCGAT  
3181 GGTGAAAGCT ATGAAATCTG TCTGACCAAT CGTGCACGTA TGAGCTATAG CCGTGAACCG  
3241 CTGGCAGCAT ATCGTCGTAT GCGTGAAGCA TCACCGGTC CGTATGGTGC ATATCTGTGT  
3301 TTTGATAGTT TTAGCGTTCT GAGCGCAAGT CCGGAAACCT TTCTGCGTAT TGATGAAGGT  
3361 GGTCTGATTG AATCACGTCC GATTAAAGGC ACCCGTGCGC GTAGCAAAGA TCCGAGCGAA  
3421 GATCAGCGTC TGCGTAGCGA TCTGCAGGCA AGCACCAAAG ATCGTGCAGA AAATCTGATG  
3481 ATTGTTGATC TGGTTCGCCA TGATCTGAAT CAGGTTTGTG GTAGTGGTAG CGTTCATGTT  
3541 CCGCATATTT TTGCAGTTGA AAGCTTTAGC AGCGTTCATC AGCTGGTTAG CACCGTTCGT  
3601 GGTCACTGTC GTAATGATAT TAGCACCATG GAAGCAATTC GTCCCTGTTT TCCTGGTGGT  
3661 AGTATGACAG GTGCACCGAA AAAACGTACC ATGGAAATTA TTGATGGTCT GGAACCTGT  
3721 GCACGTGGTG TTTATAGTGG TGCATTAGGT TGGATTAGCT TTAGCGGTAG TGCAGAACTG  
3781 AGCATTGTTA TTCGTACCGC AGTGCTGCAT AAACAGCAGG CAGAATTTGG TATTGGTGGT  
3841 GCAATTGTTG CACATAGCGA TCCGAATGAA GAGCTTGAAG AGACGCTGGT CAAAGCCAGC  
3901 GTGCCTTATT ACAGTTTTTA CGCAGGGAGC GAAAAATGAA TAGTAATCAG TAAGGAGATA  
3961 AAGAATGAAC ATGACCGAAC ATCGTCATAT GAGCCCGACC ACACCGAGCG CAATCTGCA  
4021 GCCGCAGCGT GATCAGCTGG ATCGTATTAA CAATCATCTG GTTGTCTGTC TGGGTGAACG  
4081 TATGAGCGTT TGTATGGATA TTGCAGAACT GAAAGCAGCA CATGATATTC CGATGATGCA  
4141 GCCTCAGCGC ATTGTTCCAG TTCTGGATCA GCTGAAAGAT AAAAGCAGTA CCGTGGTCT  
4201 GCGTCCGAT TATGTTTACA GCGTTTTTAA ACTGATCATC GAGGAAACCT GCATCCAAGA  
4261 AGAACAGCTG ATTCAGCGTC GTCGTAATCA GGTCAGCGT AGCTAACGTA AATATAAGGA  
4321 GGTCAAACAT GAATACCAAT ACCGTTGTGG TTTTAGGTGG TGCAGGTCTG ATTTGGTAGCA  
4381 TGATTAGCCG TATTCTGAAA CAGTATGGTT ATTTTGTTCG TGTGGTTGAT CGTCGTCCGG  
4441 CAGAATTTGA ATGTGAATAT CATGAAATGG ACGTGACCAA ACCGTTTAAAT GATACCGGTG  
4501 CAGTTTTTCG TAATGCAACC GCAGTTGTTT TTGCACTGCC GGAAGCGGTT GCAGTTAGCG  
4561 CAATCCGTG GGTACCACC TTTCTGAGCA GCGAAGTTGT TCTGATCCG ACCTGTAGCG

4621 TTCAGGGTCC GTTCTATAAA GCACTGAAAG CAGCAGCACC GCGTCAGCCG TTTGTTGGTG  
4681 TTAATCCGAT GTTTAGCCCG AAAGTGGCGG TGCAGGGTCG TAGCGTTGCC GTTTGTGTTG  
4741 AAGATACCCA GGCAGCACAG ACCTTTATG AACGTCATCT GATGGAAGCC GGTATGAAAA  
4801 TTCGTCGTAT GACCCCGAGC GCACATGATG AACTGATGGC ACTGTGTGAG GCACATGCCG  
4861 ATGCAGCAAT TTTAGGTTTT GGTATGGCAC TGGCAAAAAG CAGCGTTGAT ATGGATATTG  
4921 TTGCAGAAAGT TATGCCTCCG CCTATGCGTA CCATGATGGC CCTGCTGAGT CGTATTCTGG  
4981 TTAATCCGCC TGAAGTTTAT TGGGATATTC AGCTGGAAAA TGATCAGGCA ACCGCACAGC  
5041 GTGATGCACT GGTTCATGGT CTGGAACGTC TGCAAGAAAA TATTGTGGAA CAGGATTATG  
5101 AGCGCTTCAA AAGCGATCTG CAGAGCGTTA GCACCGCACT GGGTAAACGT CTGAATGCCG  
5161 GTGCAGTTGA TTGTCAGCAC CTGTTTAGCC TGCTGAATTA ACCAGGCATC AAATAAAACG  
5221 AAAGGCTCAG TCGAAAAGACT GGGCCTTTCG TTTTATCTGT TGTTTGTCGG TGAACGCTCT  
5281 CTAAGTAGAGT CACACTGGCT CACCTTCGGG TGGCCTTTC TCGTTTTATA CCTAGGGCGT  
5341 TCGGCTGCCG CGAGCGGTAT CAGCTCACTC AAAGGCGGTA ATACGGTTAT CCACAGAATC  
5401 AGGGGATAAC GCAGGAAAGA ACATGTGAGC AAAAGGCCAG CAAAAGGCCA GGAACCGTAA  
5461 AAAGGCCCGG TTGCTGGCGT TTTTCCATAG GCTCCGCCCC CCTGACGAGC ATCACAACAA  
5521 TCGACGCTCA AGTCAGAGGT GCGGAAACCC GACAGGACTA TAAAGATACC AGGCGTTTCC  
5581 CCCTGGAAGC TCCCTCGTGC GCTCTCCTGT TCCGACCCTG CCGCTTACCG GATACCTGTC  
5641 CGCCTTTCTC CCTTCGGGAA GCGTGGCGCT TTCTCATAGC TCACGCTGTA GGTATCTCAG  
5701 TTCGGTGTAG GTCGTTGCT CCAAGCTGGG CTGTGTGCAC GAACCCCCCG TTCAGCCCGA  
5761 CCGCTGCGCC TTATCCGGTA ACTATCGTCT TGAGTCCAAC CCGTAAGAC ACGACTTATC  
5821 GCCACTGGCA GCAGCCACTG GTAACAGGAT TAGCAGAGCG AGGTATGTAG GCGGTGCTAC  
5881 AGAGTTCTTG AAGTGGTGGC CTAACACGG CTACACTAGA AGGACAGTAT TTGGTATCTG  
5941 CGCTCTGCTG AAGCCAGTTA CCTTCGGAAA AAGAGTTGGT AGCTCTTGAT CCGGCAAACA  
6001 AACCACCGCT GGTAGCGGTG GTTTTTTTGT TTGCAAGCAG CAGATTACGC GCAGAAAAAA  
6061 AGGATCTCAA GAAGATCCTT TGATCTTTTC TACGGGGTCT GACGCTCAGT GGAACGAAAA  
6121 CTCACGTTAA GGGATTTTGG TCATGACTA

//

# pJTS111

LOCUS JTS111 4514 bp ds-DNA circular 06-DEC-2017

DEFINITION .

FEATURES Location/Qualifiers

CDS complement(1000..1626)  
/label="tetR"  
CDS 1742..2794  
/label="aroG\_fbr"  
protein\_bind 1648..1666  
/label="Q1"  
misc\_feature complement(21..815)  
/label="Kan/neoR"  
misc\_feature 1715..1741  
/label="PapA\_RBS2"  
terminator 3340..3468  
/label="dbl\_terminator"  
rep\_origin complement(3602..4313)  
/label="p15a"  
terminator 4404..4509  
/label="TO"  
promoter 1627..1699  
/label="tet promoter region"  
CDS 2815..3339  
/label="aroL"  
protein\_bind 1678..1694  
/label="Q2"

ORIGIN

```
1 CTCGAACCCC AGAGTCCC GC TCAGAAGAAC TCGTCAAGAA GGCGATAGAA GGCGATGCGC
61 TGCGAATCGG GAGCGGCGAT ACCGTAAAGC ACGAGGAAGC GGTCAGCCCA TTCGCCGCCA
121 AGTCTTTCAG CAATATCACG GGTAGCCAAC GCTATGTCCT GATAGCGGTC CGCCACACCC
181 AGCCGGCCAC AGTCGATGAA TCCAGAAAAG CGGCCATTTT CCACCATGAT ATTCGGCAAG
241 CAGGCATCGC CATGGGTCAC GACGAGATCC TCGCCGTCGG GCATGCGCGC CTTGAGCCTG
301 GCGAACAGTT CCGCTGGCGC GAGCCCCTGA TGCTCTTCGT CCAGATCATC CTGATCGACA
361 AGACCGGCTT CCATCCGAGT ACGTGCTCGC TCGATGCGAT GTTTCGCTTG GTGGTCAAT
421 GGGCAGGTAG CCGGATCAAG CGTATGCAGC CGCCGCATTG CATCAGCCAT GATGGATACT
481 TTCTCGGCAG GAGCAAGGTG AGATGACAGG AGATCCTGCC CCGGCCTTC GCCCAATAGC
541 ATGCCAGTCCC TTCCCCTTC AGTGACAACG TCGAGCACAG CTGCGCAAGG AACGCCCGTC
601 GTGGCCAGCC ACGATAGCCG CGCTGCCTCG TCCTGCAGTT CATTAGGGC ACCGGACAGG
661 TCGGTCTTGA CAAAAAGAAC CGGGCGCCCC TCGCTGACA GCCGGAACAC GGCGGCATCA
721 GAGCAGCCGA TTGTCTGTTG TGCCAGTCA TAGCCGAATA GCCTCTCCAC CCAAGCGGCC
781 GGAGAACCTG CGTGCAATCC ATCTTGTTCA ATCATGCGAA ACGATCCTCA TCCTGTCTCT
841 TGATCAGATC ATGATCCCCT GCGCCATCAG ATCCTTGCGG GCAAGAAAGC CATCCAGTTT
901 ACTTTGCAGG GCTTCCCAAC CTTACCAGAG GCGCCCCAG CTGGCAATTC CGACGTCGGT
961 GCCTAATGAG TGAGCTAACT TACATTAATT GCGTTGCGCT TAAGACCCAC TTTCACATTT
1021 AAGTTGTTTT TCTAATCCGC ATATGATCAA TTCAAGGCCG AATAAGAAGG CTGGCTCTGC
1081 ACCTTGGTGA TCAAATAATT CGATAGCTTG TCCTAATAAT GGCGGCATAC TATCAGTAGT
1141 AGGTGTTTTCC CTTTCTTCTT TAGCGACTTG ATGCTCTTGA TCTTCCAATA CGCAACCTAA
1201 AGTAAAATGC CCCACAGCGC TGAGTGCATA TAATGCATTC TCTAGTGAAA AACCTTGTTG
1261 GCATAAAAAG GCTAATTGAT TTTCGAGAGT TTCATACTGT TTTTCTGTAG GCCGTGTACC
1321 TAAATGTACT TTTGCTCCAT CGCGATGACT TAGTAAAGCA CATCTAAAAC TTTTAGCGTT
1381 ATTACGTAAA AAATCTTGCC AGCTTTCCCC TTCTAAAGGG CAAAAGTGAG TATGGTGCCT
1441 ATCTAACATC TCAATGGCTA AGGCGTCGAG CAAAGCCCGC TTATTTTTTA CATGCCAATA
1501 CAATGTAGGC TGCTCTACAC CTAGCTTCTG GCGGAGTTTA CCGGTTGTTA AACCTTCGAT
1561 TCCGACCTCA TTAAGCAGCT CTAATGCGCT GTTAATCACT TTACTTTTTAT CTAATCTAGA
1621 CATCATTAAT TCCTAATTTT TGTGACACT CTATCGTTGA TAGAGTTATT TTACCCTCC
```

1681 CTATCAGTGA TAGAGAAAAG AATTCAAAAG ATCTAAATAA CCTAAACGAG AGGAAAGAAT  
1741 AATGAATTAT CAGAACGACG ATTTACGCAT CAAAGAAATC AAAGAGTTAC TTCCTCCTGT  
1801 CGCATTGCTG GAAAAATFCC CCGCTACTGA AAATGCCGCG AATACGGTTG CCCATGCCCG  
1861 AAAAGCGATC CATAAGATCC TGAAGGTAA TGATGATCGC CTGTTGGTTG TGATTGGCCC  
1921 ATGCTCAATT CATGATCCTG TCGCGGCAAA AGAGTATGCC ACTCGCTTGC TGGCGCTGCG  
1981 TGAAGAGCTG AAAGATGAGC TGGAAATCGT AATGCGCGTC TATTTTGAAA AGCCGCGTAC  
2041 CACGGTGGGC TGGAAAGGGC TGATTAACGA TCCGCATATG GATAATAGCT TCCAGATCAA  
2101 CGACGGTCTG CGTATAGCCC GTAAATTGCT GCTTGATATT AACGACAGCG GTCTGCCAGC  
2161 GGCAGGTGAG TTTCTCAACA TGATCACCCC ACAATATCTC GCTGACCTGA TGAGCTGGGG  
2221 CGCAATTGGC GCACGTACCA CCGAATCGCA GGTGCACCGC GAACTGGCAT CAGGGCTTTC  
2281 TTGTCCGCTC GGCTTCAAAA ATGGCACCGA CGGTACGATT AAAGTGGCTA TCGATGCCAT  
2341 TAATGCCGCC GGTGCGCCGC ACTGCTTCTT GTCCGTAACG AAATGGGGGC ATTCGGCGAT  
2401 TGTGAATACC AGCGGTAACG GCGATTGCCA TATCATTCTG CGCGGCGGTA AAGAGCCTAA  
2461 CTACAGCGCG AAGCACGTTG CTGAAGTGAA AGAAGGGCTG AACAAAGCAG GCCTGCCAGC  
2521 ACAGGTGATG ATCGATTTCA GCCATGCTAA CTCGTCCAAA CAATTCAAAA AGCAGATGGA  
2581 TGTTTGTGCT GACGTTTGCC AGCAGATTGC CGGTGGCGAA AAGGCCATTA TTGGCGTGAT  
2641 GGTGGAAAGC CATCTGGTGG AAGCAATCA GAGCCTGGAG AGCGGGGAGC CGCTGGCCTA  
2701 CGGTAAGAGC ATCACCGATG CCTGCATCGG CTGGGAAGAT ACCGATGCTC TGTTACGTCA  
2761 ACTGGCGAAT GCAGTAAAAG CGCGTCGCGG GTAAGGATCT AAAGGAGGCC ATCCATGACA  
2821 CAACCTCTTT TTCTGATCGG GCCTCGGGGC TGTGGTAAAA CAACGGTCCG AATGGCCCTT  
2881 GCCGATTCGC TTAACCGTCG GTTTGTGCGT ACCGATCAGT GGTGCAATC ACAGCTCAAT  
2941 ATGACGGTCC CGGAGATCGT CGAAAGGGAA GAGTGGGCGG GATTTGCGCG CAGAGAAACG  
3001 GCGGCGCTGG AAGCGGTAAC TGCGCCATCC ACCGTTATCG CTACAGGCGG CGGCATTATT  
3061 CTGACGGAAT TTAATCGTCA CTTATGCAA AATAACGGGA TCGTGGTTTA TTTGTGTGCG  
3121 CCAGTATCAG TCCTGGTTAA CCGACTGCAA GCTGCACCGG AAGAAGATTT ACGGCCAACC  
3181 TTAACGGGAA AACCGTGTAG CGAAGAAGTT CAGGAAGTGC TGGAGAACG CGATGCGCTA  
3241 TATCGCGAAG TTGCGCATAT TATCATCGAC GCAACAAACG AACCCAGCCA GGTGATTTCT  
3301 GAAATTGCGA GCGCCCTGGC ACAGACGATC AATGTTAAC CAGGCATCAA ATAAACGAA  
3361 AGGCTCAGTC GAAAGACTGG GCCTTTCGTT TTATCTGTTG TTTGTGCGTG AACGCTCTCT  
3421 ACTAGAGTCA CACTGGCTCA CCTTCGGGTG GGCTTTCTG CGTTTATACC TAGGGCGTTC  
3481 GGCTGCGGCG AGCGGTATCA GCTCACTCAA AGGCGGTAAT ACGGTTATCC ACAGAATCAG  
3541 GGGATAACGC AGGAAAGAAC ATGTGAGCAA AAGGCCAGCA AAAGGCCAGG AACCGTAAAA  
3601 AGATATATTC CGCTTCCTCG CTCACTGACT CGCTACGCTC GGTGTTTCCA CTGCGGCGAG  
3661 CGGAAATGGC TTACGAACGG GCGGAGATT TCCTGGAAGA TGCCAGGAAG ATACTTAACA  
3721 GGGAAAGTGA AGGGCCGCGG CAAAGCCGTT TTCCATAGG CTCGCCCCC CTGACAAGCA  
3781 TCACGAAATC TGACGCTCAA ATCAGTGGTG GCGAAACCCG ACAGGACTAT AAAGATACCA  
3841 GGCGTTTCCC CCTGGCGGCT CCCTCGTGCG CTCTCCTGTT CCTGCCTTTC GGTTTACCGG  
3901 TGTCATTCCG CTGTTATGGC CGCGTTTGTG TCATTCCACG CCTGACACTC AGTCCGGGT  
3961 AGGCAGTTCG CTCCAAGCTG GACTGTATGC ACGAACCCCG CGTTCAGTCC GACCGCTGCG  
4021 CCTTATCCGG TAACTATCGT CTTGAGTCCA ACCCGGAAAG ACATGCAAAA GCACCACTGG  
4081 CAGCAGCCAC TGTAATTGA TTTAGAGGAG TTAGTCTTGA AGTCATGCGC CGGTTAAGGC  
4141 TAAACTGAAA GGACAAGTTT TGGTACTGC GCTCCTCCAA GCCAGTTACC TCGGTTCAAA  
4201 GAGTTGGTAG CTCAGAGAAC CTTGCAAAA CCGCCCTGCA AGGCGGTTTT TTCGTTTTCA  
4261 GAGCAAGAGA TTACGCGCAG ACCAAAACGA TCTCAAGAAG ATCATCTTAT TAATCAGATA  
4321 AAATATTTCT AGATTTCACT GCAATTTATC TCTTCAAATG TAGCACCTGA AGTCAGCCCC  
4381 ATACGATATA AGTTGTTACT AGTGCTTGGG TTCTACCAA TAAAAACGC CCGGCGCAA  
4441 CCGAGCGTTC TGAACAAATC CAGATGGAGT TCTGAGGTCA TTAAGGATC TATCAACAGG  
4501 AGTCCAAGCG AGCT

//

# pDSY2F

LOCUS pDSY2f 3014 bp ds-DNA circular 14-SEP-2016

DEFINITION .

FEATURES

	Location/Qualifiers
misc_feature	2806..2911 /label="T0" /ApEinfo_revcolor=#ffef86 /ApEinfo_fwdcolor=#ffef86
CDS	1139..1855 /label="sfGFP" /ApEinfo_revcolor=#ff9ccd /ApEinfo_fwdcolor=#ff9ccd
misc_feature	969..1112 /label="pAF_sTRSV1_155 Aptazyme" /ApEinfo_revcolor=#f58a5e /ApEinfo_fwdcolor=#f58a5e
misc_feature	961..968 /label="5' Insulator" /ApEinfo_revcolor=#85dae9 /ApEinfo_fwdcolor=#85dae9
misc_feature	complement(2118..2800) /label="colE1 origin" /ApEinfo_revcolor=#9eafd2 /ApEinfo_fwdcolor=#9eafd2
misc_feature	1113..1119 /label="3' Insulator" /ApEinfo_revcolor=#faac61 /ApEinfo_fwdcolor=#faac61
misc_feature	1856..1984 /label="dbl term" /ApEinfo_revcolor=#75c6a9 /ApEinfo_fwdcolor=#75c6a9
misc_feature	919..935 /label="T7 promoter" /ApEinfo_revcolor=#faac61 /ApEinfo_fwdcolor=#faac61
misc_feature	1120..1138 /label="Bglbrick RBS" /ApEinfo_revcolor=#d6b295 /ApEinfo_fwdcolor=#d6b295
misc_feature	complement(2941..3014) /label="Amp" /ApEinfo_revcolor=#b1ff67 /ApEinfo_fwdcolor=#b1ff67
misc_feature	complement(1..782) /label="Amp" /ApEinfo_revcolor=#b1ff67 /ApEinfo_fwdcolor=#b1ff67
misc_feature	936..960 /label="T7 UTR" /ApEinfo_revcolor=#ffef86 /ApEinfo_fwdcolor=#ffef86

ORIGIN

```
1 GTGTAGATAA CTACGATACG GGAGGGCTTA CCATCTGGCC CCAGTGCTGC AATGATACCG
61 CGAGACCCAC GTCACCGGC TCCAGATTTA TCAGCAATAA ACCAGCCAGC CGGAAGGGCC
```

121 GAGCGCAGAA GTGGTCCTGC AACTTTATCC GCCTCCATCC AGTCTATTAA TTGTTGCCGG  
181 GAAGCTAGAG TAAGTAGTTC GCCAGTTAAT AGTTTGCGCA ACGTTGTTGC CATTGCTACA  
241 GGCATCGTGG TGTCACGCTC GTCGTTTGGT ATGGCTTCAT TCAGCTCCGG TCCCAACGA  
301 TCAAGGCGAG TTACATGATC CCCCATGTTG TGCAAAAAAG CGGTTAGCTC CTTCGGTCCT  
361 CCGATCGTTG TCAGAAAGTAA GTTGGCCGCA GTGTTATCAC TCATGGTTAT GGCAGCACTG  
421 CATAATTCTC TTACTGTTCAT GCCATCCGTA AGATGCTTTT CTGTGACTGG TGAGTACTCA  
481 ACCAAGTCAT TCTGAGAATA GTGTATGCGG CGACCGAGTT GCTCTTGCCC GGCCTCAATA  
541 CGGGATAATA CCGCGCCACA TAGCAGAACT TTAAAAGTGC TCATCATTGG AAAACGTTCT  
601 TCGGGGCGAA AACTCTCAAG GATCTTACCG CTGTTGAGAT CCAGTTCGAT GTAACCCACT  
661 CTCGAGCCCA ACTGATCTTC AGCATCTTTT ACTTTCACCA GCGTTTCTGG GTGAGCAAAA  
721 ACAGGAAGGC AAAATGCCGC AAAAAAGGGA ATAAGGGCGA CACGGAAATG TTGAATACTC  
781 ATACTCTTCC TTTTTCATA TTATTGAAGC ATTTATCAGG GTTATTGTCT CATGAGCGGA  
841 TACATATTTG AATGTATTTA GAAAAATAAA CAAATAGGGG TTCCGCGCAC ATTTCCCCGA  
901 AAAGTGCCAC CTGACGTCTA ATACGACTCA CTATAGGGAC GACGACAGGC ACCCGAACTC  
961 CGTCCCTTGG GAATGCCTCA TAACAGGTGA TCAGTAGCCT GTACAGCTTC GGCTGCGTCC  
1021 TACTATACGG ACTATGAGGC TCGAGAAAGA ATTCTGTTAT GAGGCATTCA CCGGTAACCG  
1081 GTCTGATGAG TCCGTGAGGA CGAAAATGCC TCTCTGGACG AAAGAGGAGA AATACTAGAT  
1141 GAGCAAAGGA GAAGAACTTT TCACTGGAGT TGTCCCAATT CTTGTTGAAT TAGATGTTGA  
1201 TGTTAATGGG CACAAATTTT CTGTCCGTGG AGAGGGTGAA GGTGATGCTA CAAACGGAAA  
1261 ACTCACCTT AAATTTATTT GCACTACTGG AAAACTACCT GTTCCGTGGC CAACACTTGT  
1321 CACTACTCTG ACCTATGGTG TTCAATGCTT TTCCCCTTAT CCGGATCACA TGAAACGGCA  
1381 TGACTTTTTT AAGAGTGCCA TGCCCGAAGG TTATGTACAG GAACGCACTA TATCTTTCAA  
1441 AGATGACGGG ACCTACAAGA CGCGTGCTGA AGTCAAGTTT GAAGGTGATA CCCTTGTTAA  
1501 TCGTATCGAG TTAAAGGGTA TTGATTTTAA AGAAGATGGA AACATTCTTG GACACAACT  
1561 CGAGTACAAC TTTAACTCAC ACAATGTATA CATCACGGCA GACAAACAAA AGAATGGAAT  
1621 CAAAGCTAAC TTCAAATTC GCCACAACGT TGAAGATGGT TCCGTTCAAC TAGCAGACCA  
1681 TTATCAACAA AATACTCCAA TTGGCGATGG CCCTGTCTT TTACCAGACA ACCATTACCT  
1741 GTCGACACAA TCTGTCTTT CGAAAATGCC CAACGAAAAG CGTGACCACA TGGTCTTCT  
1801 TGAGTTTGTA ACTGTCTGTG GGATTACACA TGGCATGGAT GAGCTCTACA AATAACCAGG  
1861 CATCAAATAA AACGAAAGGC TCAGTCGAAA GACTGGGCCT TTCGTTTTAT CTGTTGTTTG  
1921 TCGGTGAACG CTCTCTACTA GAGTCACACT GGCTCACCTT CGGGTGGGCC TTTCTGCGTT  
1981 TATACCTAGG GCGTTCGGCT GCGGCGAGCG GTATCAGCTC ACTCAAAGGC GGTAATACGG  
2041 TTATCCACAG AATCAGGGGA TAACGCAGGA AAGAACATGT GAGCAAAGG CCAGCAAAG  
2101 GCCAGGAACC GTAAAAGGC GCGTTGCTG GCGTTTTTCC ATAGGCTCCG CCCCCTGAC  
2161 GAGCATCACA AAAATCGACG CTCAAGTCAG AGGTGGCGAA ACCCGACAGG ACTATAAAGA  
2221 TACCAGGCGT TTCCCCTTGG AAGCTCCCTC GTGCGCTCTC CTGTTCCGAC CCTGCCCTT  
2281 ACCGGATACC TGTCGGCTT TCTCCCTTGG GGAAGCGTGG CGCTTCTCA TAGCTCACGC  
2341 TGTAGGTATC TCAGTTCGGT GTAGGTGCTT CGCTCCAAGC TGGGCTGTGT GCACGAACCC  
2401 CCCGTTGAGC CCGACCGCTG CGCCTTATCC GGTAACATC GTCTTGAGTC CAACCCGGTA  
2461 AGACACGACT TATCGCCACT GGCAGCAGCC ACTGGTAACA GGATTAGCAG AGCGAGGTAT  
2521 GTAGGCGGTG CTACAGAGTT CTTGAAGTGG TGGCCTA ACTCGCTACAC TAGAAGGACA  
2581 GTATTTGGTA TCTGCGCTCT CTGAAGCCA GTTACCTTCG GAAAAAGAGT TGGTAGCTCT  
2641 TGATCCGGCA AACAAACCAC CGCTGGTAGC GGTGGTTTTT TTGTTTGCAA GCAGCAGATT  
2701 ACGCGCAGAA AAAAAGGATC TCAAGAAGAT CCTTTGATCT TTTCTACGGG GTCTGACGCT  
2761 CAGTGAACG AAAACTCACG TTAAGGGATT TTGGTCATGA CTAGTCTTG GATTCTCACC  
2821 AATAAAAAAC GCCCGCGCGC AACCGAGCGT TCTGAACAAA TCCAGATGGA GTTCTGAGGT  
2881 CATTACTGGA TCTATCAACA GGAGTCCAAG CGAGCTCGTA AACTTGGTCT GACAGTTACC  
2941 AATGCTTAAT CAGTGAGGCA CCTATCTCAG CGATCTGTCT ATTTCTGTTA TCCATAGTTG  
3001 CCTGACTCCC CGTC

//



# pJTS16

LOCUS pJTS16 6724 bp ds-DNA circular 20-JUN-2016  
DEFINITION .  
FEATURES Location/Qualifiers  
misc\_feature complement(5739..6594)  
/label="Amp"  
/ApEinfo\_revcolor=#ff9ccd  
/ApEinfo\_fwdcolor=#ff9ccd  
misc\_feature 1124..1162  
/label="Operator\_I1\_I2"  
/ApEinfo\_revcolor=#85dae9  
/ApEinfo\_fwdcolor=#85dae9  
RBS 3625..3642  
/label="PapC\_Mehl\_RBS"  
/ApEinfo\_revcolor=#ff9ccd  
/ApEinfo\_fwdcolor=#ff9ccd  
terminator 5604..5709  
/label="T0"  
/ApEinfo\_revcolor=#b1ff67  
/ApEinfo\_fwdcolor=#b1ff67  
promoter complement(1036..1064)  
/label="araC\_promoter"  
/ApEinfo\_revcolor=#c6c9d1  
/ApEinfo\_fwdcolor=#c6c9d1  
promoter 1161..1188  
/label="pBAD"  
/ApEinfo\_revcolor=#b4abac  
/ApEinfo\_fwdcolor=#b4abac  
RBS 1226..1241  
/label="PapA\_Mehl\_RBS"  
/ApEinfo\_revcolor=#f58a5e  
/ApEinfo\_fwdcolor=#f58a5e  
rep\_origin 4916..5598  
/label="ColE1"  
/ApEinfo\_revcolor=#9eafd2  
/ApEinfo\_fwdcolor=#9eafd2  
misc\_feature 1072..1093  
/label="Operator\_O1"  
/ApEinfo\_revcolor=#c7b0e3  
/ApEinfo\_fwdcolor=#c7b0e3  
CDS complement(7..885)  
/label="araC"  
/ApEinfo\_revcolor=#84b0dc  
/ApEinfo\_fwdcolor=#84b0dc  
CDS 3295..3624  
/label="PapB\_Opt"  
/ApEinfo\_revcolor=#f58a5e  
/ApEinfo\_fwdcolor=#f58a5e  
CDS 3643..4629  
/label="PapC\_Opt"  
/ApEinfo\_revcolor=#84b0dc  
/ApEinfo\_fwdcolor=#84b0dc  
RBS 3274..3294  
/label="PapB\_Mehl\_RBS"  
/ApEinfo\_revcolor=#d6b295

```

misc_feature      /ApEinfo_fwdcolor=#d6b295
                  1115..1128
                  /label="CAP_Site"
                  /ApEinfo_revcolor=#faac61
                  /ApEinfo_fwdcolor=#faac61
CDS               1242..3273
                  /label="PapA_Opt"
                  /ApEinfo_revcolor=#f58a5e
                  /ApEinfo_fwdcolor=#f58a5e
misc_feature      914..931
                  /label="Operator_O2"
                  /ApEinfo_revcolor=#ff9ccd
                  /ApEinfo_fwdcolor=#ff9ccd
terminator        4654..4782
                  /label="dbl_termimator"
                  /ApEinfo_revcolor=#85dae9
                  /ApEinfo_fwdcolor=#85dae9

```

ORIGIN

```

1  GACGTCTTAT GACAACTTGA CGGCTACATC ATTCACITTT TCTTCAACAC CGGCACGGAA
61  CTCGCTCGGG CTGGCCCCGG TGCATTTTTT AAATACCCGC GAGAAATAGA GTTGATCGTC
121 AAAACCAACA TTGCGACCGA CGGTGGCGAT AGGCATCCGG GTGGTGTCTA AAAGCAGCTT
181 CGCCTGGCTG ATACGTTGGT CCTCGCGCCA GCTTAAGACG CTAATCCCTA ACTGCTGGCG
241 GAAAAGATGT GACAGACGCG ACGGCACAAA GCAAACATGC TGTGCGACGC TGGCGATATC
301 AAAATGCTG TCTGCCAGGT GATCGCTGAT GACTGACAA GCCTCGCGTA CCCGATTATC
361 CATCGGTGGA TGGAGCGACT CGTTAATCGC TTCCATGCGC CGCAGTAACA ATTGCTCAAG
421 CAGATTTATC GCCAGCAGCT CCGAATAGCG CCCTTCCCCT TGCCCCGCGT TAATGATTTG
481 CCCAAACAGG TCGCTGAAAT CCGGCTGGTG CGCTTCATCC GGGCGAAAGA ACCCCGTATT
541 GGCAATATTT GACGGCCAGT TAAGCCATTC ATGCCAGTAG GCGCGCGGAC GAAAGTAAAC
601 CCACTGGTGA TACCATTGCG GAGCCTCCGG ATGACGACCG TAGTGATGAA TCTCTCCTGG
661 CGGGAACAGC AAAATATCAC CCGGTCGGCA AACAAATTCT CGTCCCCTGAT TTTTACCAC
721 CCCCTGACCG CGAATGGTGA GATTGAGAAT ATAACCTTTC ATTCCCAGCG GTCGGTCGAT
781 AAAAAAATCG AGATAACCGT TGGCCTCAAT CGGCGTTAAA CCCGCCACCA GATGGGCATT
841 AAACGAGTAT CCCGGCAGCA GGGGATCATT TTGCGTTTCA GCCATACTTT TCATATCCC
901 GCCATTCAGA GAAGAAACCA ATTTGCCATA TTGCATCAGA CATTGCCGTC ACTGCGTCTT
961 TTACTGGCTC TTCTCGCTAA CCAAACCGGT AACCCCGCTT ATTAAAAGCA TTCTGTAACA
1021 AAGCGGGACC AAAGCCATGA CAAAACCGCG TAACAAAAGT GTCTATAATC ACGGCAGAAA
1081 AGTCCACATT GATTATTTGC ACGGCGTAC ACCTTGTCTAT GCCATAGCAT TTTTATCCAT
1141 AAGATTAGCG GATTCTACCT GACGCTTTTT ATCGCAACTC TCTACTGTTT CTCCATACCC
1201 GTTTTTTTGG GAATTCAAAA GATCTCACAC AGGAAACAGC TATGCGTACC CTGCTGATTG
1261 ATAACATATG TAGCTTTACC CACAACCTGT TTCAGTATAT CCGTGAAGCA ACCGGTCAGC
1321 CTCGGTTTGT TGTTCGGAAT GATGAGATT GGAGCCGTCT GCCGCTGGAA GATTTTATAG
1381 CAATTGTTGT TAGTCCGGGT CCGGTTAGTC CGGATCGTGA ACGTGATTTT GGTATTAGCC
1441 GTCGTGCAAT TACCGATAGC GGTCTGCCGG TTCTGGGTGT TTGTCTGGGT CATCAGGGTA
1501 TTGCACAGCT GTTTGGTGGC ACCGTTGGTC TGGCACCGGA ACCGATGCAT GGTCGTGTTA
1561 GCGAAGTTTC TCATACCGGT GAAGATGTTT TTCGTGGTCT GCCGAGCCCG TTTACCGCAG
1621 TTCGTTATCA TAGCCTGGCA GCAACCGATC TGCCGGATGA ACTGGAACCG CTGGCCTGGT
1681 CAGATGATGG TGTGTTATG GGTCTGCGTC ATCGTGAAAA ACCGCTGTGG GCAAGCAGCA
1741 GCACCGGTGT TCATCGTCAG CGTCTGCGTC CGGGTGATCA TGGTCAGCTG CCTCGTCCGC
1801 GTCCACGTCC GCCTCCGGGT ACAAGTCGTC GTGGTGTCTT GCCTGTTCGT ACACCGCGTG
1861 CACCGCGTCG TCGTGACGCA GGTCTGCGTC GCGGTACTCC GCGTCTGCCA GCACGTCTTC
1921 GTGCTCCCGC TAGCGGTTGG ACCGAGCAC CGAGCAGCAA AGCACCGCGT GACTGTCTGC
1981 CACGTCGTCG CCCTCGTCCG GCACGTCGTC TTCCGCATCT GCCTCGCCGT CGTCGGCGTC
2041 GCCTGCGTCC TCGGCTGCGT CGTCATCATG ATCCGGGTCG TGGTGATCCG CTGCAGCTGC
2101 CTGGTGGTGC AGCAGGTACA GCCGGTGGTA GTCGCCGTCC TCGTCTGTCG CTGCGTGTTC
2161 AGCCACGTCT GCGTCTGCTG CCACGCTGTC GTGCCGAAGG TGGTGATCAT CGTCTGCTTC
2221 GTAGCACCGG TCCGGCTCCG CGTCGCGCTG TTCCTCTGCG TCGCCCACGT CATCGTCTTC
2281 GCCACCTGGC ACGTCTGCTG CTGCTGTCAG GACCGCGTCC TCCTGGTCCA CGTCGCGCTC

```

2341 GGCCACGGCT GGCAGCTGGT GATGGTCGCG ATCCGCATCG TCCTGGCCGT CCACGCCCTG  
2401 CCGAAGCAGA TCCGCGTCAT GGTCTGCGTG GTCCGCGTGG TGGTGGACGG CTGCGTCCTC  
2461 CAGGTAGCCG TACCCTCGT CAGGGTCGTC TGGGTGCTCC GCAGCGTCGT GTTGTGCGTG  
2521 ATCTGCTGA TCAGCATGGT CATCGTGCAG ATCGTGGTGA CGGTCCGGCA GCACTGCTGC  
2581 GTGCGGCACC TCATCAACCG CGTCCGGTTT GGCCTCCTGC ACGCGTTCCG CGTGCAGTTG  
2641 GTGCACAGCG TCTGGCACGT GCAGTTCCGC ATGATCGGCG TCGTCGTCGC CGTCTGTGTT  
2701 AGGCACATCA GGGTGATCCG CCACCGGGTC GTACCGGTGG TGGCGGTCGT GCCGCACCTC  
2761 GTCGTCCAGG TCGTCTGGT GAAGGTCCTG GTCGTGAACC GGATGATCGC CGTCCGGGAC  
2821 CTCAGGCTCC TCAGCAGCGG CTGCGTGATC GTCTGCGTCC TCGTGCCCTC GCACTGCGTG  
2881 GTGAGTCGTC CAGGCTCGT GCACCGGCAG GCGTTGATCA TCCTGGCACC GCAGCAGCCC  
2941 GTCATCAGCA TCGTCGGCTG CGCACACGGC GTCTGCCTCG TCGTCTGCAT GATCGTCGTG  
3001 CACAAGAGGC AACCCATGGT GACCACCGTC CTCCGGGTGG TCGCCCTCCA GGCCGTCTGA  
3061 CACGTGGTGC ACGTATGGTT CGTCCGCAAC GCCGTGCGCG TCCGCAGCAT CGTCATCCGC  
3121 ATCATCGTGC CGGTGTCGCG CCTGGTCGCG TTCGGCGTCC GCGTGGGGAT CGTGTACCAC  
3181 TGCGTCTGG CGGTGGTGTG CAGGCCGATC GTGGTCAGGG TCCTCGTCAT GGCCATCGTC  
3241 CACGGCGTCA GCGTAGTGGT GGCCGTCCGA TGACACCAAC AAGGACCATA GCATATGACC  
3301 GAACAGAATG AACTGCAGGT TGCAGCAGCA CGTGGTGCAC GTCGTCCCGC TCGTGATGCA  
3361 AGCGGTTCAT GTGCAGCACC GCATCGTCCCT CGTTGTCCGC ATCGTGCAGT TCAGGTTCCG  
3421 GCACGCCGTC CGGATGATGC AGCAGTCCCT GGTCAGCCAG GTCAGGGCCA GGGTCGTCCT  
3481 CTGCGTCTGC GTCCACGTCC TCGTCTGATT GTTCCGGGTG AACCGCTGCG TCGCGATCAT  
3541 CATGGTGATG TTCCCGCTCG CGGTCCGGGT GATGAACCTG GTGAACCGGA TGGCCGTGGT  
3601 CCTGGCGAAC CGGTATGTG TAAATGTAC TAAGGAGGTT GTATGAGCGG TTTTCCGCGT  
3661 AGCGTTGTTG TTGGTGGTAG CGGTGCAGTG GGTGGTATGT TTGCAGGTCT GCTGCGTGAA  
3721 GCAGGTAGCC GTACCCTGGT TGTGATCTG GTTCCGCTC CGGGTCGTC GGATGCATGT  
3781 CTGGTTGGTG ATGTTACCGC ACCGGGTCCG GAACTGGCAG CAGCACTGCG TGATGCAGAT  
3841 TGTGTGCTGC TGGCGTTC AAGAGTGT GCACTGAAAG CAGTTGCACC GTTTACCGT  
3901 CTGATGCTGC CGGGTGCAC TGTGGCAGAT ACCCTGAGCG TTCGTACCGG TATGGCAGCA  
3961 GAGCTGGCAG CACATGCACC GGGTGTTCAG CATGTTGGTC TGAATCCGAT GTTTGCACCG  
4021 GCAGCAGGTA TGACAGGCCG TCCGGTTGCA GCAGTTGTTA CCCGTGATGG TCCTGGTGTG  
4081 ACCGCACTGC TGCGTCTGGT TGAAGGTGGT GGTGGTCGTC CTGTTCTGCT GACAGCCGAA  
4141 GAACATGATC GTACCACCGC AGCAACCCAG GCACTGACCC ATGCAGTTAT TCTGAGCTTT  
4201 GGTCTGGCAC TGGCACGTCT GGGTGTGAT GTTCGTGCAC TGGCAGCCAC CGCACCCTC  
4261 CCGCATCAAG TTCTGCTGGC CCTGTGGCA CGTGTCTGG GTGGTAGTCC GGAAGTTTAT  
4321 GGTGATATTC AGCGTAGCAA TCCGCGTGCA GCAAGCGCAC GTCGTGCCCT GGCTGAAGCC  
4381 CTGCGTAGCT TTGCAGCACT GATTGGTGAT GATCCTGATC GTGCCGAAGA TCCGGACCGT  
4441 GCAGATGACC CGGATCGTAC CGATAATCCT GGTCATCCCG GTGGTTGTGA TGGTGCAGGT  
4501 AATCTGGATG GTGTTTTTGA AGAAGTGCCT CGCCTGATGG GTCCTGAGCT GGCTGCAGGC  
4561 CAGGATCATT GTCAAGAACT GTTTCGTACC CTGCATCGTA CAGATGATGA AGGTGAAAAA  
4621 GATCGCTAAG GATCCAAACT CGAGTAAGGA TCTCCAGGCA TCAAATAAAA CGAAAGGCTC  
4681 AGTCGAAAGA CTGGGCCTTT CGTTTTATCT GTTGTTTGTC GGTGAACGCT CTCTACTAGA  
4741 GTCACACTGG CTCACCTTCG GGTGGCCTT TCTGCGTTA TACCTAGGC GTTCGGCTGC  
4801 GCGGAGCGGT ATCAGCTCAC TCAAAGCCG TAATACGGT ATCCACAGAA TCAGGGGATA  
4861 ACGCAGGAAA GAACATGTGA CAAAAGGCC AGCAAAGGC CAGGAACCGT AAAAAGGCCG  
4921 CGTTGCTGGC GTTTTTCCAT AGGCTCCGCC CCCCTGACGA GCATCACAAA AATCGACGCT  
4981 CAAGTCAGAG GTGGCGAAAC CCGACAGGAC TATAAAGATA CCAGGCGTTT CCCCTGGAA  
5041 GCTCCCTCGT GCGCTCTCCT GTTCCGACCC TGCCGCTTAC CGGATACCTG TCCGCCTTTC  
5101 TCCCTTCGGG AAGCGTGGCG CTTTCTCATA GCTCACGCTG TAGGTATCTC AGTTCGGTGT  
5161 AGGTGCTTCC CTCCAAGCTG GGCTGTGTGC ACGAACCCCC CGTTCAGCCC GACCGCTGCG  
5221 CCTTATCCGG TAACATATCGT CTTGAGTCCA ACCCGTAAG ACACGACTTA TCGCCACTGG  
5281 CAGCAGCCAC TGGTAACAGG ATTAGCAGAG CGAGGTATGT AGGCGGTGCT ACAGAGTTCT  
5341 TGAAGTGGTG GCCTAACTAC GGCTACACTA GAAGGACAGT ATTTGTGATC TGCGCTCTGC  
5401 TGAAGCCAGT TACCTTCGGA AAAAGAGTTG GTAGCTCTTG ATCCGGCAAA CAAACCACCG  
5461 CTGGTAGCGG TGGTTTTTTT GTTTGCAAGC AGCAGATTAC GCGCAGAAAA AAAGGATCTC  
5521 AAGAAGATCC TTTGATCTTT TCTACGGGGT CTGACGCTCA GTGGAACGAA AACTCACGTT  
5581 AAGGGATTTT GGTCATGACT AGTGCTTGGT TTCTACCAA TAAAAACGC CCGGCGGCAA  
5641 CCGAGCGTTC TGAACAAATC CAGATGGAGT TCTGAGGTCA TTAAGGATC TATCAACAGG  
5701 AGTCCAAGCG AGCTCGTAAA CTTGGTCTGA CAGTTACCAA TGCTTAATCA GTGAGGCACC

5761 TATCTCAGCG ATCTGTCTAT TTCGTTTCATC CATAGTTGCC TGACTCCCCG TCGTGTAGAT  
5821 AACTACGATA CGGGAGGGCT TACCATCTGG CCCCAGTGCT GCAATGATAC CGCGAGACCC  
5881 ACGCTCACCG GCTCCAGATT TATCAGCAAT AAACCAGCCA GCCGGAAGGG CCGAGCGCAG  
5941 AAGTGGTCCT GCAACTTTAT CCGCCTCCAT CCAGTCTATT AATTGTTGCC GGGGAAGCTAG  
6001 AGTAAGTAGT TCGCCAGTTA ATAGTTTGCG CAACGTTGTT GCCATTGCTA CAGGCATCGT  
6061 GGTGTCACGC TCGTCGTTTG GTATGGCTTC ATTCAGCTCC GGTTCCCAAC GATCAAGGCG  
6121 AGTTACATGA TCCCCATGT TGTGCAAAAA AGCGGTTAGC TCCTTCGGTC CTCCGATCGT  
6181 TGTCAGAAGT AAGTTGGCCG CAGTGTATC ACTCATGGTT ATGGCAGCAC TGCATAATTC  
6241 TCTTACTGTC ATGCCATCCG TAAGATGCTT TTCTGTGACT GGTGAGTACT CAACCAAGTC  
6301 ATTTCTGAGAA TAGTGTATGC GCGACCGAG TTGCTCTTGC CCGGCGTCAA TACGGGATAA  
6361 TACCGCGCCA CATAGCAGAA CTTTAAAAGT GCTCATCATT GGAAAACGTT CTTCGGGGCG  
6421 AAAACTCTCA AGGATCTTAC CGCTGTTGAG ATCCAGTTCG ATGTAACCCA CTCGTGCACC  
6481 CAACTGATCT TCAGCATCTT TTACTTTCAC CAGCGTTTCT GGGTGAGCAA AAACAGGAAG  
6541 GCAAAATGCC GCAAAAAAGG GAATAAGGGC GACACGGAAA TGTTGAATAC TCATACTCTT  
6601 CCTTTTTCAA TATTATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG GATACATATT  
6661 TGAATGTATT TAGAAAAATA AACAAATAGG GGTTCGCGC ACATTTCCCC GAAAAGTGCC  
6721 ACCT

//

## pJTS76D

LOCUS pJTS76D 6202 bp ds-DNA circular 08-APR-2017  
DEFINITION .  
FEATURES Location/Qualifiers  
CDS 4244..5230  
/label="PapC\_Opt"  
/ApEinfo\_revcolor=#84b0dc  
/ApEinfo\_fwdcolor=#84b0dc  
misc\_feature complement(138..993)  
/label="Amp"  
/ApEinfo\_revcolor=#ff9ccd  
/ApEinfo\_fwdcolor=#ff9ccd  
protein\_bind 1778..1796  
/label="Q1"  
/ApEinfo\_revcolor=#84b0dc  
/ApEinfo\_fwdcolor=#84b0dc  
protein\_bind 1808..1824  
/label="Q2"  
/ApEinfo\_revcolor=#d59687  
/ApEinfo\_fwdcolor=#d59687  
terminator 5255..5383  
/label="dbl\_termiminator"  
/ApEinfo\_revcolor=#85dae9  
/ApEinfo\_fwdcolor=#85dae9  
RBS 1845..1864  
/label="BglBrick RBS"  
/ApEinfo\_revcolor=#b7e6d7  
/ApEinfo\_fwdcolor=#b7e6d7  
promoter 1757..1829  
/label="tet promoter region"  
/ApEinfo\_revcolor=#f58a5e  
/ApEinfo\_fwdcolor=#f58a5e  
CDS complement(1130..1756)  
/label="tetR"  
/ApEinfo\_revcolor=#d59687  
/ApEinfo\_fwdcolor=#d59687  
rep\_origin 5517..6199  
/label="ColE1"  
/ApEinfo\_revcolor=#9eafd2  
/ApEinfo\_fwdcolor=#9eafd2  
RBS 4226..4243  
/label="PapC\_Mehl\_RBS"  
/ApEinfo\_revcolor=#ff9ccd  
/ApEinfo\_fwdcolor=#ff9ccd  
RBS 3875..3895  
/label="PapB\_Mehl\_RBS"  
/ApEinfo\_revcolor=#d6b295  
/ApEinfo\_fwdcolor=#d6b295  
terminator 3..108  
/label="T0"  
/ApEinfo\_revcolor=#b1ff67  
/ApEinfo\_fwdcolor=#b1ff67  
CDS 3896..4225  
/label="PapB\_Opt"  
/ApEinfo\_revcolor=#f58a5e

```
misc_feature 1865..3874 /ApEinfo_fwdcolor=#f58a5e
              /label="PapA_Opt (corrected)"
              /ApEinfo_revcolor=#85dae9
              /ApEinfo_fwdcolor=#85dae9
```

ORIGIN

```
1 GTGCTTGGAT TCTCACCAAT AAAAAACGCC CGGCGGCAAC CGAGCGTTCT GAACAAATCC
61 AGATGGAGTT CTGAGGTCAT TACTGGATCT ATCAACAGGA GTCCAAGCGA GCTCGTAAAC
121 TTGGTCTGAC AGTTACCAAT GCTTAATCAG TGAGGCACCT ATCTCAGCGA TCTGTCTATT
181 TCGTTCATCC ATAGTTGCCCT GACTCCCCGT CGTGTAGATA ACTACGATAC GGGAGGGCTT
241 ACCATCTGGC CCCAGTGCTG CAATGATACC GCGAGACCCA CGCTCACCGG CTCCAGATTT
301 ATCAGCAATA AACCAGCCAG CCGGAAGGGC CGAGCGCAGA AGTGGTCCTG CAACTTTATC
361 CGCCTCCATC CAGTCTATTA ATTGTTGCCG GGAAGCTAGA GTAAGTAGTT CGCCAGTTAA
421 TAGTTTGGCG AACGTTGTTG CCATTGCTAC AGGCATCGTG GTGTCACGCT CGTCGTTTGG
481 TATGGCTTCA TTCAGCTCCG GTTCCCAACG ATCAAGGCGA GTTACATGAT CCCCCATGTT
541 GTGCAAAAAA GCGGTTAGCT CCTTCGGTCC TCCGATCGTT GTCAGAAGTA AGTTGGCCGC
601 AGTGTATCA CTGATGGTTA TGGCAGCACT GCATAATTCT CTTACTGTCA TGCCATCCGT
661 AAGATGCTTT TCTGTGACTG GTGAGTACTC AACCAAGTCA TTCTGAGAAT AGTGTATGCG
721 GCGACCGAGT TGCTCTTGCC CGGCGTCAAT ACGGGATAAT ACCGCGCCAC ATAGCAGAAC
781 TTTAAAAGTG CTCATCATTG GAAAACGTTT TCCGGGCGA AAACCTCTCA GGATCTTACC
841 GCTGTTGAGA TCCAGTTCGA TGTAACCCAC TCGTGCACCC AACTGATCTT CAGCATCTTT
901 TACTTTCACC AGCGTTTCTG GGTGAGCAAA AACAGGAAGG CAAAATGCCG CAAAAAAGGG
961 AATAAGGGCG ACACGGAAAT GTTGAATACT CATACTCTTC CTTTTTCAAT ATTATTGAAG
1021 CATTTATCAG GGTATTGTG TCATGAGCGG ATACATATTT GAATGTATTT AGAAAAATAA
1081 ACAAATAGGG GTTCCGCGCA CATTCCCGG AAAAGTGCCA CCTGACGCTC TAAGACCCAC
1141 TTTACATTTT AAGTTGTTTT TCTAATCCGC ATATGATCAA TTCAAGCCCG AATAAGAAGG
1201 CTGGCTCTGC ACCTTGGTGA TCAAATAAAT CGATAGCTTG TCGTAATAAT GCGGCGATAC
1261 TATCAGTAGT AGGTGTTTCC CTTTCTTCTT TAGCGACTTG ATGCTCTTGA TCTTCCAATA
1321 CGCAACCTAA AGTAAAATGC CCCACAGCGC TGAGTGCATA TAATGCATTC TCTAGTGAAA
1381 AACCTTGTG GCATAAAAAG GCTAATTGAT TTTGAGAGT TTCATACTGT TTTTCTGTAG
1441 GCCGTGTACC TAAATGTACT TTTGCTCCAT CGCGATGACT TAGTAAAGCA CATCTAAAAC
1501 TTTTAGCGTT ATTACGTA AAATCTTGCC AGCTTTCCCC TTCTAAAGGG CAAAAGTGAG
1561 TATGGTGCC ATCTAACATC TCAATGGCTA AGGCGTCGAG CAAAGCCCG TTATTTTTTA
1621 CATGCCAATA CAATGTAGGC TGCTCTACAC CTAGCTTCTG GCGGAGTTTA CGGGTTGTTA
1681 AACCTTCGAT TCCGACCTCA TTAAGCAGCT CTAATGCGCT GTTAATCACT TTACTTTTAT
1741 CTAATCTAGA CATCATTAAT TCCTAATTTT TGTTGACACT CTATCGTTGA TAGAGTTATT
1801 TTACCACTCC CTATCAGTGA TAGAGAAAAG AATTCAAAAAG ATCTTTTAAAG AAGGAGATAT
1861 ACATATGCGT ACCCTGCTGA TTGATAACTA TGATAGCTTT ACCCAGAACC TGTTTCAGTA
1921 TATCGGTGAA GCAACCGGTC AGCCTCCGGT TGTTCCGAAT GATGCAGATT GGAGCCGCTC
1981 GCCGCTGGAA GATTTTGATG CAATTGTTGT TAGTCCGGGT CCGGGTAGTC CGGATCGTGA
2041 ACGTGATTTT GGTATTAGCC GTCGTGCAAT TACCATAGC GGTCTGCCG TGCTGGGTGT
2101 TTGTCTGGGT CATCAGGGTA TTGCACAGCT GAGCGCAGAA CCGATGCATG GTCGTGTTAG
2161 CGAAGTTCGT CATACCGGTG AAGATGTTTT TCGTGGTCTG CCGAGCCCG TTACCGCAGT
2221 TCGTTATCAT AGCCTGGCAG CAACCGATCT GCCGGATGAA CTGGAACCGG TGGCATGGTC
2281 AGATGATGGT GTTGTATG GTCTGCGTCA TCGTGAAAAA CCGCTGATGG GTGTTCAAGT
2341 TCCGCTGAA AGCATTGGTA GCGATTTTGG TCGTGAAATT ATGGCCAATT TTCGTGATCT
2401 GGCCTGGCA CATCATCGTG CACGTCGTGA TGCAGCAGAT TGGGGTTATG AACTGCATGT
2461 TCGTCTGTT GATGTTCTGC CTGATGCCGA AGAGGTGCGT CGTGCAGCAT GTCCGGCAGA
2521 AGGTGCAACC TTTTGGCTGG ATAGCAGCAG CGTTCTGGAA GGTGCATCAC CGTTTAGCTT
2581 TCTGGGTGAT GATCGTGGTC CGCTGGCAGA ATATCTGACC TATCGTGTG CAGATGGTGT
2641 GGTTAGCGTT CGTGGTAGTG ATGGCACCAC CACCCGTGAT GCCGCAACCC TGTTTAGTTA
2701 TCTGGAAGAA CAGCTGGAAC CTCCGGCAGG TCCTGTGCA CCGGATCTGC CGTTTGAGTT
2761 TAATCTGGGT TATGTTGGTT ATCTGGGCTA TGAAGTAAA GCAGAAAACA CCGGTGATCC
2821 GGCAGTCCG GCACCGCATC CTGATGCAGC CTTTCTGTTT GCAGATCGTG CCATTGCACT
2881 GGATCATCAA GAAGGTTGTT GTTATCTGCT GGCCCTGGAT CGTCTGGCC ATGATGATGG
2941 CGCACGTGCA TGGCTGCGTG AAACCGCAGA AACCTGACC GGTCTGGCAG TTCGTGTTCC
3001 TCCGCTCCG ACACCGCAA TGTTTTTGG TGTCCGGAA GCAGCAGCAG GTTTTGGTCC
```

3061 TCTGGCACGT GCACGCCATG ATAAAGATGC AAGCGCACTG CGTAATGGTG AAAGCTATGA  
3121 AATTTGTCTG ACCAATATGG TTACCGCACC GACCGAAGCC ACCGCACTGC CGCTGTATAG  
3181 TGCCTGCGT CGTATTTTAC CGGTTCCGAG CGGTGCACTG CTGGAATTTT CGGAAC TGAG  
3241 CGTTCTGAGC GCAAGTCCGG AACGTTTTCT GACCATTGGT GCCGATGGTG GTGTTGAAAG  
3301 CAAACCGATT AAAGGCACCC GTCCGCGTGG TGCCCCCTGCG GAAGAGGATG AACGTCTGCG  
3361 TGCAGATCTG GCAGGTCGCG AAAAAAGATCG TGCAGAAAAT CTGATGATTG TTGATCTGGT  
3421 TCGCAATGAT CTGAATAGCG TTTGTGCAAT TGGTAGTGTT CATGTTCCGC GTCTGTTTGA  
3481 AGTTGGTGAC CTGGCACCGG TTCATCAGCT GGTTAGCACC ATTCGTGGTC GCCTGCGTCC  
3541 GGGTACAAGC ACCGCAGCAT GTGTTCTGTC CGCATTTCGG GGTGGTAGCA TGACAGGTGC  
3601 ACCGAAAAAA CGTCCGATGG AAATTATTGA TCGTCTGGAA GAGGGTCCCTC GTGGTGTCT  
3661 GCCAGGTGCA CTGGGTTGGT TTGCACTGAG CGGTGCCGCA GATCTGAGCA TTGTTATTCG  
3721 TACCATTGTT CTGGCAGATG GTCGTGCCGA ATTTGGTGTT GGTGGTGCGA TTGTTAGCCT  
3781 GAGCGATCAA GAAGAAGAAT TTCGTCAGAC CGTTGTAAAA GCACGTGCAA TGGTGACCGC  
3841 ACTGGATGGT AGCGCAGTTG CCGGTGCACG TTAACACCAA CAAGGACCAT AGCATATGAC  
3901 CGAACAGAAT GAACTGCAGG TTGCAGCAGC ACGTGGTGCA CGTCGTCCGC GTCGTGATGC  
3961 AAGCGGTCAT GGTGCAGCAC CGCATCGTCC TCGTTGTCCG CATCGTGCAG TTCAGGTCC  
4021 GGCACGCCGT CCGGATGATG CAGCACGTCC TGGTCAGCCA GGTGAGGGCC AGGGTCTGTC  
4081 TCTGCGTCGT CGTCCACGTC CTCGTGCTAT TGTTCCGGGT GAACCGCTGC GTCGCGATCA  
4141 TCATGGTGAT GTTCCGCGTC GCGGTCCGGG TGATGAACCT GGTGAACCGG ATGGCCGTGG  
4201 TCCTGGCGAA CCGGTTATGT ATTAATGTA CTAAGGAGGT TGTATGAGCG GTTTTCCGCG  
4261 TAGCGTTGTT GTTGGTGGTA GCGGTGCAGT GGGTGGTATG TTTGCAGGTC TGCTGCGTGA  
4321 AGCAGGTAGC CGTACCCTGG TTGTTGATCT GGTTCCGCCT CCGGGTCGTC CGGATGCATG  
4381 TCTGGTTGGT GATGTTACCG CACCGGGTCC GGAAGTGGCA GCAGCACTGC GTGATGCAGA  
4441 TCTGGTGCTG CTGGCCGTTT ATGAAGATGT TGCAGTAAA GCAGTTGCAC CCGTTACCCG  
4501 TCTGATGCGC CCGGGTGCAC TGCTGGCAGA TACCCTGAGC GTTCGTACCG GTATGGCAGC  
4561 AGAGCTGGCA GCACATGCAC CCGGTGTTCA GCATGTTGGT CTGAATCCGA TGTTTGCACC  
4621 GGCAGCAGGT ATGACAGGCC TCCCGGTTGC AGCAGTTGTT ACCCGTGATG GTCCTGGTGT  
4681 GACCGCACTG CTGCGTCTGG TTGAAGGTGG TGGTGGTCTG CCTGTTCGTC TGACAGCCGA  
4741 AGAACATGAT CGTACCACCG CAGCAACCCA GGCAGTACC CATGCAGTTA TTCTGAGCTT  
4801 TGGTCTGGCA CTGGCACGTC TGGGTGTTGA TGTTGCTGCA CTGGCAGCCA CCGCACCGCC  
4861 TCCGCATCAA GTTCTGCTGG CCCTGCTGGC ACGTGTTCG GGTGGTAGTC CGGAAGTTTA  
4921 TGGTGATATT CAGCGTAGCA ATCCGCTGTC AGCAAGCGCA CGTCGTGCC TGGCTGAAGC  
4981 CCTGCGTAGC TTTGCAGCAC TGATTGGTGA TGATCTGAT CGTGCCGAAG ATCCGGACCG  
5041 TGCAGATGAC CCGGATCGTA CCGATAATCC TGGTCATCCG GGTGGTGTGT ATGGTGCAGG  
5101 TAATCTGGAT GGTGTTTTTG AAGAAGTCCG TCGCCTGATG GGTCCGAGC TGGCTGCAGG  
5161 CCAGGATCAT TGTCAGAAGC TGTTTCGTAC CCTGCATCGT ACAGATGATG AAGGTGAAAA  
5221 AGATCGCTAA GGATCCAAAC TCGAGTAAGG ATCTCCAGGC ATCAAATAAA ACGAAAGGCT  
5281 CAGTCGAAAG ACTGGGCCTT TCGTTTTATC TGTTGTTTGT CCGTGAACGC TCTCTACTAG  
5341 AGTCACACTG GCTCACCTTC GGGTGGGCCT TTCTGCGTTC ATACCTAGGG CGTTCGGCTG  
5401 CCGCGAGCGG TATCAGCTCA CTCAAAAGCG GTAATACGGT TATCCACAGA ATCAGGGGAT  
5461 AACGCAGGAA AGAACATGTG AGCAAAAGGC CAGCAAAAGG CCAGGAACCG TAAAAAGGCC  
5521 GCGTTGCTGG CGTTTTTCCA TAGGCTCCGC CCCCCTGACG AGCATACAA AAATCGACGC  
5581 TCAAGTCAGA GGTGGCGAAA CCCGACAGGA CTATAAAGAT ACCAGGCGTT TCCCCCTGGA  
5641 AGTCCCTCG TGCGCTCTCC TGTTCCGACC CTGCCGCTTA CCGGATACCT GTCCGCCTTT  
5701 CTCCCTTCGG GAAGCGTGGC GCTTTCTCAT AGCTCACGCT GTAGGTATCT CAGTTCGGTG  
5761 TAGGTCGTTT GCTCCAAGCT GGGCTGTGTG CACGAACCCC CCGTTCAGCC CGACCGCTGC  
5821 GCCTTATCCG GTAACATATC TCTTGAGTCC AACCCGGTAA GACACGACTT ATCGCCACTG  
5881 GCAGCAGCCA CTGGTAACAG GATTAGCAGA GCGAGGTATG TAGGCGGTGC TACAGAGTTC  
5941 TTGAAGTGGT GGCCTAACTA CGGCTACACT AGAAGGACAG TATTTGGTAT CTGCGCTCTG  
6001 CTGAAGCCAG TTACCTTCGG AAAAAAGAGT GGTAGCTCTT GATCCGGCAA ACAAACCACC  
6061 GCTGGTAGCG GTGGTTTTTT TGTTTGCAAG CAGCAGATTA CGCGCAGAAA AAAAGGATCT  
6121 CAAGAAGATC CTTTGATCTT TTCTACGGGG TCTGACGCTC AGTGGAACGA AAACCTCACGT  
6181 TAAGGGATTT TGGTCATGAC TA

//

# pJTS76W

LOCUS pJTS76W 6214 bp ds-DNA circular 10-OCT-2017  
DEFINITION .  
FEATURES Location/Qualifiers  
CDS complement(1130..1756)  
/label="tetR"  
/ApEinfo\_revcolor=#d59687  
/ApEinfo\_fwdcolor=#d59687  
terminator 3..108  
/label="T0"  
/ApEinfo\_revcolor=#b1ff67  
/ApEinfo\_fwdcolor=#b1ff67  
misc\_feature complement(138..993)  
/label="Amp"  
/ApEinfo\_revcolor=#ff9ccd  
/ApEinfo\_fwdcolor=#ff9ccd  
protein\_bind 1808..1824  
/label="Q2"  
/ApEinfo\_revcolor=#d59687  
/ApEinfo\_fwdcolor=#d59687  
protein\_bind 1778..1796  
/label="Q1"  
/ApEinfo\_revcolor=#84b0dc  
/ApEinfo\_fwdcolor=#84b0dc  
promoter 1757..1829  
/label="tet promoter region"  
/ApEinfo\_revcolor=#f58a5e  
/ApEinfo\_fwdcolor=#f58a5e  
misc\_feature 3882..3925  
/label="PapB\_RBS1"  
/ApEinfo\_revcolor=#75c6a9  
/ApEinfo\_fwdcolor=#75c6a9  
misc\_feature 3926..4237  
/label="PapB\_Opt (genomic) "  
/ApEinfo\_revcolor=#d59687  
/ApEinfo\_fwdcolor=#d59687  
CDS 4256..5242  
/label="PapC\_Opt"  
/ApEinfo\_revcolor=#84b0dc  
/ApEinfo\_fwdcolor=#84b0dc  
terminator 5267..5395  
/label="dbl\_termiminator"  
/ApEinfo\_revcolor=#85dae9  
/ApEinfo\_fwdcolor=#85dae9  
rep\_origin 5529..6211  
/label="ColE1"  
/ApEinfo\_revcolor=#9eafd2  
/ApEinfo\_fwdcolor=#9eafd2  
misc\_feature 1845..1871  
/label="PapA\_RBS2"  
/ApEinfo\_revcolor=#f58a5e  
/ApEinfo\_fwdcolor=#f58a5e  
RBS 4238..4255  
/label="PapC\_Mehl\_RBS"  
/ApEinfo\_revcolor=#ff9ccd



```
misc_feature      /ApEinfo_fwdcolor=#ff9ccd
                  1872..3881
                  /label="PapA_Opt (corrected)"
                  /ApEinfo_revcolor=#85dae9
                  /ApEinfo_fwdcolor=#85dae9
```

ORIGIN

```
  1 GTGCTTGGAT TCTCACCAAT AAAAAACGCC CGGCGGCAAC CGAGCGTTCT GAACAAATCC
 61 AGATGGAGTT CTGAGGTCAT TACTGGATCT ATCAACAGGA GTCCAAGCGA GCTCGTAAAC
121 TTGGTCTGAC AGTTACCAAT GCTTAATCAG TGAGGCACCT ATCTCAGCGA TCTGTCTATT
181 TCGTTCATCC ATAGTTGCCCT GACTCCCCGT CGTGTAGATA ACTACGATAC GGGAGGGCTT
241 ACCATCTGGC CCCAGTGCTG CAATGATACC GCGAGACCCA CGCTCACCGG CTCCAGATTT
301 ATCAGCAATA AACCAGCCAG CCGGAAGGGC CGAGCGCAGA AGTGGTCCTG CAACTTTATC
361 CGCCTCCATC CAGTCTATTA ATTGTTGCCG GGAAGCTAGA GTAAGTAGTT CGCCAGTTAA
421 TAGTTTGGCG AACGTTGTTG CCATTGCTAC AGGCATCGTG GTGTCACGCT CGTCGTTTGG
481 TATGGCTTCA TTCAGCTCCG GTTCCCAACG ATCAAGGCGA GTTACATGAT CCCCCATGTT
541 GTGCAAAAAA GCGGTTAGCT CCTTCGGTCC TCCGATCGTT GTCAGAAGTA AGTTGGCCGC
601 AGTGTATCA  CTCATGGTTA TGGCAGCACT GCATAATTCT CTTACTGTCA TGCCATCCGT
661 AAGATGCTTT TCTGTGACTG GTGAGTACTC AACCAAGTCA TTCTGAGAAT AGTGTATGCG
721 GCGACCGAGT TGCTCTTGCC CGGCGTCAAT ACGGGATAAT ACCGCGCCAC ATAGCAGAAC
781 TTTAAAAGTG CTCATCATTG GAAAACGTTT TTCGGGGCGA AAACCTCTCA GGATCTTACC
841 GCTGTTGAGA TCCAGTTCGA TGTAACCCAC TCGTGCACCC AACTGATCTT CAGCATCTTT
901 TACTTTCACC AGCGTTTCTG GGTGAGCAAA AACAGGAAGG CAAAATGCCG CAAAAAAGGG
961 AATAAGGGCG ACACGGAAAT GTTGAATACT CATACTCTTC CTTTTTCAAT ATTATTGAAG
1021 CATTTATCAG GGTATTGTGTC TCATGAGCGG ATACATATTT GAATGTATTT AGAAAAATAA
1081 ACAAATAGGG GTTCCGCGCA CATTCCCCG AAAAGTGCCA CCTGACGCTC TAAGACCCAC
1141 TTTACATATTT AAGTTGTTTT TCTAATCCGC ATATGATCAA TTCAAGGCCG AATAAGAAGG
1201 CTGGCTCTGC ACCTTGGTGA TCAAATAAAT CGATAGCTTG TCGTAATAAT GGCGGCATAC
1261 TATCAGTAGT AGGTGTTTCC CTTTCTTCTT TAGCGACTTG ATGCTCTTGA TCTTCCAATA
1321 CGCAACCTAA AGTAAAATGC CCCACAGCGC TGAGTGCATA TAATGCATTC TCTAGTGAAA
1381 AACCTTGTG GCATAAAAAG GCTAATTGAT TTTGAGAGT TTCATACTGT TTTTCTGTAG
1441 GCCGTGTACC TAAATGTACT TTTGCTCCAT CGCGATGACT TAGTAAAGCA CATCTAAAAC
1501 TTTTAGCGTT ATTACGTAAA AAATCTTGCC AGCTTTCCCC TTCTAAAGGG CAAAAGTGAG
1561 TATGGTGCC ATCTAACATC TCAATGGCTA AGGCGTCGAG CAAAGCCCG TTATTTTTTA
1621 CATGCCAATA CAATGTAGGC TGCTCTACAC CTAGCTTCTG GCGGAGTTA CGGGTTGTTA
1681 AACCTTCGAT TCCGACCTCA TTAAGCAGCT CTAATGCGCT GTTAATCACT TTACTTTTAT
1741 CTAATCTAGA CATCATTAAT TCCTAATTTT TGTTGACACT CTATCGTTGA TAGAGTTATT
1801 TTACCACTCC CTATCAGTGA TAGAGAAAAG AATTCAAAAAG ATCTAAAATA CCTAAACGAG
1861 AGGAAAGAAT AATGCGTACC CTGCTGATTG ATAACTATGA TAGCTTTACC CAGAACCTGT
1921 TTCAGTATAT CCGTGAAGCA ACCGGTCAGC CTCCGGTTGT TCCGAATGAT GCAGATTGGA
1981 GCCGTCTGCC GCTGGAAGAT TTTGATGCAA TTGTTGTTAG TCCGGGTCGG GGTAGTCCGG
2041 ATCGTGAACG TGATTTTGGT ATTAGCCGTC GTGCAATTAC CGATAGCGGT CTGCCGGTGC
2101 TGGGTGTTTG TCTGGGTCAT CAGGGTATTG CACAGCTGAG CGCAGAACCG ATGCATGGTC
2161 GTGTTAGCGA AGTTTCGTCAT ACCGGTGAAG ATGTTTTTCG TGGTCTGCCG AGCCCGTTTA
2221 CCGCAGTTCC TTATCATAGC CTGGCAGCAA CCGATCTGCC GGATGAACTG GAACCGCTGG
2281 CATGGTCAGA TGATGGTGTT GTTATGGGTC TGCGTCATCG TGAAAAACCG CTGATGGGTG
2341 TTCAGTTTCC GCCTGAAAGC ATTGGTAGCG ATTTTGGTCG TGAAATTATG GCCAATTTTC
2401 GTGATCTGGC ACTGGCACAT CATCGTGCAC GTCGTGATGC AGCAGATTGG GGTATGAAC
2461 TGCATGTTCC TCGTGTGAT GTTCTGCCTG ATGCCGAAGA GGTGCGTCGT GCAGCATGTC
2521 CGGCAGAAGG TGCAACCTTT TGGCTGGATA GCAGCAGCGT TCTGGAAGGT GCATCACCGT
2581 TTAGCTTTCT GGGTGATGAT CGTGGTCCGC TGGCAGAATA TCTGACCTAT CGTGTTCAG
2641 ATGGTGTGGT TAGCGTTCGT GGTAGTGATG GCACCACCAC CCGTGTATGCC GCAACCCTGT
2701 TTAGTTATCT GGAAGAACAG CTGGAACCTC CGGCAGGTCC TGTTGCACCG GATCTGCCGT
2761 TTGAGTTTAA TCTGGGTTAT GTTGGTTATC TGGGCTATGA ACTGAAAGCA GAAACCACCG
2821 GTGATCCGGC AGTTCGGGCA CCGCATCCTG ATGCAGCCTT TCTGTTTGA GATCGTGCCA
2881 TTGCACTGGA TCATCAAGAA GGTGTTGTTT ATCTGCTGGC CCTGGATCGT CGTGGCCATG
2941 ATGATGGCGC ACGTGCATGG CTGCGTGAAA CCGCAGAAAC CCTGACCGGT CTGGCAGTTC
3001 GTGTTCTGCC GCGTCCGACA CCGGCAATGG TTTTGGTGT TCCGGAAGCA GCAGCAGGTT
```

3061 TTGGTCTCT GGCACGTGCA CGCCATGATA AAGATGCAAG CGCACTGCCT AATGGTGAAA  
3121 GCTATGAAAT TTGTCTGACC AATATGGTTA CCGCACCGAC CGAAGCCACC GCACTGCCGC  
3181 TGTATAGTGC ACTGCGTCGT ATTTACCCGG TTCCGAGCGG TGCACCTGCT GAATTTCCGG  
3241 AACTGAGCGT TCTGAGCGCA AGTCCGGAAC GTTTTCTGAC CATTGGTGCC GATGGTGGTG  
3301 TTGAAAGCAA ACCGATTTAA GGCACCCGTC CGCGTGGTGC CCCTGCGGAA GAGGATGAAC  
3361 GTCTGCGTGC AGATCTGGCA GGTCCGCGAAA AAGATCGTGC AGAAAATCTG ATGATTGTTG  
3421 ATCTGGTTCG CAATGATCTG AATAGCGTTT GTGCAATTGG TAGTGTTTAT GTTCCGCGTC  
3481 TGTTTGAAGT TGGTGACCTG GCACCGGTTT ATCAGCTGGT TAGCACCATT CGTGGTCCGC  
3541 TGCGTCCGGG TACAAGCACC GCAGCATGTG TTCGTGCCGC ATTTCCGGGT GGTAGCATGA  
3601 CAGGTGCACC GAAAAACGTT CCGATGGAAA TTATTGATCG TCTGGAAGAG GGTCCCTCGT  
3661 GTGTTCTGCC AGGTGCACTG GGTGGGTTTG CACTGAGCGG TGCCCGAGAT CTGAGCATTG  
3721 TTATTCTGAC CATTGTTCTG GCAGATGGTC GTGCCGAATT TGGTGTGGT GGTGCGATTG  
3781 TTAGCCTGAG CGATCAAGAA GAAGAATTTT GTCAGACCGT TGTTAAAGCA CGTGCAATGG  
3841 TGACCGCACT GGATGGTAGC GCAGTTGCCG GTGCACGTTA ATCGGCCGCT ACCATAAACG  
3901 TATCACAAAA CTAAGGAGGT TCCCAATGAC CGAACAGAAT GAACTGCAGC GTCTGCGTGC  
3961 AGAACTGGAT GCACTGGATG GCACCCTGCT GGATACCGTT CGTCTGCTGA TTGATCTGGG  
4021 TGTTCTGATT GCACGTTATA AAAGCCGTC TGGTGTCCG ATGATGCAGC CTGGTCTGTT  
4081 TAGCCTGGTT AAAGATCGTG CAGCACGTTA TGCAGCAGAT CATGGTCTGG ATGAAAGTTT  
4141 TCTGGTGAAT CTGTATGATG TGATCATCAC CGAAATGTGC CGTGTGAAG ATCTGGTTAT  
4201 GAGCCGTGAA AGCCTGACCG CAGAAGATCG TCGTTAAATG TACTAAGGAG GTTGTATGAG  
4261 CGGTTTTCCG CGTAGCGTTG TTGTTGGTGG TAGCCGTTGCA GTGGGTGGTA TGTTTGCAGG  
4321 TCTGCTGCGT GAAGCAGGTA GCCGTACCCT GGTTGTTGAT CTGGTTCCCG CTCCGGGTCG  
4381 TCCGGATGCA TGCTGGTTG GTGATGTTAC CGCACCGGGT CCGGAACTGG CAGCAGCACT  
4441 GCGTGATGCA GATCTGGTGC TGCTGGCCGT TCATGAAGAT GTTGCACTGA AAGCAGTTGC  
4501 ACCGGTTACC CGTCTGATGC GTCCGGGTGC ACTGCTGGCA GATACCCTGA GCGTTCGTAC  
4561 CCGTATGGCA GCAGAGCTGG CAGCACATGC ACCGGGTGTT CAGCATGTTG GTCTGAATCC  
4621 GATGTTTCCA CCGGCAGCAG GTATGACAGG CCGTCCGGTT GCAGCAGTTG TTACCCGTTA  
4681 TGGTCTGGT GTGACCGCAC TGCTGCGTCT GGTGAAGGT GGTGGTGGT GCCTGTTCTG  
4741 TCTGACAGCC GAAGAACATG ATCGTACCAC CGCAGCAACC CAGGCACTGA CCCATGCAGT  
4801 TATTCTGAGC TTTGGTCTGG CACTGGCAGC TCTGGGTGTT GATGTTCTGT CACTGGCAGC  
4861 CACCCGACCG CCTCCGCATC AAGTTCTGCT GGCCCTGCTG GCACGTGTTT TGGGTGGTAG  
4921 TCCGGAAGTT TATGGTGATA TTCAGCGTAG CAATCCGCGT GCAGCAAGCG CACGTCGTGC  
4981 CCTGGCTGAA GCCCTGCGTA GCTTTCGAGC ACTGATTGGT GATGATCCTG ATCGTGCCGA  
5041 AGATCCGAC CGTGCAGATG ACCCGGATCG TACCGATAAT CCTGGTCATC CGGGTGGTTG  
5101 TGATGGTGCA GGTAATCTGG ATGGTGTGTT TGAAGAACTG CGTCCGCTGA TGGGTCCTGA  
5161 GCTGGCTGCA GGCCAGGATC ATTGTCAAGA ACTGTTTCGT ACCCTGCATC GTACAGATGA  
5221 TGAAGGTGAA AAAGATCGCT AAGGATCCAA ACTCGAGTAA GGATCTCCAG GCATCAAATA  
5281 AAACGAAAGG CTCAGTCGAA AGACTGGGCC TTTCTGTTTA TCTGTTGTTT GTCGGTGAAC  
5341 GCTCTCTACT AGAGTCACAC TGGCTCACCT TCGGGTGGGC CTTTCTGCGT TTATACCTAG  
5401 GCGTTCGGC TGCGGCGAGC GGTATCAGCT CACTCAAAGG CGGTAATACG GTTATCCACA  
5461 GAATCAGGGG ATAACGCAGG AAAGAACATG TGAGCAAAG GCCAGCAAAA GGCCAGGAAC  
5521 CGTAAAAAGG CCGCTTGTCT GCGTTTTTTC CATAGGCTCC GCCCCCTGA CGAGCATCAC  
5581 AAAAATCGAC GCTCAAGTCA GAGGTGGCGA AACCCGACAG GACTATAAAG ATACCGGCG  
5641 TTTCCCTGCT GAAGCTCCCT CGTGCCTCTT CCTGTTCCGA CCCTGCGCTT TACCGGATAC  
5701 CTGTCGCTT TTCTCCCTTC GGAAGCGTG GCGCTTTCTC ATAGCTCACG CTGTAGGTAT  
5761 CTCAGTTCGG TGTAGGTCGT TCGCTCCAAG CTGGGCTGTG TGCACGAACC CCCCGTTCAG  
5821 CCCGACCGCT GCGCCTTATC CGGTAACATC CGTCTTGAGT CCAACCCGGT AAGACACGAC  
5881 TTATCGCCAC TGGCAGCAGC CACTGGTAAC AGGATTAGCA GAGCGAGGTA TGTAGGCGGT  
5941 GCTACAGAGT TCTTGAAGTG GTGGCCTAAC TACGGCTACA CTAGAAGGAC AGTATTTGGT  
6001 ATCTGCGCTC TGCTGAAGCC AGTTACCTTC GGAAAAAGAG TTGGTAGCTC TTGATCCGGC  
6061 AAACAACCCA CCGCTGGTAG CGGTGGTTTT TTTGTTGCA AGCAGCAGAT TACGCGCAGA  
6121 AAAAAAGGAT CTCAAGAAGA TCCTTTGATC TTTTCTACGG GGTCTGACGC TCAGTGGAAC  
6181 GAAAACCTCAC GTTAAGGGAT TTTGGTCATG ACTA

//